filename,arm_name,intervention_type,screening_window,1_month,3_months,6_months,9_months,12_months,core_treatment_screening_window,core_treatment_1_month,core_treatment_3_months,core_treatment_6_months,core_treatment_9_months,core_treatment_12_months,imaging_diagnostics_screening_window,imaging_diagnostics_1_month,imaging_diagnostics_3_months,imaging_diagnostics_6_months,imaging_diagnostics_9_months,imaging_diagnostics_12_months,labs_screening_window,labs_1_month,labs_3_months,labs_6_months,labs_9_months,labs_12_months,clinic_visits_screening_window,clinic_visits_1_month,clinic_visits_3_months,clinic_visits_6_months,clinic_visits_9_months,clinic_visits_12_months,cycle_length_days,treatment_duration_rule,visit_pattern,assumptions
23358972,FOLFIRI + sunitinib (Arm A),intervention,1,5,11,18,26,36,0,3,7,11,16,22,1,0,0,0,0,0,0,2,4,7,10,14,0,0,0,0,0,0,42,until progression (calculated up to Day +365),"Screening (Day -X); C1D1, C1D8, C1D15, C1D22, C1D29; C2D1, C2D8, C2D15, C2D22, C2D29; ... C9D1, C9D8, C9D15, C9D22, C9D29. All range-columns (e.g., Day 8 (±3)) were mapped to one nominal date.","All screening activities are assumed to occur on a single in-person day within the screening window, with the highest precedence category (imaging_diagnostics) assigned.; Treatment continues for the full 365-day horizon for calculation purposes, as per 'until progression' rule.; A 6-week (42-day) cycle length is used, with FOLFIRI administered on Day 1, Day 15, and Day 29 of each cycle. Sunitinib is administered daily for 4 weeks (Day 1-28) of each cycle.; For Arm A, in-person visits occur on Day 1, Day 8, Day 15, Day 22, and Day 29 of each 42-day cycle, as indicated by 'X' marks in the Schedule of Activities table (pages 34-35).; For Arm B, in-person visits occur on Day 1, Day 15, and Day 29 of each 42-day cycle, as indicated by 'X' marks in the Schedule of Activities table (pages 38-39). Activities marked 'SOC' (Standard of Care) or not explicitly marked with 'X' in the Arm B table are not counted as trial-mandated in-person contact days, in line with protocol text on page 32 for 'FOLFIRI alone'.; Despite the 'Sunitinib/Placebo' row being empty for daily administration in the Arm B table, the main text on page 12 states 'placebo will be given in similar fashion in Arm B' as sunitinib in Arm A (daily for 4 weeks). However, the in-person contact for drug administration is primarily on Day 1 with FOLFIRI infusion. The daily oral administration itself does not add additional in-person contact days beyond the scheduled visits.; Category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to assign a single primary category for each contact day.; ECG on Day 29 of the first 3 cycles is counted as imaging_diagnostics but subsumed by core_treatment on those days due to precedence.; Tumour Imaging on Day 1 of every cycle (from C2) is counted as imaging_diagnostics but subsumed by core_treatment due to precedence.; Brain CT/MRI on Day 1 of every 3 cycles (from C2) is counted as imaging_diagnostics but subsumed by core_treatment due to precedence.; Urinalysis and Symptom Questionnaire on Day 1 of odd-numbered cycles (from C3) are counted as labs/clinic_visits but subsumed by core_treatment due to precedence.; Study Randomization on C1D1 is counted as clinic_visits but subsumed by core_treatment due to precedence."
23358972,FOLFIRI + placebo (Arm B),control,1,3,7,11,15,21,0,3,7,11,15,21,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,42,until progression (calculated up to Day +365),"Screening (Day -X); C1D1, C1D15, C1D29; C2D1, C2D15, C2D29; ... C9D1, C9D15, C9D29. All range-columns (e.g., Day 8 (±3)) were mapped to one nominal date.","All screening activities are assumed to occur on a single in-person day within the screening window, with the highest precedence category (imaging_diagnostics) assigned.; Treatment continues for the full 365-day horizon for calculation purposes, as per 'until progression' rule.; A 6-week (42-day) cycle length is used, with FOLFIRI administered on Day 1, Day 15, and Day 29 of each cycle. Placebo is assumed to be administered on FOLFIRI infusion days (Day 1, Day 15, Day 29) as per main text, but this does not add additional in-person contact days.; For Arm B, in-person visits occur on Day 1, Day 15, and Day 29 of each 42-day cycle, as indicated by 'X' marks in the Schedule of Activities table (pages 38-39). Activities marked 'SOC' (Standard of Care) or not explicitly marked with 'X' in the Arm B table are not counted as trial-mandated in-person contact days, in line with protocol text on page 32 for 'FOLFIRI alone'.; Category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to assign a single primary category for each contact day.; ECG on Day 29 of the first 3 cycles is counted as imaging_diagnostics but subsumed by core_treatment on those days due to precedence.; Tumour Imaging on Day 1 of every cycle (from C2) is counted as imaging_diagnostics but subsumed by core_treatment due to precedence.; Brain CT/MRI on Day 1 of every 3 cycles (from C2) is counted as imaging_diagnostics but subsumed by core_treatment due to precedence.; Study Randomization on C1D1 is counted as clinic_visits but subsumed by core_treatment due to precedence."
23940216,cediranib 30 mg monotherapy,intervention,1,5,9,13,17,22,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,3,4,4,4,4,21,until progression,"Screening (Day -X), Day 0, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, then every 21 days (Day 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357). Range-columns were mapped to one nominal date.","Screening is counted as one in-person day, occurring within the Day -28 to Day -1 window.; Day 1 (Day 0 in the system) is a distinct in-person day from Screening, as indicated by separate columns in the Schedule of Events (SoE).; Dispensing of study medication (cediranib or lomustine/placebo) implies an in-person visit for administration or collection.; All 'X' marks in Table 1 for non-optional procedures indicate an in-person contact day, unless superseded by a footnote or a higher-precedence category.; Treatment is assumed to continue until progression, which for calculation purposes is extended to at least Day 365.; The 'Every 3 weeks' and 'Every 6 weeks' columns in the SoE define the repeating schedule for assessments after the initial 6 weeks.; For category assignment, the precedence rule core_treatment > imaging_diagnostics > labs > clinic_visits was applied.; Optional procedures (e.g., 'Optional Tumour sample', 'Pharmacogenetic blood sample') are not counted as mandatory contact days."
23940216,cediranib 20 mg in combination with lomustine,intervention,1,5,9,13,17,22,0,2,5,9,13,18,1,0,0,0,0,0,0,3,4,4,4,4,0,0,0,0,0,0,21,until progression,"Screening (Day -X), Day 0, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, then every 21 days (Day 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357). Range-columns were mapped to one nominal date.","Screening is counted as one in-person day, occurring within the Day -28 to Day -1 window.; Day 1 (Day 0 in the system) is a distinct in-person day from Screening, as indicated by separate columns in the Schedule of Events (SoE).; Dispensing of study medication (cediranib or lomustine/placebo) implies an in-person visit for administration or collection.; All 'X' marks in Table 1 for non-optional procedures indicate an in-person contact day, unless superseded by a footnote or a higher-precedence category.; Treatment is assumed to continue until progression, which for calculation purposes is extended to at least Day 365.; The 'Every 3 weeks' and 'Every 6 weeks' columns in the SoE define the repeating schedule for assessments after the initial 6 weeks.; For category assignment, the precedence rule core_treatment > imaging_diagnostics > labs > clinic_visits was applied.; Optional procedures (e.g., 'Optional Tumour sample', 'Pharmacogenetic blood sample') are not counted as mandatory contact days.; Lomustine administration occurs every 6 weeks, but cediranib dispensing and most other assessments follow a 3-week cycle after the initial weekly phase."
23940216,cediranib matched placebo in combination with lomustine,control,1,5,9,13,17,22,0,2,5,9,13,18,1,0,0,0,0,0,0,3,4,4,4,4,0,0,0,0,0,0,21,until progression,"Screening (Day -X), Day 0, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, then every 21 days (Day 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357). Range-columns were mapped to one nominal date.","Screening is counted as one in-person day, occurring within the Day -28 to Day -1 window.; Day 1 (Day 0 in the system) is a distinct in-person day from Screening, as indicated by separate columns in the Schedule of Events (SoE).; Dispensing of study medication (cediranib or lomustine/placebo) implies an in-person visit for administration or collection.; All 'X' marks in Table 1 for non-optional procedures indicate an in-person contact day, unless superseded by a footnote or a higher-precedence category.; Treatment is assumed to continue until progression, which for calculation purposes is extended to at least Day 365.; The 'Every 3 weeks' and 'Every 6 weeks' columns in the SoE define the repeating schedule for assessments after the initial 6 weeks.; For category assignment, the precedence rule core_treatment > imaging_diagnostics > labs > clinic_visits was applied.; Optional procedures (e.g., 'Optional Tumour sample', 'Pharmacogenetic blood sample') are not counted as mandatory contact days.; Lomustine administration occurs every 6 weeks, but placebo dispensing and most other assessments follow a 3-week cycle after the initial weekly phase."
27264120,Letrozole 2.5 mg po daily x 5 years,intervention,1,1,1,1,1,2,0,0,0,0,0,0,1,1,1,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,,5 years or until recurrence/second malignancy,"Screening (Day -X), Day 0, Day 365. All listed procedures for each time point are consolidated into a single in-person contact day.","The MA.17R Patient Evaluation Flow Sheet (Appendix XVI, page 93) is used as the primary schedule of events, with Day 0 being the day of randomization/start of treatment.; All procedures listed for a given time point (e.g., 'Within 60 days prior to randomization', 'Every 12 months from randomization') are assumed to occur on a single in-person contact day for the most conservative lower estimate. This single day is then assigned to one primary category based on the defined precedence (core_treatment > imaging_diagnostics > labs > clinic_visits).; For the screening window, all pre-randomization investigations (Clinical Evaluation, Haematology, Biochemistry, Whole Blood Sample, Mammogram, Chest x-ray, DEXA Scan, Toxicity, Quality of Life) are assumed to occur on a single contact day within the Day -28 to Day -1 window. The highest precedence activity on this day is imaging_diagnostics (Mammogram, Chest x-ray, DEXA Scan).; For Day 0 and subsequent annual visits (Day 365), all listed procedures (Clinical Evaluation, Haematology, Biochemistry, Quality of Life, Whole Blood Sample, Mammogram) are assumed to occur on a single contact day. The highest precedence activity on these days is imaging_diagnostics (Mammogram).; Conditional 'Other Investigations' (for recurrence) are excluded from routine contact days as patients are expected to be disease-free at entry and during routine follow-up.; Optional 'Plasma Lipid Profile' is excluded from mandatory contact days.; 'Tumour/Tissue Blocks' collection refers to existing tissue and does not require a new in-person contact day.; Treatment (Letrozole/Placebo) is daily oral and does not count as in-person contact days."
27264120,Placebo daily x 5 years,control,1,1,1,1,1,2,0,0,0,0,0,0,1,1,1,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,,5 years or until recurrence/second malignancy,"Screening (Day -X), Day 0, Day 365. All listed procedures for each time point are consolidated into a single in-person contact day.","The MA.17R Patient Evaluation Flow Sheet (Appendix XVI, page 93) is used as the primary schedule of events, with Day 0 being the day of randomization/start of treatment.; All procedures listed for a given time point (e.g., 'Within 60 days prior to randomization', 'Every 12 months from randomization') are assumed to occur on a single in-person contact day for the most conservative lower estimate. This single day is then assigned to one primary category based on the defined precedence (core_treatment > imaging_diagnostics > labs > clinic_visits).; For the screening window, all pre-randomization investigations (Clinical Evaluation, Haematology, Biochemistry, Whole Blood Sample, Mammogram, Chest x-ray, DEXA Scan, Toxicity, Quality of Life) are assumed to occur on a single contact day within the Day -28 to Day -1 window. The highest precedence activity on this day is imaging_diagnostics (Mammogram, Chest x-ray, DEXA Scan).; For Day 0 and subsequent annual visits (Day 365), all listed procedures (Clinical Evaluation, Haematology, Biochemistry, Quality of Life, Whole Blood Sample, Mammogram) are assumed to occur on a single contact day. The highest precedence activity on these days is imaging_diagnostics (Mammogram).; Conditional 'Other Investigations' (for recurrence) are excluded from routine contact days as patients are expected to be disease-free at entry and during routine follow-up.; Optional 'Plasma Lipid Profile' is excluded from mandatory contact days.; 'Tumour/Tissue Blocks' collection refers to existing tissue and does not require a new in-person contact day.; Treatment (Letrozole/Placebo) is daily oral and does not count as in-person contact days."
27569442,MAP (Good Responders),intervention,1,7,16,35,39,39,0,6,15,33,37,37,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,2,2,35,29 weeks,"Screening (Day -28), C1D1 (Day 0), C1D2 (Day 1), C1MTX1 (Day 21), C1MTX2 (Day 22), C1MTX3 (Day 28), C1MTX4 (Day 29), QOL1 (Day 30), C2D1 (Day 35), C2D2 (Day 36), C2MTX1 (Day 56), C2MTX2 (Day 57), C2MTX3 (Day 63), C2MTX4 (Day 64), Surgery (Day 70), C3D1 (Day 77), C3D2 (Day 78), C3MTX1 (Day 98), C3MTX2 (Day 99), C3MTX3 (Day 105), C3MTX4 (Day 106), C4D1 (Day 112), C4D2 (Day 113), C4MTX1 (Day 133), C4MTX2 (Day 134), C4MTX3 (Day 140), C4MTX4 (Day 141), C5D1 (Day 147), C5D2 (Day 148), QOL2 (Day 150), C5MTX1 (Day 161), C5MTX2 (Day 162), C5MTX3 (Day 168), C5MTX4 (Day 169), C6D1 (Day 175), C6D2 (Day 176), C6MTX1 (Day 189), C6MTX2 (Day 190), C6MTX3 (Day 196), C6MTX4 (Day 197). Range-columns were mapped to individual nominal dates.","Screening is one in-person day for all required baseline assessments (imaging, labs, H&P, etc.). Imaging is prioritized for categorization.; Surgery (Week 11) is one in-person day, categorized as core_treatment.; Drug administration days (IV infusions) are in-person contact days.; Leucovorin rescue days, when not overlapping with other drug administration, are counted as separate in-person core_treatment days.; QOL assessments are considered in-person clinic visits.; For MAP Cycles 5-6 (Weeks 22-29), Cisplatin administration was assumed based on text description (Page 20, Section 4.4) despite its omission from the table (Page 21, Table 4.4.1).; Calendar days are calculated from Day 0 (C1D1). Week N Day X is Day (N-1)*7 + (X-1)."
27569442,MAPifn (Good Responders),intervention,1,7,16,35,48,51,0,6,15,33,46,49,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,2,2,35,104 weeks,"Screening (Day -28), C1D1 (Day 0), C1D2 (Day 1), C1MTX1 (Day 21), C1MTX2 (Day 22), C1MTX3 (Day 28), C1MTX4 (Day 29), QOL1 (Day 30), C2D1 (Day 35), C2D2 (Day 36), C2MTX1 (Day 56), C2MTX2 (Day 57), C2MTX3 (Day 63), C2MTX4 (Day 64), Surgery (Day 70), C3D1 (Day 77), C3D2 (Day 78), C3MTX1 (Day 98), C3MTX2 (Day 99), C3MTX3 (Day 105), C3MTX4 (Day 106), C4D1 (Day 112), C4D2 (Day 113), C4MTX1 (Day 133), C4MTX2 (Day 134), C4MTX3 (Day 140), C4MTX4 (Day 141), C5D1 (Day 147), C5D2 (Day 148), QOL2 (Day 150), C5MTX1 (Day 161), C5MTX2 (Day 162), C5MTX3 (Day 168), C5MTX4 (Day 169), C6D1 (Day 175), C6D2 (Day 176), C6MTX1 (Day 189), C6MTX2 (Day 190), C6MTX3 (Day 196), C6MTX4 (Day 197), Interferon weekly (Day 203, 210, 217, 224, 231, 238, 245, 252), Interferon monthly (Day 259, 287, 315, 343). Range-columns were mapped to individual nominal dates.","Screening is one in-person day for all required baseline assessments (imaging, labs, H&P, etc.). Imaging is prioritized for categorization.; Surgery (Week 11) is one in-person day, categorized as core_treatment.; Drug administration days (IV infusions) are in-person contact days.; Leucovorin rescue days, when not overlapping with other drug administration, are counted as separate in-person core_treatment days.; QOL assessments are considered in-person clinic visits.; For MAP Cycles 5-6 (Weeks 22-29), Cisplatin administration was assumed based on text description (Page 20, Section 4.4) despite its omission from the table (Page 21, Table 4.4.1).; For Pegylated Interferon alfa-2b, weekly/monthly observations (a-g) are considered in-person contact days, combined with the SubQ administration.; Calendar days are calculated from Day 0 (C1D1). Week N Day X is Day (N-1)*7 + (X-1)."
27569442,MAP (Poor Responders),control,1,7,16,35,39,39,0,6,15,33,37,37,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,2,2,35,29 weeks,"Screening (Day -28), C1D1 (Day 0), C1D2 (Day 1), C1MTX1 (Day 21), C1MTX2 (Day 22), C1MTX3 (Day 28), C1MTX4 (Day 29), QOL1 (Day 30), C2D1 (Day 35), C2D2 (Day 36), C2MTX1 (Day 56), C2MTX2 (Day 57), C2MTX3 (Day 63), C2MTX4 (Day 64), Surgery (Day 70), C3D1 (Day 77), C3D2 (Day 78), C3MTX1 (Day 98), C3MTX2 (Day 99), C3MTX3 (Day 105), C3MTX4 (Day 106), C4D1 (Day 112), C4D2 (Day 113), C4MTX1 (Day 133), C4MTX2 (Day 134), C4MTX3 (Day 140), C4MTX4 (Day 141), C5D1 (Day 147), C5D2 (Day 148), QOL2 (Day 150), C5MTX1 (Day 161), C5MTX2 (Day 162), C5MTX3 (Day 168), C5MTX4 (Day 169), C6D1 (Day 175), C6D2 (Day 176), C6MTX1 (Day 189), C6MTX2 (Day 190), C6MTX3 (Day 196), C6MTX4 (Day 197). Range-columns were mapped to individual nominal dates.","Screening is one in-person day for all required baseline assessments (imaging, labs, H&P, etc.). Imaging is prioritized for categorization.; Surgery (Week 11) is one in-person day, categorized as core_treatment.; Drug administration days (IV infusions) are in-person contact days.; Leucovorin rescue days, when not overlapping with other drug administration, are counted as separate in-person core_treatment days.; QOL assessments are considered in-person clinic visits.; For MAP Cycles 5-6 (Weeks 22-29), Cisplatin administration was assumed based on text description (Page 20, Section 4.4) despite its omission from the table (Page 21, Table 4.4.1).; Calendar days are calculated from Day 0 (C1D1). Week N Day X is Day (N-1)*7 + (X-1)."
27569442,MAPIE (Poor Responders),intervention,1,7,16,38,54,56,0,6,15,36,52,54,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,2,2,28,40 weeks,"Screening (Day -28), C1D1 (Day 0), C1D2 (Day 1), C1MTX1 (Day 21), C1MTX2 (Day 22), C1MTX3 (Day 28), C1MTX4 (Day 29), QOL1 (Day 30), C2D1 (Day 35), C2D2 (Day 36), C2MTX1 (Day 56), C2MTX2 (Day 57), C2MTX3 (Day 63), C2MTX4 (Day 64), Surgery (Day 70), C3D1 (Day 77), C3D2 (Day 78), C3MTX1 (Day 98), C3MTX2 (Day 99), C4D1-5 (Day 105-109), C4MTX1 (Day 126), C4MTX2 (Day 127), C5D1-3 (Day 133-135), QOL2 (Day 140), C5MTX1 (Day 154), C5MTX2 (Day 155), C6D1-5 (Day 161-165), C6MTX1 (Day 182), C6MTX2 (Day 183), C7D1 (Day 189), C7D2 (Day 190), C7MTX1 (Day 210), C7MTX2 (Day 211), C8D1-5 (Day 217-221), C8MTX1 (Day 238), C8MTX2 (Day 239), C9D1-3 (Day 245-247), C9MTX1 (Day 266), C9MTX2 (Day 267), C9MTX3 (Day 273), C9MTX4 (Day 274). Range-columns were mapped to individual nominal dates.","Screening is one in-person day for all required baseline assessments (imaging, labs, H&P, etc.). Imaging is prioritized for categorization.; Surgery (Week 11) is one in-person day, categorized as core_treatment.; Drug administration days (IV infusions) are in-person contact days.; Leucovorin rescue days, when not overlapping with other drug administration, are counted as separate in-person core_treatment days.; QOL assessments are considered in-person clinic visits.; For MAPIE Cycles 5 (Week 20-23) and 9 (Week 36-40), Etoposide administration was assumed based on text description (Page 33, Section 4.10; Page 35, Section 4.11) despite its omission from the tables (Page 34, Table 4.10.1; Page 36, Table 4.11.1).; Calendar days are calculated from Day 0 (C1D1). Week N Day X is Day (N-1)*7 + (X-1)."
30516102,Trastuzumab emtansine 3.6 mg/kg q3w for 14 cycles,intervention,1,3,10,19,28,32,0,2,5,9,13,14,1,0,2,4,5,7,0,1,3,6,10,11,0,0,0,0,0,0,21,14 cycles,"Screening (Day -28), C1D1 (Day 0), C1D14 (Day 14), C2D1 (Day 21), C2D14 (Day 35), C3D1 (Day 42), C3D14 (Day 56), C4D1 (Day 63), C4D14 (Day 77), C5D1 (Day 84), FU ECHO/MUGA (Day 90), C5D14 (Day 98), C6D1 (Day 105), C6D14 (Day 119), C7D1 (Day 126), C7D14 (Day 140), C8D1 (Day 147), C8D14 (Day 161), C9D1 (Day 168), FU ECHO/MUGA (Day 180), C9D14 (Day 182), C10D1 (Day 189), C10D14 (Day 203), C11D1 (Day 210), C11D14 (Day 224), C12D1 (Day 231), C12D14 (Day 245), C13D1 (Day 252), C13D14 (Day 266), C14D1 (Day 273), C14D14 (Day 287), Study Drug Completion Visit (Day 303), FU ECHO/MUGA (Day 365). Range-columns (e.g., Day 14-21) were mapped to one nominal date (e.g., Day 14).","Screening visit is counted as one in-person day (Day -28) where all screening assessments occur.; A column labeled as a day-range (e.g., 'Day 14–21') is a single mandatory in-person visit, calendarized to the earliest day in the range (e.g., Day 14).; Study Drug Completion Visit (SDCV) is estimated at Day 303 (Day 273 + 30 days). ECHO/MUGA is not performed at SDCV as the C14D14 ECHO/MUGA was within 6 weeks prior.; Follow-up ECHO/MUGA visits at 3, 6, and 12 months are counted relative to Day 0 (randomization) based on their placement in the 'Survival Follow-Up' column and footnote m, and are distinct in-person visits.; Optional PK/biomarker samples do not add new contact days but are considered part of existing visit days.; Category precedence applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
30516102,Trastuzumab 6 mg/kg q3w for 14 cycles,control,1,3,10,19,28,32,0,2,5,9,13,14,1,0,2,4,5,7,0,1,3,6,10,11,0,0,0,0,0,0,21,14 cycles,"Screening (Day -28), C1D1 (Day 0), C1D14 (Day 14), C2D1 (Day 21), C2D14 (Day 35), C3D1 (Day 42), C3D14 (Day 56), C4D1 (Day 63), C4D14 (Day 77), C5D1 (Day 84), FU ECHO/MUGA (Day 90), C5D14 (Day 98), C6D1 (Day 105), C6D14 (Day 119), C7D1 (Day 126), C7D14 (Day 140), C8D1 (Day 147), C8D14 (Day 161), C9D1 (Day 168), FU ECHO/MUGA (Day 180), C9D14 (Day 182), C10D1 (Day 189), C10D14 (Day 203), C11D1 (Day 210), C11D14 (Day 224), C12D1 (Day 231), C12D14 (Day 245), C13D1 (Day 252), C13D14 (Day 266), C14D1 (Day 273), C14D14 (Day 287), Study Drug Completion Visit (Day 303), FU ECHO/MUGA (Day 365). Range-columns (e.g., Day 14-21) were mapped to one nominal date (e.g., Day 14).","Screening visit is counted as one in-person day (Day -28) where all screening assessments occur.; A column labeled as a day-range (e.g., 'Day 14–21') is a single mandatory in-person visit, calendarized to the earliest day in the range (e.g., Day 14).; Study Drug Completion Visit (SDCV) is estimated at Day 303 (Day 273 + 30 days). ECHO/MUGA is not performed at SDCV as the C14D14 ECHO/MUGA was within 6 weeks prior.; Follow-up ECHO/MUGA visits at 3, 6, and 12 months are counted relative to Day 0 (randomization) based on their placement in the 'Survival Follow-Up' column and footnote m, and are distinct in-person visits.; Optional PK/biomarker samples do not add new contact days but are considered part of existing visit days.; Category precedence applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
31327689,Investigational arm (Arm A): Pembrolizumab + Lenalidomide + Dexamethasone,intervention,2,3,7,13,19,26,0,2,4,7,10,14,1,1,1,1,1,1,1,0,2,5,8,11,0,0,0,0,0,0,28,until progression,"Screening (Day -14, Day -1), C1D1, C1D22, C2D1, C2D15, C3D1, C3D8, C4D1, C4D22, C5D1, C5D15, C6D1, C6D8, C7D1, C7D22, C8D1, C8D15, C9D1, C9D8, C10D1, C10D22, C11D1, C11D15, C12D1, C12D8, C13D1, C13D22. Range-columns (e.g., 'Day 14–21') were not present as distinct in-person visits beyond the specified Dexamethasone days, which are self-administered.","Screening is counted as 2 in-person days due to the mandatory requirement for two pregnancy tests at different time points (10-14 days prior to C1D1 and within 24 hours prior to C1D1) and the extensive list of other in-person screening procedures (bone marrow biopsy, imaging, comprehensive labs, physical exam).; The 'Bone Marrow Aspirate for Bone Marrow Exploratory Sub-Study' is considered an in-person imaging/diagnostic procedure and drives the category for days it occurs.; Treatment is assumed to continue for the full 365-day horizon, as per 'until progression' rule, therefore, 'Discontinuation' and '30 days post Discon' visits are not included in the 365-day count.; Pembrolizumab administration days are determined by C1D1 and then every 21 days (Q3W), as stated in the text, overriding the specific cycle day numbers listed in the table if they contradict the 'every 21 days' rule (e.g., C2D22 is Day 21, C3D15 is Day 43, C4D8 is Day 64, etc., relative to C1D1=Day 0). The table on Page 41 lists the cycle day, not the absolute day from C1D1, for Pembrolizumab. The absolute days are calculated based on the 28-day cycle length and Q3W administration.; For category assignment, the precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was strictly applied. If a day involved a core treatment, it was categorized as 'core_treatment', even if other procedures (e.g., labs, clinic visits) also occurred."
31327689,Control arm (Arm B): Lenalidomide + Dexamethasone,control,2,1,4,7,10,13,0,0,0,0,0,0,1,1,2,2,2,2,1,0,2,5,8,11,0,0,0,0,0,0,28,until progression,"Screening (Day -14, Day -1), C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1. Range-columns (e.g., 'Day 14–21') were not present as distinct in-person visits beyond the specified Dexamethasone days, which are self-administered.","Screening is counted as 2 in-person days due to the mandatory requirement for two pregnancy tests at different time points (10-14 days prior to C1D1 and within 24 hours prior to C1D1) and the extensive list of other in-person screening procedures (bone marrow biopsy, imaging, comprehensive labs, physical exam).; The 'Bone Marrow Aspirate for Bone Marrow Exploratory Sub-Study' is considered an in-person imaging/diagnostic procedure and drives the category for days it occurs.; Treatment is assumed to continue for the full 365-day horizon, as per 'until progression' rule, therefore, 'Discontinuation' and '30 days post Discon' visits are not included in the 365-day count.; For Arm B, the protocol explicitly states 'Subjects in Arm B only need 1 visit per month on Day 1 of each cycle' (Page 39, Note d).; For category assignment, the precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was strictly applied. If a day involved an imaging/diagnostic procedure, it was categorized as 'imaging_diagnostics', even if other procedures (e.g., labs, clinic visits) also occurred."
34087126,Daratumumab plus pomalidomide and dexamethasone (DaraPomDex),intervention,2,5,13,27,40,52,0,5,11,17,20,23,1,0,0,0,0,0,1,0,0,0,0,0,0,0,2,10,20,29,28,until progression,"Screening (2 days). Cycles 1-2: Day 1, Day 8, Day 15, Day 22. Cycles 3-6: Day 1, Day 8, Day 15, Day 22. Cycles 7+: Day 1, Day 8, Day 15, Day 22. All range-columns were mapped to one nominal date.","Screening period involves 2 distinct in-person visits: one for general clinic assessments, labs, and diagnostics (FEV1, ECG, imaging), and a separate day for the invasive bone marrow procedure.; Assessments marked 'As clinically indicated' are not counted as regularly scheduled in-person visits.; Pomalidomide and Dexamethasone are oral, self-administered, and do not drive an in-person visit unless other protocol-mandated in-person procedures occur on the same day.; For the DaraPomDex arm, Daratumumab administration (IV or SC) is the primary driver for in-person visits on its scheduled days, taking precedence over other assessments.; For both arms, Vital Signs and Weight assessments on Days 8, 15, 22 (where applicable per cycle) are considered in-person contact days.; CT/MRI for STP is performed on C1D1, C4D1, C7D1, C10D1, C13D1 if present at baseline. For DaraPomDex, these days are already Core Treatment days. For PomDex, these are Imaging days.; Whole Blood for Biomarker Assessments is performed on C3D1, C6D1, C12D1. For DaraPomDex, these days are already Core Treatment days. For PomDex, these are Lab days."
34087126,Pomalidomide and dexamethasone (PomDex),control,2,5,13,28,40,52,0,0,0,0,0,0,1,1,2,5,6,7,1,1,2,3,4,6,0,3,9,20,30,39,28,until progression,"Screening (2 days). Cycles 1-2: Day 1, Day 8, Day 15, Day 22. Cycles 3-6: Day 1, Day 8, Day 15, Day 22. Cycles 7+: Day 1, Day 8, Day 15, Day 22. All range-columns were mapped to one nominal date.","Screening period involves 2 distinct in-person visits: one for general clinic assessments, labs, and diagnostics (FEV1, ECG, imaging), and a separate day for the invasive bone marrow procedure.; Assessments marked 'As clinically indicated' are not counted as regularly scheduled in-person visits.; Pomalidomide and Dexamethasone are oral, self-administered, and do not drive an in-person visit unless other protocol-mandated in-person procedures occur on the same day.; For the DaraPomDex arm, Daratumumab administration (IV or SC) is the primary driver for in-person visits on its scheduled days, taking precedence over other assessments.; For both arms, Vital Signs and Weight assessments on Days 8, 15, 22 (where applicable per cycle) are considered in-person contact days.; CT/MRI for STP is performed on C1D1, C4D1, C7D1, C10D1, C13D1 if present at baseline. For DaraPomDex, these days are already Core Treatment days. For PomDex, these are Imaging days.; Whole Blood for Biomarker Assessments is performed on C3D1, C6D1, C12D1. For DaraPomDex, these days are already Core Treatment days. For PomDex, these are Lab days."
34110925,Reduced-dose craniospinal radiation (18.00 Gy) + Smaller volume boost (tumor bed) (Ages 3-7),intervention,4,23,35,45,56,66,0,23,34,40,48,55,2,0,1,2,3,4,1,0,0,3,5,7,1,0,0,0,0,0,Alternating 42 days (Regimen A) and 28 days (Regimen B) for maintenance chemotherapy.,"9 cycles of maintenance chemotherapy following 6 weeks of radiation and 4 weeks of rest, or until progression, whichever is earlier.","Screening: Day -28 (H&P/Clinic), Day -20 (MRI), Day -15 (CSF/Labs), Day -10 (Audiogram). Chemoradiotherapy (Day 0-43): Day 0, 1, 2, 3, 4, 7, 8, 9, 10, 11, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25, 28, 29, 30, 31, 32, 35, 36, 37, 38, 39 (radiation days), Day 43 (VCR). Maintenance Cycle A (6 weeks): CkD1, CkD8, CkD15, CkD42. Maintenance Cycle B (4 weeks): CkD1, CkD2, CkD8, CkD22. Follow-up: Day 90, Day 180, Day 270, Day 365.","Day 0 is the start of radiation therapy, which begins within 31 days of definitive surgery.; Screening visits are assumed to occur on distinct days within the Day -28 to Day -1 window.; Radiation therapy is administered 5 days/week (Monday-Friday) for 6 weeks.; Vincristine during chemoradiotherapy is administered weekly on the same day as a radiation fraction, starting one week after the first radiation dose.; Maintenance chemotherapy cycles begin immediately after the 4-week rest period following chemoradiotherapy.; All listed assessments in the Schedule of Events tables (pages 16, 19, 21) and follow-up tables (page 26) require an in-person visit.; For days with multiple procedures, the category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to assign a single primary category.; The follow-up visits listed as '3 Months', '6 Months', '9 Months', '1 Year' are mapped to Day 90, Day 180, Day 270, and Day 365 respectively, relative to Day 0.; The 'children 8 years of age and older Arm was completed' means only the 3-7 year old age group is considered for active accrual and schedule extraction."
34110925,Reduced-dose craniospinal radiation (18.00 Gy) + Standard volume boost (entire posterior fossa) (Ages 3-7),intervention,4,23,35,45,56,66,0,23,34,40,48,55,2,0,1,2,3,4,1,0,0,3,5,7,1,0,0,0,0,0,Alternating 42 days (Regimen A) and 28 days (Regimen B) for maintenance chemotherapy.,"9 cycles of maintenance chemotherapy following 6 weeks of radiation and 4 weeks of rest, or until progression, whichever is earlier.","Screening: Day -28 (H&P/Clinic), Day -20 (MRI), Day -15 (CSF/Labs), Day -10 (Audiogram). Chemoradiotherapy (Day 0-43): Day 0, 1, 2, 3, 4, 7, 8, 9, 10, 11, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25, 28, 29, 30, 31, 32, 35, 36, 37, 38, 39 (radiation days), Day 43 (VCR). Maintenance Cycle A (6 weeks): CkD1, CkD8, CkD15, CkD42. Maintenance Cycle B (4 weeks): CkD1, CkD2, CkD8, CkD22. Follow-up: Day 90, Day 180, Day 270, Day 365.","Day 0 is the start of radiation therapy, which begins within 31 days of definitive surgery.; Screening visits are assumed to occur on distinct days within the Day -28 to Day -1 window.; Radiation therapy is administered 5 days/week (Monday-Friday) for 6 weeks.; Vincristine during chemoradiotherapy is administered weekly on the same day as a radiation fraction, starting one week after the first radiation dose.; Maintenance chemotherapy cycles begin immediately after the 4-week rest period following chemoradiotherapy.; All listed assessments in the Schedule of Events tables (pages 16, 19, 21) and follow-up tables (page 26) require an in-person visit.; For days with multiple procedures, the category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to assign a single primary category.; The follow-up visits listed as '3 Months', '6 Months', '9 Months', '1 Year' are mapped to Day 90, Day 180, Day 270, and Day 365 respectively, relative to Day 0.; The 'children 8 years of age and older Arm was completed' means only the 3-7 year old age group is considered for active accrual and schedule extraction."
34110925,Standard-dose craniospinal radiation (23.40 Gy) + Smaller volume boost (tumor bed) (Ages 3-7),intervention,4,23,35,45,56,66,0,23,34,40,48,55,2,0,1,2,3,4,1,0,0,3,5,7,1,0,0,0,0,0,Alternating 42 days (Regimen A) and 28 days (Regimen B) for maintenance chemotherapy.,"9 cycles of maintenance chemotherapy following 6 weeks of radiation and 4 weeks of rest, or until progression, whichever is earlier.","Screening: Day -28 (H&P/Clinic), Day -20 (MRI), Day -15 (CSF/Labs), Day -10 (Audiogram). Chemoradiotherapy (Day 0-43): Day 0, 1, 2, 3, 4, 7, 8, 9, 10, 11, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25, 28, 29, 30, 31, 32, 35, 36, 37, 38, 39 (radiation days), Day 43 (VCR). Maintenance Cycle A (6 weeks): CkD1, CkD8, CkD15, CkD42. Maintenance Cycle B (4 weeks): CkD1, CkD2, CkD8, CkD22. Follow-up: Day 90, Day 180, Day 270, Day 365.","Day 0 is the start of radiation therapy, which begins within 31 days of definitive surgery.; Screening visits are assumed to occur on distinct days within the Day -28 to Day -1 window.; Radiation therapy is administered 5 days/week (Monday-Friday) for 6 weeks.; Vincristine during chemoradiotherapy is administered weekly on the same day as a radiation fraction, starting one week after the first radiation dose.; Maintenance chemotherapy cycles begin immediately after the 4-week rest period following chemoradiotherapy.; All listed assessments in the Schedule of Events tables (pages 16, 19, 21) and follow-up tables (page 26) require an in-person visit.; For days with multiple procedures, the category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to assign a single primary category.; The follow-up visits listed as '3 Months', '6 Months', '9 Months', '1 Year' are mapped to Day 90, Day 180, Day 270, and Day 365 respectively, relative to Day 0.; The 'children 8 years of age and older Arm was completed' means only the 3-7 year old age group is considered for active accrual and schedule extraction."
34110925,Standard-dose craniospinal radiation (23.40 Gy) + Standard volume boost (entire posterior fossa) (Ages 3-7),intervention,4,23,35,45,56,66,0,23,34,40,48,55,2,0,1,2,3,4,1,0,0,3,5,7,1,0,0,0,0,0,Alternating 42 days (Regimen A) and 28 days (Regimen B) for maintenance chemotherapy.,"9 cycles of maintenance chemotherapy following 6 weeks of radiation and 4 weeks of rest, or until progression, whichever is earlier.","Screening: Day -28 (H&P/Clinic), Day -20 (MRI), Day -15 (CSF/Labs), Day -10 (Audiogram). Chemoradiotherapy (Day 0-43): Day 0, 1, 2, 3, 4, 7, 8, 9, 10, 11, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25, 28, 29, 30, 31, 32, 35, 36, 37, 38, 39 (radiation days), Day 43 (VCR). Maintenance Cycle A (6 weeks): CkD1, CkD8, CkD15, CkD42. Maintenance Cycle B (4 weeks): CkD1, CkD2, CkD8, CkD22. Follow-up: Day 90, Day 180, Day 270, Day 365.","Day 0 is the start of radiation therapy, which begins within 31 days of definitive surgery.; Screening visits are assumed to occur on distinct days within the Day -28 to Day -1 window.; Radiation therapy is administered 5 days/week (Monday-Friday) for 6 weeks.; Vincristine during chemoradiotherapy is administered weekly on the same day as a radiation fraction, starting one week after the first radiation dose.; Maintenance chemotherapy cycles begin immediately after the 4-week rest period following chemoradiotherapy.; All listed assessments in the Schedule of Events tables (pages 16, 19, 21) and follow-up tables (page 26) require an in-person visit.; For days with multiple procedures, the category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to assign a single primary category.; The follow-up visits listed as '3 Months', '6 Months', '9 Months', '1 Year' are mapped to Day 90, Day 180, Day 270, and Day 365 respectively, relative to Day 0.; The 'children 8 years of age and older Arm was completed' means only the 3-7 year old age group is considered for active accrual and schedule extraction."
34874182,Arm A: palbociclib (2 yrs) + Endocrine Treatment (5+ yrs),intervention,1,2,6,9,12,16,0,1,4,7,10,14,0,0,0,0,0,0,1,1,2,2,2,2,0,0,0,0,0,0,28,"palbociclib for 2 years, endocrine therapy until progression","Screening, C1D1, C1D14, C2D1, C2D14, CkD1 (for C3-C26). Range-columns were mapped to one nominal date.","The 'Screening Phase' column in Table 2 represents a single in-person visit for all listed assessments.; The 'Time Window for Assessments (days)' for Arm A and Arm B for Day 0 (-7 to +2) and Day 14 (+/-2) are interpreted as nominal visit days at Day 0 and Day 14 respectively for calculation purposes.; For Arm A, Cycle 1 Day 14 (C1D14) and Cycle 2 Day 14 (C2D14) are counted as in-person contact days due to mandatory safety laboratory testing at the research center, as per footnote 'v' in Table 2.; For Arm B, Day 14 visits are not counted as in-person contact days because laboratory testing is 'at the discretion of the provider' (footnote 'v'), implying it is not a mandatory in-person visit for all participants.; For cycles beyond C2, no Day 14 visits are explicitly listed with in-person assessments in Table 2 for either arm, therefore only Day 1 visits are counted as in-person.; The 'IP Dispensing; IP and Non-IP Drug Compliance' assessment is considered a 'core_treatment' activity for both arms, as it relates to the administration and adherence monitoring of the primary study intervention (palbociclib for Arm A, endocrine therapy for Arm B).; PRO and Adherence questionnaires are completed during planned clinic visits and do not add separate contact days.; The category precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied for days with multiple activities."
34874182,Arm B: Endocrine treatment (5+ yrs),control,1,1,4,7,10,14,0,1,4,7,10,14,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,endocrine therapy until progression,"Screening, C1D1, CkD1 (for C2-C26). Range-columns were mapped to one nominal date.","The 'Screening Phase' column in Table 2 represents a single in-person visit for all listed assessments.; The 'Time Window for Assessments (days)' for Arm A and Arm B for Day 0 (-7 to +2) and Day 14 (+/-2) are interpreted as nominal visit days at Day 0 and Day 14 respectively for calculation purposes.; For Arm A, Cycle 1 Day 14 (C1D14) and Cycle 2 Day 14 (C2D14) are counted as in-person contact days due to mandatory safety laboratory testing at the research center, as per footnote 'v' in Table 2.; For Arm B, Day 14 visits are not counted as in-person contact days because laboratory testing is 'at the discretion of the provider' (footnote 'v'), implying it is not a mandatory in-person visit for all participants.; For cycles beyond C2, no Day 14 visits are explicitly listed with in-person assessments in Table 2 for either arm, therefore only Day 1 visits are counted as in-person.; The 'IP Dispensing; IP and Non-IP Drug Compliance' assessment is considered a 'core_treatment' activity for both arms, as it relates to the administration and adherence monitoring of the primary study intervention (palbociclib for Arm A, endocrine therapy for Arm B).; PRO and Adherence questionnaires are completed during planned clinic visits and do not add separate contact days.; The category precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied for days with multiple activities."
35665782,T-DXd,intervention,2,5,13,26,39,53,0,2,5,9,13,18,2,3,8,17,26,35,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening Day 1 (biopsy), Screening Day 2 (main screening), then C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, ... C18D1, C18D8. Range-columns ('Day 8 (±1 d)', 'Day 15 (±1 d)') were mapped to nominal dates Day 7 and Day 14 respectively.","The 'Schedule of Events – Treatment and Follow-up Period' (Table 17.2) defines the minimum required in-person visits for both treatment arms. Any drug administration on days not listed as a visit in Table 17.2, but requiring in-person attendance, would be an additional contact day. However, for Physician's Choice, the drug administration days (Day 1, 8, 15) align with the SoE visit days, so no additional contact days are added for drug administration.; For Physician's Choice, a 21-day cycle is assumed based on the statement 'cycles for physician's choice should be 21 days in duration if there are multiple options in the label approved in the country of drug administration or the NCCN guidelines' (Page 37), overriding conflicting mentions of 28-day cycles for some comparators.; Screening involves two distinct in-person contact days: one for a fresh tumor tissue biopsy (if archival tissue is unavailable/insufficient, which is a mandatory procedure if needed per Section 6.2 and 4.1.5/6) and one for the main screening procedures, given the separate 'Tissue Screening' and 'Screening' columns in Table 17.1.; Tumor assessments (CT/MRI) scheduled 'every 6 weeks +7 days from randomization date' (Page 11, 20) are assumed to coincide with Day 1 of Cycles 3, 5, 7, etc. (Day 42, 84, 126, etc.), and thus do not add additional contact days beyond the scheduled Day 1 visits.; Optional visits or procedures (e.g., optional fresh tumor tissue biopsy at C3D1, optional pharmacogenomics blood sample at C1D1) are excluded from contact day counts.; For Day 8 (±1 d) and Day 15 (±1 d) visits, the nominal dates used for calendarization are Day 7 and Day 14, respectively, as per the rule to use the earliest day in the range.; Treatment is assumed to continue until Day 365 for calculation purposes, as per 'until progression' rule."
35665782,Physician's Choice,control,2,5,13,26,39,53,0,0,0,0,0,0,2,5,13,26,39,53,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening Day 1 (biopsy), Screening Day 2 (main screening), then C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, ... C18D1, C18D8. Range-columns ('Day 8 (±1 d)', 'Day 15 (±1 d)') were mapped to nominal dates Day 7 and Day 14 respectively.","The 'Schedule of Events – Treatment and Follow-up Period' (Table 17.2) defines the minimum required in-person visits for both treatment arms. Any drug administration on days not listed as a visit in Table 17.2, but requiring in-person attendance, would be an additional contact day. However, for Physician's Choice, the drug administration days (Day 1, 8, 15) align with the SoE visit days, so no additional contact days are added for drug administration.; For Physician's Choice, a 21-day cycle is assumed based on the statement 'cycles for physician's choice should be 21 days in duration if there are multiple options in the label approved in the country of drug administration or the NCCN guidelines' (Page 37), overriding conflicting mentions of 28-day cycles for some comparators.; Screening involves two distinct in-person contact days: one for a fresh tumor tissue biopsy (if archival tissue is unavailable/insufficient, which is a mandatory procedure if needed per Section 6.2 and 4.1.5/6) and one for the main screening procedures, given the separate 'Tissue Screening' and 'Screening' columns in Table 17.1.; Tumor assessments (CT/MRI) scheduled 'every 6 weeks +7 days from randomization date' (Page 11, 20) are assumed to coincide with Day 1 of Cycles 3, 5, 7, etc. (Day 42, 84, 126, etc.), and thus do not add additional contact days beyond the scheduled Day 1 visits.; Optional visits or procedures (e.g., optional fresh tumor tissue biopsy at C3D1, optional pharmacogenomics blood sample at C1D1) are excluded from contact day counts.; For Day 8 (±1 d) and Day 15 (±1 d) visits, the nominal dates used for calendarization are Day 7 and Day 14, respectively, as per the rule to use the earliest day in the range.; Treatment is assumed to continue until Day 365 for calculation purposes, as per 'until progression' rule."
35704479,Active Monitoring Arm,control,1,1,1,2,2,3,0,0,0,0,0,0,1,1,1,2,2,3,0,0,0,0,0,0,0,0,0,0,0,0,180,until progression or up to 5 years,"Visit 0 (Screening), Visit 1 (Randomization), Visit 2 (Day 180), Visit 3 (Day 365), and subsequent 6-month visits up to 5 years.","Visit 0 (Screening) is considered one in-person contact day, occurring within the screening window (Day -28 to Day -1).; Visit 1 (Randomization) is considered one in-person contact day (Day 0).; Subsequent visits (Visit 2, Visit 3, etc.) occur every 6 months (nominal dates: Day 180, Day 365, etc.).; All procedures marked with 'X' in the Appendix I table for the Active Monitoring Arm (Page 62) for a given visit are counted as occurring on that single contact day.; Category assignment for each contact day is based on the highest precedence procedure performed that day. For all visits in this arm, High Resolution Anoscopy (HRA) and Anal Biopsy are the highest precedence procedures, classifying these days as 'imaging_diagnostics'."
35704479,Treatment Arm,intervention,1,2,4,5,5,6,0,2,4,4,4,4,1,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,180,until progression or up to 5 years,"Visit 0 (Screening), Visit 1 (Randomization), Visit 1A (Day 21), Visit 1B (Day 42), Visit 1C (Day 63), Visit 2 (Day 180), Visit 3 (Day 365), and subsequent 6-month visits up to 5 years.","Visit 0 (Screening) is considered one in-person contact day, occurring within the screening window (Day -28 to Day -1).; Visit 1 (Randomization) is considered one in-person contact day (Day 0).; For the 'Treatment Arm', the TCA treatment schedule (Page 64) was used as the representative schedule due to its higher frequency of interim treatment visits within the first 6 months compared to Imiquimod/5-FU or IRC/Hyfrecation/Laser, providing a conservative (higher) estimate of contact days. Treatment Under Anesthesia (TUA) is considered a last resort for a small percentage of participants.; TCA application visits (Visit 1, 1A, 1B, 1C) are considered 'Core Treatment' days.; Visit 1A, 1B, 1C for TCA are interpreted as distinct visits at Day 21, Day 42, and Day 63 respectively, following Day 0, based on 'every 3 weeks up to 4 times within 12 weeks' (Page 31, 4.2.1.2.a).; Subsequent visits (Visit 2, Visit 3, etc.) occur every 6 months (nominal dates: Day 180, Day 365, etc.).; All procedures marked with 'X' in the Appendix I table for the Treatment Arm with TCA (Page 64) for a given visit are counted as occurring on that single contact day.; Category assignment for each contact day is based on the highest precedence procedure performed that day (Core Treatment for treatment application days, Imaging/Diagnostics for follow-up HRA/biopsy days, and Imaging/Diagnostics for Visit 0)."
35728048,Single-agent Azacitidine,control,1,9,25,51,73,96,0,7,18,35,50,66,1,0,1,3,4,4,0,2,6,13,19,26,0,0,0,0,0,0,28,until progression,"Screening (Day -28 to -1, 1 day); Cycle 1: Day 1, 3, 5, 8, 9 (core_treatment), Day 14, 20 (labs); Subsequent Cycles (C2+): Day 1, 3, 5, 8, 9 (core_treatment), Day 14, 20 (labs); Additional Bone Marrow Aspirate/Biopsy on Day 22 for Cycles 2, 4, 6, 9 (imaging_diagnostics).","The 'Screening' column in the Schedule of Events (SoE) represents one in-person contact day, categorized as 'imaging_diagnostics' due to the presence of 12-lead ECG and Chest X-ray, applying category precedence.; Treatment duration is assumed to continue until Day +365 for calculation purposes, as per 'until progression' rule. The End-of-Treatment (EOT) visit and subsequent follow-up visits are therefore assumed to fall outside the Day +365 window.; Visit columns labeled with ranges (e.g., 'Day 15 ±1 day', 'Day 21 ±1 day', 'Day 22 +6 days') are interpreted as single mandatory in-person visits occurring on the earliest day of the range for calendarization (Day 14, Day 20, Day 22 respectively).; All procedures marked 'X' in the SoE table require an in-person visit unless explicitly stated as optional or tele-visit (none found for mandatory procedures).; Category precedence applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
35728048,Pevonedistat plus Azacitidine,intervention,1,9,25,51,73,96,0,7,18,35,50,66,1,0,1,3,4,4,0,2,6,13,19,26,0,0,0,0,0,0,28,until progression,"Screening (Day -28 to -1, 1 day); Cycle 1: Day 1, 3, 5, 8, 9 (core_treatment), Day 14, 20 (labs); Subsequent Cycles (C2+): Day 1, 3, 5, 8, 9 (core_treatment), Day 14, 20 (labs); Additional Bone Marrow Aspirate/Biopsy on Day 22 for Cycles 2, 4, 6, 9 (imaging_diagnostics).","The 'Screening' column in the Schedule of Events (SoE) represents one in-person contact day, categorized as 'imaging_diagnostics' due to the presence of 12-lead ECG and Chest X-ray, applying category precedence.; Treatment duration is assumed to continue until Day +365 for calculation purposes, as per 'until progression' rule. The End-of-Treatment (EOT) visit and subsequent follow-up visits are therefore assumed to fall outside the Day +365 window.; Visit columns labeled with ranges (e.g., 'Day 15 ±1 day', 'Day 21 ±1 day', 'Day 22 +6 days') are interpreted as single mandatory in-person visits occurring on the earliest day of the range for calendarization (Day 14, Day 20, Day 22 respectively).; All procedures marked 'X' in the SoE table require an in-person visit unless explicitly stated as optional or tele-visit (none found for mandatory procedures).; Category precedence applied: core_treatment > imaging_diagnostics > labs > clinic_visits.; The presence of pevonedistat administration on Days 1, 3, and 5 in the combination arm does not change the primary category of these days from 'core_treatment', as azacitidine is also administered on these days (and others), and drug administration takes precedence."
35759733,Regimen I: CT-2103 (135mg/m²) q 28-days x 12,intervention,1,3,7,14,20,24,0,2,4,7,10,12,1,0,0,0,0,0,0,1,3,7,10,12,0,0,0,0,0,0,28,12 months (12 cycles of 28 days),"Screening (Day -7), C1D1, C1D10, C2D1, C2D10, C3D1, C3D10, C4D1, C4D10, C5D1, C5D10, C6D1, C6D10, C7D1, C7D10, C8D1, C8D10, C9D1, C9D10, C10D1, C10D10, C11D1, C11D10, C12D1, C12D10.","The numbers and 'X' in the '7.1 Observations and Tests' table (Page 18) indicate required in-person assessments, not the number of visits or forms. Footnotes clarify specific timings.; All 'Prior to Study' assessments (History, Physical Exam, Labs, Chest X-Ray, EKG, CT scan, QOL) are assumed to occur on a single in-person screening day (e.g., Day -7). This day is categorized as 'imaging_diagnostics' due to the presence of CT scan, EKG, and Chest X-Ray.; For Regimen I and II, the 'Nadir (8-12 days)' visit for CBC & Differential and Platelets is interpreted as a mandatory in-person lab visit mid-cycle, assigned to Day 10 of each cycle for calendarization.; The 'Prior to Each Course or Monthly During 1st Year' column for Regimen I and II implies Day 0 of each cycle. This visit includes drug infusion, Hx, Px, Labs, and QOL, and CT scans on specific cycles. Due to drug infusion, these days are categorized as 'core_treatment'.; CT scans are scheduled on Day 0 of Cycles 1, 3, 5, 7, 9, 11 (6 scans in the first year) based on the '6' in the 'CT scan of abdomen/pelvis' row under 'Prior to Each Course or Monthly During 1st Year' column.; QOL assessments are scheduled at Baseline (Day 0 of C1), Day 0 of C3, C5, C7, and C12 (End of Treatment) based on Footnote 7. These are included in the Day 0 visit for the respective cycles.; The 'Chest X-Ray: 1' in the 'Prior to Each Course or Monthly During 1st Year' column is interpreted as one Chest X-Ray on Day 0 of Cycle 1."
35759733,Regimen II: Paclitaxel (135mg/m²) q 28-days x 12,intervention,1,3,7,14,20,24,0,2,4,7,10,12,1,0,0,0,0,0,0,1,3,7,10,12,0,0,0,0,0,0,28,12 months (12 cycles of 28 days),"Screening (Day -7), C1D1, C1D10, C2D1, C2D10, C3D1, C3D10, C4D1, C4D10, C5D1, C5D10, C6D1, C6D10, C7D1, C7D10, C8D1, C8D10, C9D1, C9D10, C10D1, C10D10, C11D1, C11D10, C12D1, C12D10.","The numbers and 'X' in the '7.1 Observations and Tests' table (Page 18) indicate required in-person assessments, not the number of visits or forms. Footnotes clarify specific timings.; All 'Prior to Study' assessments (History, Physical Exam, Labs, Chest X-Ray, EKG, CT scan, QOL) are assumed to occur on a single in-person screening day (e.g., Day -7). This day is categorized as 'imaging_diagnostics' due to the presence of CT scan, EKG, and Chest X-Ray.; For Regimen I and II, the 'Nadir (8-12 days)' visit for CBC & Differential and Platelets is interpreted as a mandatory in-person lab visit mid-cycle, assigned to Day 10 of each cycle for calendarization.; The 'Prior to Each Course or Monthly During 1st Year' column for Regimen I and II implies Day 0 of each cycle. This visit includes drug infusion, Hx, Px, Labs, and QOL, and CT scans on specific cycles. Due to drug infusion, these days are categorized as 'core_treatment'.; CT scans are scheduled on Day 0 of Cycles 1, 3, 5, 7, 9, 11 (6 scans in the first year) based on the '6' in the 'CT scan of abdomen/pelvis' row under 'Prior to Each Course or Monthly During 1st Year' column.; QOL assessments are scheduled at Baseline (Day 0 of C1), Day 0 of C3, C5, C7, and C12 (End of Treatment) based on Footnote 7. These are included in the Day 0 visit for the respective cycles.; The 'Chest X-Ray: 1' in the 'Prior to Each Course or Monthly During 1st Year' column is interpreted as one Chest X-Ray on Day 0 of Cycle 1."
35759733,Regimen III: No anti-cancer treatment until evidence of disease progression,control,1,2,4,7,10,12,0,0,0,0,0,0,1,1,2,4,5,6,0,1,2,3,5,6,0,0,0,0,0,0,30,until progression (monthly surveillance for at least 12 months),"Screening (Day -7), Month 1 (Day 0), Month 2 (Day 30), Month 3 (Day 60), Month 4 (Day 90), Month 5 (Day 120), Month 6 (Day 150), Month 7 (Day 180), Month 8 (Day 210), Month 9 (Day 240), Month 10 (Day 270), Month 11 (Day 300), Month 12 (Day 330).","The numbers and 'X' in the '7.1 Observations and Tests' table (Page 18) indicate required in-person assessments, not the number of visits or forms. Footnotes clarify specific timings.; All 'Prior to Study' assessments (History, Physical Exam, Labs, Chest X-Ray, EKG, CT scan, QOL) are assumed to occur on a single in-person screening day (e.g., Day -7). This day is categorized as 'imaging_diagnostics' due to the presence of CT scan, EKG, and Chest X-Ray.; For Regimen III (surveillance), 'monthly' visits are interpreted as occurring on Day 0, Day 30, Day 60, etc., for the first year, based on the text 'monthly during the first year for those randomized to the surveillance arm' (Footnote 6, Page 18) and 'Submit monthly D2R and T forms to include required CA-125 value and pertinent history/physical information' (Page 14).; Each monthly visit for Regimen III includes History, Physical Exam, and CA-125 (labs and clinic_visits).; CT scans are scheduled on Day 0, Day 60, Day 120, Day 180, Day 240, Day 300 (6 scans in the first year) based on the '6' in the 'CT scan of abdomen/pelvis' row under 'Prior to Each Course or Monthly During 1st Year' column. These days are categorized as 'imaging_diagnostics'.; QOL assessments are scheduled at Baseline (Day 0), Month 2 (Day 30), Month 4 (Day 90), Month 6 (Day 150), and Month 12 (Day 330) based on Footnote 7. These are included in the respective monthly visits.; The 'Chest X-Ray: 1' in the 'Prior to Each Course or Monthly During 1st Year' column is interpreted as one Chest X-Ray on Day 0 of Month 1."
35763704,Atezolizumab + ddAC-PacHP,intervention,2,4,12,22,26,30,0,3,10,19,23,27,1,1,2,2,2,2,1,0,0,1,1,1,0,0,0,0,0,0,"{'Cycles 1-4': 14, 'Cycles 5-22': 21}","Atezolizumab/placebo, trastuzumab, and pertuzumab continue for a total duration of 52 weeks of HER2-targeted therapy from C5D1 (Day 56), so until Day 421. Paclitaxel is weekly for 12 continuous weeks (Cycles 5-8). Doxorubicin and Cyclophosphamide are Q2W for 4 cycles (Cycles 1-4).","Screening (2 days), C1D1, C2D1, C3D1, C4D1, C5D1, C5D8, C5D15, C6D1, C6D8, C6D15, C7D1, C7D8, C7D15, C8D1, C8D8, C8D15, Pre-Surgery Visit, Surgery, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1. Additional ECHO/MUGA days on Day 21 and Day 49. Range-columns were mapped to one nominal date where applicable (e.g., weekly paclitaxel days).","PK/ADA and biomarker samples at screening are collected on existing blood draw days and do not add distinct contact days.; Screening involves a minimum of 2 distinct in-person days: one for clinic/labs and one for imaging/biopsy.; Paclitaxel is administered weekly during Cycles 5-8 as per text description (12 continuous weeks), overriding the simplified Schedule of Activities table which only marks Day 1 of each cycle for paclitaxel.; ECHO/MUGA scans after C2D1 and C4D1 are distinct in-person days (e.g., Day 21 and Day 49). Subsequent 'every 3 months' ECHO/MUGA scans are assumed to occur on the same day as a scheduled Core Treatment visit if the nominal date falls within a few days of a Core Treatment Day 1 (e.g., Day 90 scan on C6D15 (Day 91), Day 180 scan on C10D1 (Day 185), Day 270 scan on C14D1 (Day 269), Day 360 scan on C18D1 (Day 353)).; A pre-surgery visit (for ECOG and platelet count) is considered a separate in-person day from surgery.; Surgery is counted as one in-person day.; Nominal dates for pre-surgery visit and surgery are estimated based on protocol windows (e.g., pre-surgery around Day 140, surgery around Day 150) to calendarize visits.; The adjuvant phase (C9D1) is estimated to start around Day 164 (Day 150 + 14 days, as per protocol 'not start until 2 weeks after surgery')."
35763704,Placebo + ddAC-PacHP,control,2,4,12,22,26,30,0,3,10,19,23,27,1,1,2,2,2,2,1,0,0,1,1,1,0,0,0,0,0,0,"{'Cycles 1-4': 14, 'Cycles 5-22': 21}","Atezolizumab/placebo, trastuzumab, and pertuzumab continue for a total duration of 52 weeks of HER2-targeted therapy from C5D1 (Day 56), so until Day 421. Paclitaxel is weekly for 12 continuous weeks (Cycles 5-8). Doxorubicin and Cyclophosphamide are Q2W for 4 cycles (Cycles 1-4).","Screening (2 days), C1D1, C2D1, C3D1, C4D1, C5D1, C5D8, C5D15, C6D1, C6D8, C6D15, C7D1, C7D8, C7D15, C8D1, C8D8, C8D15, Pre-Surgery Visit, Surgery, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1. Additional ECHO/MUGA days on Day 21 and Day 49. Range-columns were mapped to one nominal date where applicable (e.g., weekly paclitaxel days).","PK/ADA and biomarker samples at screening are collected on existing blood draw days and do not add distinct contact days.; Screening involves a minimum of 2 distinct in-person days: one for clinic/labs and one for imaging/biopsy.; Paclitaxel is administered weekly during Cycles 5-8 as per text description (12 continuous weeks), overriding the simplified Schedule of Activities table which only marks Day 1 of each cycle for paclitaxel.; ECHO/MUGA scans after C2D1 and C4D1 are distinct in-person days (e.g., Day 21 and Day 49). Subsequent 'every 3 months' ECHO/MUGA scans are assumed to occur on the same day as a scheduled Core Treatment visit if the nominal date falls within a few days of a Core Treatment Day 1 (e.g., Day 90 scan on C6D15 (Day 91), Day 180 scan on C10D1 (Day 185), Day 270 scan on C14D1 (Day 269), Day 360 scan on C18D1 (Day 353)).; A pre-surgery visit (for ECOG and platelet count) is considered a separate in-person day from surgery.; Surgery is counted as one in-person day.; Nominal dates for pre-surgery visit and surgery are estimated based on protocol windows (e.g., pre-surgery around Day 140, surgery around Day 150) to calendarize visits.; The adjuvant phase (C9D1) is estimated to start around Day 164 (Day 150 + 14 days, as per protocol 'not start until 2 weeks after surgery')."
35922251,Cemiplimab Arm,intervention,1,6,9,13,17,22,0,2,5,9,13,18,1,0,0,0,0,0,0,4,4,4,4,4,0,0,0,0,0,0,21,until progression (up to 96 weeks),"Screening (Day -7); Treatment: Cemiplimab infusion (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357); ADA collection (Day 2, 6, 10, 14). All range-columns were mapped to one nominal date or a series of single dates as specified (e.g., 'Days 1-5' for Topotecan).","Screening visit is assumed to occur on Day -7.; The 'cycle length = 6 weeks' in Table 1 header refers to the assessment cycle for imaging, while Cemiplimab drug administration is every 3 weeks (21-day cycle).; Footnote 12 regarding ADA collection for Cemiplimab was interpreted as distinct in-person visits on Day 2, 6, 10, 14 of Cycle 1 (relative to C1D1/Day 0), and then only on Day 1 of specified subsequent 21-day cycles (which coincide with infusion days).; PK (Footnote 11) and Soluble Biomarkers (Footnote 13) collections for Cemiplimab are assumed to occur on Day 1 of specified 21-day cycles, which are Cemiplimab infusion days, and thus subsumed under 'core_treatment'.; All other assessments (e.g., vital signs, physical exams, general labs, EORTC QLQ-C30, concomitant medications) listed in Table 1 for Day 1 and Day 22 of the 6-week cycle are assumed to occur on Cemiplimab infusion days (Day 0, Day 21, Day 42, etc.) and are subsumed under 'core_treatment'.; Imaging (CT/MRI) on Day 42 of specific 6-week cycles (Day 42, 84, 126, 168, 252, 336) coincides with Cemiplimab infusion days (Day 1 of a 21-day cycle), so 'core_treatment' takes precedence for these days.; Treatment duration is calculated up to Day +365, consistent with the 'up to 96 weeks' rule."
35922251,IC Chemotherapy Control Arm,control,1,10,25,45,65,90,0,10,25,45,65,90,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression (up to 96 weeks),"Screening (Day -7); Treatment: Topotecan infusion (Day 0-4, 21-25, 42-46, 63-67, 84-88, 105-109, 126-130, 147-151, 168-172, 189-193, 210-214, 231-235, 252-256, 273-277, 294-298, 315-319, 336-340, 357-361). All range-columns were mapped to a series of single dates.","Screening visit is assumed to occur on Day -7.; The Topotecan regimen (1 mg/m² daily IV for 5 days, every 21 days) was selected as the representative IC chemotherapy option due to its higher frequency of in-person contact days compared to other IC options, adhering to the 'most conservative lower estimate' rule (implying higher burden).; The 'cycle length = 6 weeks' in Table 1 header refers to the assessment cycle for imaging, while Topotecan drug administration is every 3 weeks (21-day cycle).; All other assessments (e.g., vital signs, physical exams, general labs, EORTC QLQ-C30, concomitant medications) listed in Table 1 for Day 1 and Day 22 of the 6-week cycle are assumed to occur on Topotecan infusion days (Day 0, Day 21, Day 42, etc.) and are subsumed under 'core_treatment'. Assessments specified 'Only for gemcitabine, irinotecan, and vinorelbine' were excluded for Topotecan.; Imaging (CT/MRI) on Day 42 of specific 6-week cycles (Day 42, 84, 126, 168, 252, 336) coincides with Topotecan infusion days (Day 1 of a 21-day cycle), so 'core_treatment' takes precedence for these days.; Treatment duration is calculated up to Day +365, consistent with the 'up to 96 weeks' rule."
35947817,DCC-2618 (150 mg QD),intervention,1,3,6,10,14,19,0,3,6,10,14,19,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,42,until progression (up to 2 years),"Screening, C1D1, C1D15, C1D29, C2D1, C2D29, C3D1, C3D29, C4D1, C4D29, C5D1, C5D29, C6D1, C6D29, C7D1, C7D29, C8D1, C8D29, C9D1, C9D29. All cycle-specific columns (Day 1, Day 15, Day 29) were mapped to one nominal date.","The 'Screening' visit is counted as one in-person day within the screening window.; Randomization is assumed to occur on Cycle 1 Day 1 (Day 0).; Nominal dates for 'Day 15 (±1 day)' and 'Day 29 (±1 day)' are interpreted as Day 14 and Day 28 respectively for calendarization.; Treatment is assumed to continue for the full 365-day horizon for scheduled visits, as patients are eligible to receive study drug for up to 2 years.; EOT (End of Treatment) and Safety Follow-Up visits are assumed to occur after the 365-day horizon if treatment continues that long, and are therefore not included in the 12-month window counts.; Any day with 'Study Drug Administration' is categorized as 'core_treatment' due to precedence rules, even if other assessments (e.g., PK sampling, imaging, labs) also occur.; The 'Screening' day is categorized as 'imaging_diagnostics' due to the presence of mandatory radiologic imaging, echocardiogram/MUGA, and ECG, which take precedence over labs and clinic visits when no core treatment is administered."
35947817,Sunitinib (50 mg QD),intervention,1,3,6,10,14,19,0,3,6,10,14,19,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,42,until progression (up to 2 years),"Screening, C1D1, C1D15, C1D29, C2D1, C2D29, C3D1, C3D29, C4D1, C4D29, C5D1, C5D29, C6D1, C6D29, C7D1, C7D29, C8D1, C8D29, C9D1, C9D29. All cycle-specific columns (Day 1, Day 15, Day 29) were mapped to one nominal date.","The 'Screening' visit is counted as one in-person day within the screening window.; Randomization is assumed to occur on Cycle 1 Day 1 (Day 0).; Nominal dates for 'Day 15 (±1 day)' and 'Day 29 (±1 day)' are interpreted as Day 14 and Day 28 respectively for calendarization.; Treatment is assumed to continue for the full 365-day horizon for scheduled visits, as patients are eligible to receive study drug for up to 2 years.; EOT (End of Treatment) and Safety Follow-Up visits are assumed to occur after the 365-day horizon if treatment continues that long, and are therefore not included in the 12-month window counts.; Any day with 'Study Drug Administration' is categorized as 'core_treatment' due to precedence rules, even if other assessments (e.g., imaging, labs) also occur.; The 'Screening' day is categorized as 'imaging_diagnostics' due to the presence of mandatory radiologic imaging, echocardiogram/MUGA, and ECG, which take precedence over labs and clinic visits when no core treatment is administered.; PK sampling is not applicable to the Sunitinib arm, as per Footnote 17 in Table 1."
36099926,Arm A (experimental arm): Atezolizumab,intervention,2,1,7,13,19,23,0,1,5,9,13,16,1,0,1,2,3,3,0,0,0,0,0,0,1,0,1,2,3,4,21,"16 cycles or 1 year (365 days), whichever occurs first (resulting in 336 days of treatment).","Screening: 1 day (clinic/labs), 1 day (imaging). Treatment: C1D1, C2D1, ..., C16D1 (16 days, all infusions). Surveillance: Month 3 (1 day clinic/labs, 1 day imaging), Month 6 (1 day clinic/labs, 1 day imaging), Month 9 (1 day clinic/labs, 1 day imaging), Month 12 (1 day clinic/labs). Range-columns were mapped to one nominal date.","The 'Screening for Randomization' column represents two distinct in-person contact days: one for the comprehensive clinic visit (including consent, physical exam, vitals, and all screening labs/tests) and a separate day for required imaging (CT/MRI).; For 'Assessments for RCC recurrence' (surveillance visits every 3 months), it is assumed that the clinical/laboratory portion and the imaging studies (CT chest, abdomen, pelvis) occur on two separate, distinct calendar days within the specified window (e.g., Day 90 for clinic/labs, Day 91 for imaging) to account for separate appointments, ensuring unique dates are counted. The imaging day is prioritized as 'imaging_diagnostics' and the clinic/lab day as 'clinic_visits'.; All assessments listed under 'Day 1' of each cycle (e.g., ECOG, clinical history, physical exam, vitals, labs, PROs, ECG, PK/ADA/biomarkers) are considered to occur on the same day as the intravenous infusion. Therefore, these days are primarily categorized as 'core_treatment' due to the drug administration.; Optional whole blood sample for RBR (Cycle 1, Day 1) is not counted as it is optional.; The nominal day for 'Day 1 (± 3 Days for Cycles ≥ 2)' is taken as Day 1 for calendarization.; The imaging for surveillance at Month 12 (Day 365) would nominally occur on Day 366, which falls outside the Day +365 window, and is therefore not counted."
36099926,Arm B (control arm): Placebo,control,2,1,7,13,19,23,0,1,5,9,13,16,1,0,1,2,3,3,0,0,0,0,0,0,1,0,1,2,3,4,21,"16 cycles or 1 year (365 days), whichever occurs first (resulting in 336 days of treatment).","Screening: 1 day (clinic/labs), 1 day (imaging). Treatment: C1D1, C2D1, ..., C16D1 (16 days, all infusions). Surveillance: Month 3 (1 day clinic/labs, 1 day imaging), Month 6 (1 day clinic/labs, 1 day imaging), Month 9 (1 day clinic/labs, 1 day imaging), Month 12 (1 day clinic/labs). Range-columns were mapped to one nominal date.","The 'Screening for Randomization' column represents two distinct in-person contact days: one for the comprehensive clinic visit (including consent, physical exam, vitals, and all screening labs/tests) and a separate day for required imaging (CT/MRI).; For 'Assessments for RCC recurrence' (surveillance visits every 3 months), it is assumed that the clinical/laboratory portion and the imaging studies (CT chest, abdomen, pelvis) occur on two separate, distinct calendar days within the specified window (e.g., Day 90 for clinic/labs, Day 91 for imaging) to account for separate appointments, ensuring unique dates are counted. The imaging day is prioritized as 'imaging_diagnostics' and the clinic/lab day as 'clinic_visits'.; All assessments listed under 'Day 1' of each cycle (e.g., ECOG, clinical history, physical exam, vitals, labs, PROs, ECG, PK/ADA/biomarkers) are considered to occur on the same day as the intravenous infusion. Therefore, these days are primarily categorized as 'core_treatment' due to the drug administration.; Optional whole blood sample for RBR (Cycle 1, Day 1) is not counted as it is optional.; The nominal day for 'Day 1 (± 3 Days for Cycles ≥ 2)' is taken as Day 1 for calendarization.; The imaging for surveillance at Month 12 (Day 365) would nominally occur on Day 366, which falls outside the Day +365 window, and is therefore not counted."
36108662,Pembrolizumab,intervention,3,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,21,"18 infusions, approximately one year","Registration Visit (Day -28), Main Screening Visit (Day -14), Pre-Infusion Checks Visit (Day -1), followed by 18 infusion visits every 21 days (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357). No range-columns were explicitly identified as multi-day treatment blocks; day-ranges for scheduling were treated as a single nominal visit date.","Day 0 is defined as the first infusion (Infusion 1 Day 1).; The 'Registration consent' and associated sample collections (PD-L1 tumor sample submission, germline whole blood, serum) are considered one in-person visit (assigned to Day -28).; The 'Main study consent' and associated comprehensive screening tests (medical history, physical exam, serology, pregnancy test, general labs, ECG, disease evaluation, HRQoL) are considered one in-person visit (assigned to Day -14).; The 'Within 10 days', 'Within 72 hours', and 'Within 24 hours' prior to treatment initiation assessments are consolidated into a single pre-infusion visit on Day -1.; Serology HIV, HBV, HCV, which is 'if clinically indicated', is assumed to be indicated for the purpose of counting.; All 'Every X weeks' assessments during the treatment period (physical exams, labs, imaging, HRQoL) coincide with the scheduled infusion days and do not create additional in-person contact days.; The End of Treatment (EOT) visit, scheduled 4 weeks after the last infusion (Day 357 + 28 = Day 385), falls outside the 12-month window and is therefore not counted.; Follow-up visits within the 12-month window coincide with infusion days and do not add additional contact days.; Category precedence was applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
36108662,Placebo,control,3,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,21,"18 infusions, approximately one year","Registration Visit (Day -28), Main Screening Visit (Day -14), Pre-Infusion Checks Visit (Day -1), followed by 18 infusion visits every 21 days (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357). No range-columns were explicitly identified as multi-day treatment blocks; day-ranges for scheduling were treated as a single nominal visit date.","Day 0 is defined as the first infusion (Infusion 1 Day 1).; The 'Registration consent' and associated sample collections (PD-L1 tumor sample submission, germline whole blood, serum) are considered one in-person visit (assigned to Day -28).; The 'Main study consent' and associated comprehensive screening tests (medical history, physical exam, serology, pregnancy test, general labs, ECG, disease evaluation, HRQoL) are considered one in-person visit (assigned to Day -14).; The 'Within 10 days', 'Within 72 hours', and 'Within 24 hours' prior to treatment initiation assessments are consolidated into a single pre-infusion visit on Day -1.; Serology HIV, HBV, HCV, which is 'if clinically indicated', is assumed to be indicated for the purpose of counting.; All 'Every X weeks' assessments during the treatment period (physical exams, labs, imaging, HRQoL) coincide with the scheduled infusion days and do not create additional in-person contact days.; The End of Treatment (EOT) visit, scheduled 4 weeks after the last infusion (Day 357 + 28 = Day 385), falls outside the 12-month window and is therefore not counted.; Follow-up visits within the 12-month window coincide with infusion days and do not add additional contact days.; Category precedence was applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
36155117,Arm A: Palbociclib + Letrozole,intervention,4,4,8,11,14,18,0,2,3,4,4,6,3,0,1,3,6,8,1,2,4,4,4,4,0,0,0,0,0,0,28,until progression,"Screening (Day -28, Day -27, Day -26, Day -25); Cycle 1 (Day 0, Day 14, Day 21); Cycle 2 (Day 28, Day 42, Day 49); Cycles ≥3 (Day 1 of each cycle: Day 56, Day 84, Day 112, Day 140, Day 168, Day 196, Day 224, Day 252, Day 280, Day 308, Day 336, Day 364). Range-columns (e.g., 'Day 14-21') were mapped to one nominal date (e.g., Day 14 or Day 21).","The 'Screening' column in the Schedule of Activities (SoA) table represents multiple in-person visits due to the complexity and specialized nature of the procedures listed. Specifically, initial clinic/labs, CT/MRI, bone scan, and ophthalmic exam are assumed to occur on separate days within the screening window.; For active treatment, if multiple procedures (e.g., core treatment, labs, imaging) are scheduled on the same nominal day, it counts as one unique healthcare contact day, and its category is determined by the precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits).; Disease assessments (CT/MRI, Bone Scan, Ophthalmic Exam) are considered to occur on their nominal due dates (e.g., Day 84 for 12-week assessment). If this nominal day coincides with a CkD1 visit, the day's primary category is assigned based on the highest precedence activity.; Mid-cycle visits (Day 14, Day 21) are only counted for Cycles 1 and 2, as indicated by the specific columns in the SoA table. For cycles 3 onwards, only CkD1 visits are considered mandatory in-person contacts, as mid-cycle columns are absent for 'Cycles ≥3' and footnote 'a' on page 35 implies monthly monitoring at the beginning of each cycle after initial cycles.; Banked Biospecimen (footnote 'h') and CDK6 Genotyping (Section 7.6) blood draws, although listed under 'Screening' in the table for the former and described for C1D1 for both, are categorized as 'labs' and are assumed to occur on C1D1 (Day 0) as part of the comprehensive C1D1 visit, based on footnote 'h' and Section 7.6 details. The 'X' for Banked Biospecimen under Screening is interpreted as the initiation of the process, with the actual collection on C1D1.; Tumor Tissue for Biomarker (footnote 'i') is assumed to involve an in-person component for tissue submission/handling at screening, categorized as imaging_diagnostics. A fresh biopsy, if required, would also be imaging_diagnostics.; Pharmacokinetic (PK) samples are collected on Day 14 of Cycles 1 and 2 (footnote 'z'), categorized as 'labs'. The 'X(Pre-dose)' under Screening for PK in the SoA table is considered a discrepancy and not counted as a separate screening PK visit, as footnote 'z' specifies C1D14 and C2D14."
36155117,Arm B: Placebo + Letrozole,control,4,4,8,11,14,18,0,2,3,4,4,6,3,0,1,3,6,8,1,2,4,4,4,4,0,0,0,0,0,0,28,until progression,"Screening (Day -28, Day -27, Day -26, Day -25); Cycle 1 (Day 0, Day 14, Day 21); Cycle 2 (Day 28, Day 42, Day 49); Cycles ≥3 (Day 1 of each cycle: Day 56, Day 84, Day 112, Day 140, Day 168, Day 196, Day 224, Day 252, Day 280, Day 308, Day 336, Day 364). Range-columns (e.g., 'Day 14-21') were mapped to one nominal date (e.g., Day 14 or Day 21).","The 'Screening' column in the Schedule of Activities (SoA) table represents multiple in-person visits due to the complexity and specialized nature of the procedures listed. Specifically, initial clinic/labs, CT/MRI, bone scan, and ophthalmic exam are assumed to occur on separate days within the screening window.; For active treatment, if multiple procedures (e.g., core treatment, labs, imaging) are scheduled on the same nominal day, it counts as one unique healthcare contact day, and its category is determined by the precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits).; Disease assessments (CT/MRI, Bone Scan, Ophthalmic Exam) are considered to occur on their nominal due dates (e.g., Day 84 for 12-week assessment). If this nominal day coincides with a CkD1 visit, the day's primary category is assigned based on the highest precedence activity.; Mid-cycle visits (Day 14, Day 21) are only counted for Cycles 1 and 2, as indicated by the specific columns in the SoA table. For cycles 3 onwards, only CkD1 visits are considered mandatory in-person contacts, as mid-cycle columns are absent for 'Cycles ≥3' and footnote 'a' on page 35 implies monthly monitoring at the beginning of each cycle after initial cycles.; Banked Biospecimen (footnote 'h') and CDK6 Genotyping (Section 7.6) blood draws, although listed under 'Screening' in the table for the former and described for C1D1 for both, are categorized as 'labs' and are assumed to occur on C1D1 (Day 0) as part of the comprehensive C1D1 visit, based on footnote 'h' and Section 7.6 details. The 'X' for Banked Biospecimen under Screening is interpreted as the initiation of the process, with the actual collection on C1D1.; Tumor Tissue for Biomarker (footnote 'i') is assumed to involve an in-person component for tissue submission/handling at screening, categorized as imaging_diagnostics. A fresh biopsy, if required, would also be imaging_diagnostics.; Pharmacokinetic (PK) samples are collected on Day 14 of Cycles 1 and 2 (footnote 'z'), categorized as 'labs'. The 'X(Pre-dose)' under Screening for PK in the SoA table is considered a discrepancy and not counted as a separate screening PK visit, as footnote 'z' specifies C1D14 and C2D14."
36162037,Arm A: nivolumab 240 mg IV Q2 weeks + ipilimumab 1 mg/kg IV Q6 weeks,intervention,1,3,7,13,20,25,0,3,7,13,20,25,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,maximum of 1 year,"Screening Visit (Day -X), then on-treatment visits on Day 0, Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 98, Day 112, Day 126, Day 140, Day 154, Day 168, Day 182, Day 196, Day 210, Day 224, Day 238, Day 252, Day 266, Day 280, Day 294, Day 308, Day 322, Day 336.","The 'Screening Visit (Before Day 1, prior to Randomization)' is counted as one distinct in-person day.; All procedures marked with 'X' in the 'Screening Visit' column of Table 2-1 occur on this single screening day.; The screening day is categorized as 'imaging_diagnostics' due to the presence of ECG and Tumor Surveillance Assessments (CT/MRI scans) which take precedence over labs and clinic visits.; All 'Day 1 Week X' columns in Tables 2-2 to 2-7 represent in-person visits for drug administration (active or placebo) and other assessments.; Drug administration (active or placebo) is categorized as 'core_treatment' and takes precedence over all other assessments occurring on the same day.; Optional assessments (e.g., Microbiome) are not counted as mandatory contact days.; Treatment duration is a maximum of 1 year (365 days). The last scheduled treatment visit (Day 1 Week 49 / Day 336) is included.; No scheduled follow-up visits fall within the Day 0 to Day 365 window after the last treatment day."
36162037,Arm B: nivolumab 480 mg IV every 4 weeks,intervention,1,3,7,13,20,25,0,3,7,13,20,25,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,maximum of 1 year,"Screening Visit (Day -X), then on-treatment visits on Day 0, Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 98, Day 112, Day 126, Day 140, Day 154, Day 168, Day 182, Day 196, Day 210, Day 224, Day 238, Day 252, Day 266, Day 280, Day 294, Day 308, Day 322, Day 336.","The 'Screening Visit (Before Day 1, prior to Randomization)' is counted as one distinct in-person day.; All procedures marked with 'X' in the 'Screening Visit' column of Table 2-1 occur on this single screening day.; The screening day is categorized as 'imaging_diagnostics' due to the presence of ECG and Tumor Surveillance Assessments (CT/MRI scans) which take precedence over labs and clinic visits.; All 'Day 1 Week X' columns in Tables 2-2 to 2-7 represent in-person visits for drug administration (active or placebo) and other assessments.; Drug administration (active or placebo) is categorized as 'core_treatment' and takes precedence over all other assessments occurring on the same day.; Optional assessments (e.g., Microbiome) are not counted as mandatory contact days.; Treatment duration is a maximum of 1 year (365 days). The last scheduled treatment visit (Day 1 Week 49 / Day 336) is included.; No scheduled follow-up visits fall within the Day 0 to Day 365 window after the last treatment day."
36265504,Open label Enzalutamide (Period 1),intervention,1,2,3,4,5,6,0,2,3,4,5,6,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,,until progression or randomization to Period 2,"Screening (Day -1), Week 1 (Day 0), Week 5 (Day 29), Week 13 (Day 85), Week 25 (Day 169), Week 37 (Day 253), Week 49 (Day 337).","The 'Screening' visit is counted as a single in-person day, with the nominal day for calculation being Day -1.; The '25 then q84wk' column defines the ongoing schedule for subjects continuing Period 1 treatment, with visits at Day 169, Day 253, and Day 337. The 'Extension Period 1n' column is not counted as additional distinct visits, as protocol-specified efficacy and laboratory assessments cease during extension periods, and drug dispensing is already covered by the '25 then q84wk' column.; The 'FU After last drug' visit is assumed to occur after Day 365 if treatment continues until near Day 365, and thus is not included in the 12-month window count.; Biomarker samples are explicitly stated as part of a 'voluntary, exploratory, biomarker sub-study' (Page 6, Page 16 footnote k) and are therefore excluded from mandatory healthcare contact days. Their exclusion did not change total contact days as other mandatory activities were present on those days."
36265504,Enzalutamide (160 mg/d) + Docetaxel (75 mg/m²/3w) + Prednisolone (10 mg/d) (Period 2),intervention,1,2,5,9,11,12,0,2,5,9,11,12,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Eligibility Assessment (Day -1), Cycle 1 Day 1 (Day 0), Cycle 2 Day 1 (Day 22), Cycle 3 Day 1 (Day 43), Cycle 4 Day 1 (Day 64), Cycle 5 Day 1 (Day 85), Cycle 6 Day 1 (Day 106), Cycle 7 Day 1 (Day 127), Cycle 8 Day 1 (Day 148), Cycle 9 Day 1 (Day 169), Cycle 10 Day 1 (Day 190), Ongoing Week 37 (Day 253), Ongoing Week 49 (Day 337).","The 'Eligibility Assessment for Period 2' visit is counted as a single in-person day, with the nominal day for calculation being Day -1.; Docetaxel is administered every 3 weeks for up to 10 cycles, establishing a 21-day cycle length for the initial treatment phase.; After 10 cycles of docetaxel (ending Day 190), the 'Ongoing (Double-Blind) Treatmentp' column dictates the continuation schedule for IMP, with visits at Day 253 (Week 37) and Day 337 (Week 49).; The 'Additional (Varies q3wk cyclesi)' and 'Extension Period 2' columns are not counted as additional distinct visits for a standard patient completing 10 docetaxel cycles, due to their conditional nature (footnote 'i') or standard of care focus (footnotes 'q', 'r') and overlap with the 'Ongoing' column for IMP dispensing.; The 'FU After last drug' visit is assumed to occur after Day 365 if treatment continues until near Day 365, and thus is not included in the 12-month window count.; Biomarker samples are explicitly stated as part of a 'voluntary, exploratory, biomarker sub-study' (Page 6, Page 16 footnote k) and are therefore excluded from mandatory healthcare contact days. Their exclusion did not change total contact days as other mandatory activities were present on those days."
36265504,Placebo (4 caps/d) + Docetaxel (75 mg/m²/3w) + Prednisolone (10 mg/d) (Period 2),control,1,2,5,9,11,12,0,2,5,9,11,12,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Eligibility Assessment (Day -1), Cycle 1 Day 1 (Day 0), Cycle 2 Day 1 (Day 22), Cycle 3 Day 1 (Day 43), Cycle 4 Day 1 (Day 64), Cycle 5 Day 1 (Day 85), Cycle 6 Day 1 (Day 106), Cycle 7 Day 1 (Day 127), Cycle 8 Day 1 (Day 148), Cycle 9 Day 1 (Day 169), Cycle 10 Day 1 (Day 190), Ongoing Week 37 (Day 253), Ongoing Week 49 (Day 337).","The 'Eligibility Assessment for Period 2' visit is counted as a single in-person day, with the nominal day for calculation being Day -1.; Docetaxel is administered every 3 weeks for up to 10 cycles, establishing a 21-day cycle length for the initial treatment phase.; After 10 cycles of docetaxel (ending Day 190), the 'Ongoing (Double-Blind) Treatmentp' column dictates the continuation schedule for IMP, with visits at Day 253 (Week 37) and Day 337 (Week 49).; The 'Additional (Varies q3wk cyclesi)' and 'Extension Period 2' columns are not counted as additional distinct visits for a standard patient completing 10 docetaxel cycles, due to their conditional nature (footnote 'i') or standard of care focus (footnotes 'q', 'r') and overlap with the 'Ongoing' column for IMP dispensing.; The 'FU After last drug' visit is assumed to occur after Day 365 if treatment continues until near Day 365, and thus is not included in the 12-month window count.; Biomarker samples are explicitly stated as part of a 'voluntary, exploratory, biomarker sub-study' (Page 6, Page 16 footnote k) and are therefore excluded from mandatory healthcare contact days. Their exclusion did not change total contact days as other mandatory activities were present on those days."
36308441,Arm A: PledOx (5 µmol/kg) + mFOLFOX6 chemotherapy,intervention,3,3,7,13,14,15,0,3,7,12,12,12,1,0,0,0,1,2,2,0,0,1,1,1,0,0,0,0,0,0,14,"up to 24 weeks (6 months) of mFOLFOX6, followed by follow-up","Screening (D-28, D-14, D-7), C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, D14C12 (EOT/M6), M9, M12. Range-columns were mapped to one nominal date.","Patients are assumed to complete the full 12 cycles of mFOLFOX6 chemotherapy, lasting 168 days (12 cycles * 14 days/cycle).; The 'Assessment Visit Month 3' column in the Schedule of Assessments (Page 23) is empty, indicating no dedicated in-person visit at this time point.; The 'EOT Visit D14C12' (Day 168) is considered the 'Assessment visit Month 6' due to footnote 11 (Page 22) stating combination of these visits if treatment continues to Cycle 12, and its timing (Week 24 is Month 6). This avoids double-counting a separate Month 6 visit.; Follow-up month visits (M9, M12) are calendarized using 30 days/month from Day 0 (e.g., M9 = Day 270, M12 = Day 360).; The 'Cold Sensitivity Patient Questionnaire (Paper Diary)' on Days 1, 2, 3 after infusion is not counted as an in-person contact day, as it is a 'Paper Diary' and remote collection is explicitly allowed for questionnaires (footnote 7, Page 9).; Randomization (D0) is explicitly stated as 'not a patient visit' (Page 8, footnote 6 on Page 22) and is therefore not counted as a contact day.; The footnote change for 'before IMP infusion*' to 'before mFOLFOX6 infusion' (Page 18, 19, 20, 21, 24, 25) confirms that the Day 1 of cycle visits continue for mFOLFOX6 administration, which is an in-person activity."
36308441,Arm B: Placebo + mFOLFOX6 chemotherapy,control,3,3,7,13,14,15,0,3,7,12,12,12,1,0,0,0,1,2,2,0,0,1,1,1,0,0,0,0,0,0,14,"up to 24 weeks (6 months) of mFOLFOX6, followed by follow-up","Screening (D-28, D-14, D-7), C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, D14C12 (EOT/M6), M9, M12. Range-columns were mapped to one nominal date.","Patients are assumed to complete the full 12 cycles of mFOLFOX6 chemotherapy, lasting 168 days (12 cycles * 14 days/cycle).; The 'Assessment Visit Month 3' column in the Schedule of Assessments (Page 23) is empty, indicating no dedicated in-person visit at this time point.; The 'EOT Visit D14C12' (Day 168) is considered the 'Assessment visit Month 6' due to footnote 11 (Page 22) stating combination of these visits if treatment continues to Cycle 12, and its timing (Week 24 is Month 6). This avoids double-counting a separate Month 6 visit.; Follow-up month visits (M9, M12) are calendarized using 30 days/month from Day 0 (e.g., M9 = Day 270, M12 = Day 360).; The 'Cold Sensitivity Patient Questionnaire (Paper Diary)' on Days 1, 2, 3 after infusion is not counted as an in-person contact day, as it is a 'Paper Diary' and remote collection is explicitly allowed for questionnaires (footnote 7, Page 9).; Randomization (D0) is explicitly stated as 'not a patient visit' (Page 8, footnote 6 on Page 22) and is therefore not counted as a contact day.; The footnote change for 'before IMP infusion*' to 'before mFOLFOX6 infusion' (Page 18, 19, 20, 21, 24, 25) confirms that the Day 1 of cycle visits continue for mFOLFOX6 administration, which is an in-person activity."
36322844,ABVE-PC,control,1,8,21,37,38,39,0,8,18,32,32,32,1,0,3,5,5,6,0,0,0,0,1,1,0,0,0,0,0,0,21,"5 cycles of chemotherapy, followed by response-adapted radiation therapy if indicated, then follow-up.","Screening (Day -1); Cycle 1 (Day 0, 1, 2, 7); Cycle 2 (Day 21, 22, 23, 28, 39); Cycle 3 (Day 42, 43, 44, 49); Cycle 4 (Day 63, 64, 65, 70); Cycle 5 (Day 84, 85, 86, 91); Post-Chemo/Pre-RT (Day 105); Radiation Therapy (Day 105-109, 112-116, 119-122); Follow-up (Day 164, 254, 344). Range-columns were mapped to one nominal date.","Screening activities (all 'X' marks in 'Baseline' column of Table 7.1) are consolidated into one in-person visit day (Day -1). Imaging/Diagnostics takes precedence for this day.; Oral Prednisone administration is not considered an in-person contact day.; Subcutaneous G-CSF administration is not considered an in-person contact day unless other in-person procedures are scheduled for that day.; Visit ranges (e.g., 'Days 18-22 of Cycle 2' for FDG-PET) are counted as a single in-person visit day, assigned to the earliest day in the range (e.g., Day 18 of the cycle, which is Day 39 overall).; Visits described as 'Prior to Cycle X' (e.g., 'Prior to Cycle 3 only') are assigned to Day 1 of that respective cycle (e.g., C3D1, C4D1).; Response-adapted Involved Site Radiation Therapy (ISRT) is included in the total contact days, assuming a patient receives it if indicated (14 fractions over approximately 3 weeks, 5 days/week).; Follow-up visits ('0 months post RT', '3 months post RT', '6 months post RT') are calculated from the last day of RT (Day 122).; Category precedence applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
36322844,Bv-AVEPC,intervention,1,8,21,37,38,39,0,8,18,32,32,32,1,0,3,5,5,6,0,0,0,0,1,1,0,0,0,0,0,0,21,"5 cycles of chemotherapy, followed by response-adapted radiation therapy if indicated, then follow-up.","Screening (Day -1); Cycle 1 (Day 0, 1, 2, 7); Cycle 2 (Day 21, 22, 23, 28, 39); Cycle 3 (Day 42, 43, 44, 49); Cycle 4 (Day 63, 64, 65, 70); Cycle 5 (Day 84, 85, 86, 91); Post-Chemo/Pre-RT (Day 105); Radiation Therapy (Day 105-109, 112-116, 119-122); Follow-up (Day 164, 254, 344). Range-columns were mapped to one nominal date.","Screening activities (all 'X' marks in 'Baseline' column of Table 7.1) are consolidated into one in-person visit day (Day -1). Imaging/Diagnostics takes precedence for this day.; Oral Prednisone administration is not considered an in-person contact day.; Subcutaneous G-CSF administration is not considered an in-person contact day unless other in-person procedures are scheduled for that day.; Visit ranges (e.g., 'Days 18-22 of Cycle 2' for FDG-PET) are counted as a single in-person visit day, assigned to the earliest day in the range (e.g., Day 18 of the cycle, which is Day 39 overall).; Visits described as 'Prior to Cycle X' (e.g., 'Prior to Cycle 3 only') are assigned to Day 1 of that respective cycle (e.g., C3D1, C4D1).; Response-adapted Involved Site Radiation Therapy (ISRT) is included in the total contact days, assuming a patient receives it if indicated (14 fractions over approximately 3 weeks, 5 days/week).; Follow-up visits ('0 months post RT', '3 months post RT', '6 months post RT') are calculated from the last day of RT (Day 122).; Category precedence applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
36327426,Durvalumab + Tremelimumab combination therapy + SoC chemotherapy,intervention,1,2,5,8,11,15,0,2,5,8,11,15,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening (Day -28), C1D1 (Day 0), C2D1 (Day 21), C3D1 (Day 42), C4D1 (Day 63), Post-chemo Durva/Pemetrexed (Day 84, Day 112, Day 140, Day 168, Day 196, Day 224, Day 252, Day 280, Day 308, Day 336, Day 364). Day 112 includes an additional Tremelimumab dose. Tumor evaluation scans at Day 42, 84, 140, 196, 252, 308, 364 overlap with drug administration.","One in-person screening day is counted, encompassing all screening procedures (consent, physical exam, labs, imaging, biopsy) within the Day -28 to Day -1 window.; For SoC chemotherapy, the Pemetrexed + Carboplatin/Cisplatin regimen (1 infusion day per 21-day cycle) was assumed as the 'most conservative lower estimate' for contact days, as the protocol lists multiple SoC options with varying visit frequencies.; Pemetrexed maintenance therapy for non-squamous patients is assumed to be administered q4w.; Tumor evaluation scans (RECIST 1.1) at Week 6, Week 12, and then q8w, are assumed to overlap with scheduled drug administration days, except for the screening scan.; Treatment continues until objective disease progression, but for this extraction, visits are enumerated up to Day +365.; All drug administration days are classified as 'core_treatment' due to the primary purpose of active treatment delivery, even if other assessments (labs, vitals) occur."
36327426,Durvalumab monotherapy + SoC chemotherapy,intervention,1,2,5,8,11,15,0,2,5,8,11,15,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening (Day -28), C1D1 (Day 0), C2D1 (Day 21), C3D1 (Day 42), C4D1 (Day 63), Post-chemo Durva/Pemetrexed (Day 84, Day 112, Day 140, Day 168, Day 196, Day 224, Day 252, Day 280, Day 308, Day 336, Day 364). Tumor evaluation scans at Day 42, 84, 140, 196, 252, 308, 364 overlap with drug administration.","One in-person screening day is counted, encompassing all screening procedures (consent, physical exam, labs, imaging, biopsy) within the Day -28 to Day -1 window.; For SoC chemotherapy, the Pemetrexed + Carboplatin/Cisplatin regimen (1 infusion day per 21-day cycle) was assumed as the 'most conservative lower estimate' for contact days, as the protocol lists multiple SoC options with varying visit frequencies.; Pemetrexed maintenance therapy for non-squamous patients is assumed to be administered q4w.; Tumor evaluation scans (RECIST 1.1) at Week 6, Week 12, and then q8w, are assumed to overlap with scheduled drug administration days, except for the screening scan.; Treatment continues until objective disease progression, but for this extraction, visits are enumerated up to Day +365.; All drug administration days are classified as 'core_treatment' due to the primary purpose of active treatment delivery, even if other assessments (labs, vitals) occur."
36327426,SoC chemotherapy alone,control,1,2,5,9,14,20,0,2,5,9,14,20,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening (Day -28), C1D1 (Day 0), C2D1 (Day 21), C3D1 (Day 42), C4D1 (Day 63), C5D1 (Day 84), C6D1 (Day 105), Post-chemo Pemetrexed (Day 133, Day 161, Day 189, Day 217, Day 245, Day 273, Day 301, Day 329, Day 357). Tumor evaluation scans at Day 42, 84 (overlap with chemo), Day 140, Day 196, Day 252, Day 308, Day 364 (additional scan days if no drug administration).","One in-person screening day is counted, encompassing all screening procedures (consent, physical exam, labs, imaging, biopsy) within the Day -28 to Day -1 window.; For SoC chemotherapy, the Pemetrexed + Carboplatin/Cisplatin regimen (1 infusion day per 21-day cycle) was assumed as the 'most conservative lower estimate' for contact days, as the protocol lists multiple SoC options with varying visit frequencies.; Arm 3 is assumed to receive 6 cycles of SoC chemotherapy (maximum allowed) to maximize contact days.; Pemetrexed maintenance therapy for non-squamous patients is assumed to be administered q4w, starting after the 6th cycle of chemotherapy (Day 105 + 28 days = Day 133).; Tumor evaluation scans (RECIST 1.1) at Week 6, Week 12, and then q8w, are assumed to overlap with scheduled drug administration days where possible. Additional scan days are counted if they do not overlap.; Treatment continues until objective disease progression, but for this extraction, visits are enumerated up to Day +365.; All drug administration days are classified as 'core_treatment' due to the primary purpose of active treatment delivery, even if other assessments (labs, vitals) occur."
36346687,Capecitabine x 8,intervention,1,2,6,10,11,12,0,0,0,0,0,0,1,0,0,0,0,0,0,2,5,8,8,8,0,0,1,2,3,4,21,8 cycles (168 days),"Screening (Day -14), C1D1 (Day 0), C2D1 (Day 21), C3D1 (Day 42), C4D1 (Day 63), C5D1 (Day 84), 3-month FU (Day 90), C6D1 (Day 105), C7D1 (Day 126), C8D1 (Day 147), 6-month FU (Day 180), 9-month FU (Day 270), 12-month FU (Day 360). Range-columns were mapped to one nominal date (e.g., 'Day 14–21' is not present as a separate visit, but cycle length is 21 days).","""Pre-rd"" represents a single in-person screening visit, assumed to occur on Day -14. This visit includes mandatory imaging, labs, and clinic visits.; ""Day 1 or day -1 of each cycle"" is interpreted as Day 1 of each cycle (C1D1, C2D1, etc.), which is an in-person visit. C1D1 is Day 0.; ""During QT Day 1 or day -1 of cycle 4"" is interpreted as Day 1 of Cycle 4 (Day 63). Its mandatory procedures are combined with the standard CkD1 procedures for that day, and it does not add an additional unique contact day.; Procedures marked with '♦' (""if clinically indicated"") are not counted as mandatory in-person contact days for the primary objective, unless explicitly stated as recommended for all (e.g., baseline bone scan).; The ""0= Rd day"" column does not represent a separate in-person contact day, as no procedures are marked as obligatory. Randomization is assumed to occur on Day 0, coinciding with C1D1.; Capecitabine administration is oral and self-administered, not requiring an in-person visit for drug delivery.; For categorization, the highest precedence mandatory procedure on a given day determines the day's category (imaging_diagnostics > labs > clinic_visits).; Pharmacogenetics sample collection is considered mandatory for all patients before treatment initiation (Page 21, Section 6.5)."
36346687,Observation,control,1,2,6,10,11,12,0,0,0,0,0,0,1,0,0,0,0,0,0,2,5,8,8,8,0,0,1,2,3,4,21,8 cycles (168 days),"Screening (Day -14), C1D1 (Day 0), C2D1 (Day 21), C3D1 (Day 42), C4D1 (Day 63), C5D1 (Day 84), 3-month FU (Day 90), C6D1 (Day 105), C7D1 (Day 126), C8D1 (Day 147), 6-month FU (Day 180), 9-month FU (Day 270), 12-month FU (Day 360). Range-columns were mapped to one nominal date (e.g., 'Day 14–21' is not present as a separate visit, but cycle length is 21 days).","""The same visit schedule will be followed for patients in the observation arm"" (Page 7) means Arm B has the identical in-person contact days and schedule as Arm A.; ""Pre-rd"" represents a single in-person screening visit, assumed to occur on Day -14. This visit includes mandatory imaging, labs, and clinic visits.; ""Day 1 or day -1 of each cycle"" is interpreted as Day 1 of each cycle (C1D1, C2D1, etc.), which is an in-person visit. C1D1 is Day 0.; ""During QT Day 1 or day -1 of cycle 4"" is interpreted as Day 1 of Cycle 4 (Day 63). Its mandatory procedures are combined with the standard CkD1 procedures for that day, and it does not add an additional unique contact day.; Procedures marked with '♦' (""if clinically indicated"") are not counted as mandatory in-person contact days for the primary objective, unless explicitly stated as recommended for all (e.g., baseline bone scan).; The ""0= Rd day"" column does not represent a separate in-person contact day, as no procedures are marked as obligatory. Randomization is assumed to occur on Day 0, coinciding with C1D1.; For categorization, the highest precedence mandatory procedure on a given day determines the day's category (imaging_diagnostics > labs > clinic_visits).; Pharmacogenetics sample collection is considered mandatory for all patients before treatment initiation (Page 21, Section 6.5)."
36455168,Pembrolizumab 200mg IV Q3W Plus Best Supportive Care,intervention,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,"until progression or 35 treatments (approx. 2 years), capped at Day +365 for this analysis","Screening (Day -28 to -1), C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1. All cycle-specific columns represent a single nominal date.","All 'X' marks in the Schedule of Events (SoE) table (Section 6.1, pages 33-37) represent mandatory in-person procedures.; The 'Screening' column in the SoE table represents a single in-person screening day, regardless of the number of procedures listed.; Each 'Cycle X' column in the SoE table represents a single in-person visit on Day 1 of that cycle.; Cycle length is 21 days ('Q3W').; Tumor imaging is performed Q6W (every 42 days) on Day 1 of cycles 3, 5, 7, 9, 11, 13, 15, 17, as per Note p and the Q6W frequency. These are considered part of the Day 1 visit for those cycles.; Urinalysis and T3, FT4, TSH are performed 'every other cycle' (Note i), meaning on Day 1 of cycles 1, 3, 5, 7, 9, 11, 13, 15, 17.; Anti-HBc antibody, HBeAb, HBV e antigen, HBsAb are performed 'every 12 weeks (84±7 days)' (Note n), meaning on Day 1 of cycles 5, 9, 13, 17. The 'X' in the C4 column for these labs was disregarded in favor of the explicit frequency in Note n.; The maximum treatment duration for this analysis is capped at Day +365, as per the 12-month time window definition, even though the protocol states 'up to 35 treatments (approx. 2 years)' (735 days).; Post-treatment follow-up visits fall outside the 365-day horizon and are not counted.; Category precedence was applied: core_treatment > imaging_diagnostics > labs > clinic_visits. Therefore, the screening day is categorized as imaging_diagnostics, and all treatment days are categorized as core_treatment due to drug administration."
36455168,Placebo IV Q3W Plus Best Supportive Care,control,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,"until progression or 35 treatments (approx. 2 years), capped at Day +365 for this analysis","Screening (Day -28 to -1), C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1. All cycle-specific columns represent a single nominal date.","All 'X' marks in the Schedule of Events (SoE) table (Section 6.1, pages 33-37) represent mandatory in-person procedures.; The 'Screening' column in the SoE table represents a single in-person screening day, regardless of the number of procedures listed.; Each 'Cycle X' column in the SoE table represents a single in-person visit on Day 1 of that cycle.; Cycle length is 21 days ('Q3W').; Tumor imaging is performed Q6W (every 42 days) on Day 1 of cycles 3, 5, 7, 9, 11, 13, 15, 17, as per Note p and the Q6W frequency. These are considered part of the Day 1 visit for those cycles.; Urinalysis and T3, FT4, TSH are performed 'every other cycle' (Note i), meaning on Day 1 of cycles 1, 3, 5, 7, 9, 11, 13, 15, 17.; Anti-HBc antibody, HBeAb, HBV e antigen, HBsAb are performed 'every 12 weeks (84±7 days)' (Note n), meaning on Day 1 of cycles 5, 9, 13, 17. The 'X' in the C4 column for these labs was disregarded in favor of the explicit frequency in Note n.; The maximum treatment duration for this analysis is capped at Day +365, as per the 12-month time window definition, even though the protocol states 'up to 35 treatments (approx. 2 years)' (735 days).; Post-treatment follow-up visits fall outside the 365-day horizon and are not counted.; Category precedence was applied: core_treatment > imaging_diagnostics > labs > clinic_visits. Therefore, the screening day is categorized as imaging_diagnostics, and all treatment days are categorized as core_treatment due to drug administration."
36473143,Nivolumab + Ipilimumab Arm (Arm A),intervention,2,3,8,14,21,28,0,3,7,13,20,27,1,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,42,until progression or max 24 months,"Screening (2 days), then Nivolumab infusions every 2 weeks (Day 0, 14, 28, 42, 56, 70, 84, 98, 112, 126, 140, 154, 168, 182, 196, 210, 224, 238, 252, 266, 280, 294, 308, 322, 336, 350, 364). Ipilimumab infusions occur every 6 weeks (Day 0, 42, 84, 126, 168, 210, 252, 294, 336) on the same day as Nivolumab. A Week 7 biopsy is also included (Day 45).","Day 0 is the first on-treatment dose administration.; Screening procedures are consolidated into two distinct in-person days: one for imaging/biopsy (imaging_diagnostics) and one for routine/pregnancy labs (labs). All other general assessments (consent, H&P, vitals, ECOG, AE, conmeds) are assumed to occur on one of these two days, subsumed by the highest precedence category.; For Arm A, 'Visits occur every 2 weeks' (Table 5.1-2, footnote 'a') means every 2-week interval (Day 0, 14, 28, etc.) is an in-person contact day for drug administration and associated assessments.; Tumor assessments (CT/MRI) and QOL assessments (FACT-H&N, EQ-5D-3L) occur every 6 weeks (Day 0, 42, 84, etc.) and are subsumed by core_treatment if on an infusion day.; PK, Biomarker, and Saliva samples are collected on specified days (Table 5.5-1, 5.6-1) and are subsumed by core_treatment if on an infusion day.; A Week 7 (Day 45) tumor biopsy is counted as a separate in-person visit (imaging_diagnostics) for Arm A as it does not coincide with a scheduled infusion day.; All drug administration days are counted as core_treatment.; Treatment continues until progression, unacceptable toxicity, or a maximum of 24 months. Calculations are performed up to Day +365."
36473143,EXTREME regimen Arm (Arm B),control,2,11,29,44,57,71,0,11,29,44,57,71,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,until progression or unacceptable toxicity,"Screening (2 days), then for 6 cycles (3-week cycles starting Day 0): Day 0 (Cetuximab, Cis/Carbo, 5-FU), Day 1-3 (5-FU), Day 7 (Cetuximab), Day 14 (Cetuximab). This pattern repeats for 6 cycles. Following the 6 cycles, weekly Cetuximab maintenance infusions occur (starting Day 126). A Week 7 biopsy is also included (Day 45).","Day 0 is the first on-treatment dose administration.; Screening procedures are consolidated into two distinct in-person days: one for imaging/biopsy (imaging_diagnostics) and one for routine/pregnancy labs (labs). All other general assessments (consent, H&P, vitals, ECOG, AE, conmeds) are assumed to occur on one of these two days, subsumed by the highest precedence category.; For Arm B, the chemotherapy phase consists of 6 cycles, each 3 weeks (21 days). Within each cycle, Cetuximab is given on Day 1, 8, and 15. Cisplatin/Carboplatin is given on Day 1. Fluorouracil is given on Day 1-4. This results in 6 unique contact days per cycle (Day 0, 1, 2, 3, 7, 14, adjusted for Day 0 start).; After 6 cycles (Day 119), maintenance Cetuximab is administered weekly. The 'weekly (or every 2 weeks)' option is interpreted as weekly for the higher contact day count.; Tumor assessments (CT/MRI) and QOL assessments (FACT-H&N, EQ-5D-3L) occur every 6 weeks (Day 0, 42, 84, etc.) and are subsumed by core_treatment if on an infusion day.; PK, Biomarker, and Saliva samples are collected on specified days (Table 5.5-1, 5.6-1) and are subsumed by core_treatment if on an infusion day.; A Week 7 (Day 45) tumor biopsy is counted for Arm B, but it falls on a 5-FU administration day (Day 45 of Cycle 3), so it is subsumed under core_treatment due to precedence.; All drug administration days are counted as core_treatment.; Treatment continues until progression or unacceptable toxicity. Calculations are performed up to Day +365."
36503738,BBI-608 plus biweekly FOLFIRI (Arm 1),intervention,2,3,7,13,20,27,1,3,7,13,20,27,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,until progression,"Screening (Day -X), Run-in Day 1 (Day -2), Cycle 1 Day 1 (Day 0), and Day 1 of subsequent 14-day cycles (Day 14, 28, 42, etc.). All range-columns were mapped to one nominal date.","All pre-randomization screening assessments (Patient History and Evaluation, Hematology, Biochemistry, Urinalysis, Cardiac Assessment, Radiology & Imaging, Blood sample collection, Pregnancy test) are consolidated into a single in-person visit within the screening window (e.g., Day -14 relative to C1D1). This day is categorized as 'imaging_diagnostics' due to the presence of CT/MRI and ECG.; The 'Run-in Day 1' for Arm 1 (Day -2 relative to C1D1) is counted as an in-person contact day due to multiple required assessments and the initiation of BBI-608 administration. This day is categorized as 'core_treatment' due to BBI-608 initiation.; The 'Run-in Day 2' for Arm 1 (Day -1 relative to C1D1) is not counted as an in-person contact day as the SoE only lists 'Adverse Event evaluation by phone'.; All assessments listed under 'Cycle 1 Day 1' and 'Additional Cycles' in the Schedule of Events tables (Appendix 1 and 2) are assumed to occur on the same day as the FOLFIRI infusion (Day 1 of each 14-day cycle), unless explicitly stated as a separate visit. These days are categorized as 'core_treatment' due to the FOLFIRI infusion.; Radiology & Imaging assessments (Every 8 weeks for 6 months, then every 12 weeks) and Sparse PK collections (C2D1, C3D1 for Arm 1) fall on scheduled FOLFIRI infusion days (CkD1) and therefore do not add additional contact days; their activities are subsumed under the 'core_treatment' category for those days.; The addition of bevacizumab is per investigator choice and is administered on Day 1 of each cycle, thus not adding separate contact days."
36503738,biweekly FOLFIRI alone (Arm 2),control,1,3,7,13,20,27,0,3,7,13,20,27,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,until progression,"Screening (Day -X), Cycle 1 Day 1 (Day 0), and Day 1 of subsequent 14-day cycles (Day 14, 28, 42, etc.). All range-columns were mapped to one nominal date.","All pre-randomization screening assessments (Patient History and Evaluation, Hematology, Biochemistry, Urinalysis, Cardiac Assessment, Radiology & Imaging, Blood sample collection, Pregnancy test) are consolidated into a single in-person visit within the screening window (e.g., Day -14 relative to C1D1). This day is categorized as 'imaging_diagnostics' due to the presence of CT/MRI and ECG.; No 'Run-in' days are applicable for Arm 2.; All assessments listed under 'Cycle 1 Day 1' and 'Additional Cycles' in the Schedule of Events tables (Appendix 1 and 2) are assumed to occur on the same day as the FOLFIRI infusion (Day 1 of each 14-day cycle), unless explicitly stated as a separate visit. These days are categorized as 'core_treatment' due to the FOLFIRI infusion.; Radiology & Imaging assessments (Every 8 weeks for 6 months, then every 12 weeks) fall on scheduled FOLFIRI infusion days (CkD1) and therefore do not add additional contact days; their activities are subsumed under the 'core_treatment' category for those days.; Sparse PK collections are not applicable for Arm 2.; The addition of bevacizumab is per investigator choice and is administered on Day 1 of each cycle, thus not adding separate contact days."
36521097,Arm A: nab-Paclitaxel plus Gemcitabine,intervention,1,4,10,20,21,22,0,4,10,18,18,18,1,0,0,1,2,3,0,0,0,1,1,1,0,0,0,0,0,0,28,6 cycles (assumed completed),"Screening, C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, C3D1, C3D8, C3D15, C4D1, C4D8, C4D15, C5D1, C5D8, C5D15, C6D1, C6D8, C6D15, Week 24 CT/MRI, EOT Visit, Week 36 CT/MRI, Week 48 CT/MRI.","Screening visit is counted as one in-person day, assumed to occur on Day -14 (within the ≤14 days prior to randomization window).; Randomization is not counted as a separate in-person contact day, as it is listed under the 'Screening' column in Table 3 and can occur on the same day as screening or C1D1.; All 6 cycles of treatment are assumed to be completed.; The End of Treatment (EOT) visit is assumed to occur on Day 182 (Day 0 + 6 cycles * 28 days/cycle + 14 days maximum post-C6D28).; CT/MRI scans scheduled for Week 8 (Day 56) and Week 16 (Day 112) coincide with Cycle 3 Day 1 and Cycle 5 Day 1, respectively. Due to drug administration, these days are categorized as 'core_treatment' per precedence rules.; CT/MRI scans scheduled for Week 24 (Day 168), Week 36 (Day 252), and Week 48 (Day 336) are dedicated imaging days as no treatment is administered on these days.; Follow-up for survival and anticancer therapy is explicitly stated to be via telephone contact or record review and is not counted as an in-person contact day.; Collection of archival tumor/normal samples at screening is not considered an in-person contact day.; Quality of Life (QoL) and CA19-9 assessments are performed on days already counted as in-person visits (Screening, C1D1, EOT, and CT/MRI days) and do not add separate contact days."
36521097,Arm B: Gemcitabine alone,control,1,4,10,20,21,22,0,4,10,18,18,18,1,0,0,1,2,3,0,0,0,1,1,1,0,0,0,0,0,0,28,6 cycles (assumed completed),"Screening, C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, C3D1, C3D8, C3D15, C4D1, C4D8, C4D15, C5D1, C5D8, C5D15, C6D1, C6D8, C6D15, Week 24 CT/MRI, EOT Visit, Week 36 CT/MRI, Week 48 CT/MRI.","Screening visit is counted as one in-person day, assumed to occur on Day -14 (within the ≤14 days prior to randomization window).; Randomization is not counted as a separate in-person contact day, as it is listed under the 'Screening' column in Table 3 and can occur on the same day as screening or C1D1.; All 6 cycles of treatment are assumed to be completed.; The End of Treatment (EOT) visit is assumed to occur on Day 182 (Day 0 + 6 cycles * 28 days/cycle + 14 days maximum post-C6D28).; CT/MRI scans scheduled for Week 8 (Day 56) and Week 16 (Day 112) coincide with Cycle 3 Day 1 and Cycle 5 Day 1, respectively. Due to drug administration, these days are categorized as 'core_treatment' per precedence rules.; CT/MRI scans scheduled for Week 24 (Day 168), Week 36 (Day 252), and Week 48 (Day 336) are dedicated imaging days as no treatment is administered on these days.; Follow-up for survival and anticancer therapy is explicitly stated to be via telephone contact or record review and is not counted as an in-person contact day.; Collection of archival tumor/normal samples at screening is not considered an in-person contact day.; Quality of Life (QoL) and CA19-9 assessments are performed on days already counted as in-person visits (Screening, C1D1, EOT, and CT/MRI days) and do not add separate contact days."
36535566,Pembrolizumab (MK-3475) monotherapy,intervention,1,4,7,11,15,20,0,2,5,9,13,18,1,0,0,0,0,0,0,2,2,2,2,2,0,0,0,0,0,0,21,"until progression (up to 35 administrations, approximately 2 years)","Screening (Visit 1), C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1. Range columns were not used for in-person visits.","Day 0 is Cycle 1 Day 1 (C1D1), the first dose administration/randomization.; The 'Screening (Visit 1)' column represents one in-person contact day for all listed procedures.; For Pembrolizumab, in-person visits for Plasma EBV DNA collection occur weekly during Cycle 1 (C1D1, C1D8, C1D15) as per footnote 'n' on Page 29. For subsequent cycles, EBV DNA collection is only on Day 1.; For Capecitabine, oral administration is not considered an in-person 'core_treatment' day. Day 1 visits are for assessments and drug dispensing/counseling.; For Gemcitabine, IV infusion occurs on Day 1 and Day 8 of each cycle, making both in-person 'core_treatment' days.; For Docetaxel, IV infusion occurs on Day 1 of each cycle, making it an in-person 'core_treatment' day.; Tumor Imaging is performed at Screening (Day 0 for categorization) and then every 6 weeks (C3D1, C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1) as per footnote 'k' on Page 28.; Other specific lab/assessment schedules (e.g., Urinalysis, TSH, PK/ADA, Correlative Blood, Optional Sub-study Blood) are applied as per footnotes on Pages 28-29.; The precedence rule for categorization (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to each unique contact day."
36535566,Standard Chemotherapy (Capecitabine),control,1,2,5,9,13,18,0,0,0,0,0,0,1,1,3,5,7,9,0,1,2,4,6,9,0,0,0,0,0,0,21,until disease progression,"Screening (Visit 1), C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1. Range columns were not used for in-person visits.","Day 0 is Cycle 1 Day 1 (C1D1), the first dose administration/randomization.; The 'Screening (Visit 1)' column represents one in-person contact day for all listed procedures.; For Capecitabine, oral administration is not considered an in-person 'core_treatment' day. Day 1 visits are for assessments and drug dispensing/counseling.; Tumor Imaging is performed at Screening (Day 0 for categorization) and then every 6 weeks (C3D1, C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1) as per footnote 'k' on Page 28.; Other specific lab/assessment schedules (e.g., Urinalysis, TSH) are applied as per footnotes on Pages 28-29.; The precedence rule for categorization (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to each unique contact day."
36535566,Standard Chemotherapy (Gemcitabine),control,1,4,9,18,26,36,0,4,9,18,26,36,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until disease progression,"Screening (Visit 1), C1D1, C1D8, C2D1, C2D8, C3D1, C3D8, C4D1, C4D8, C5D1, C5D8, C6D1, C6D8, C7D1, C7D8, C8D1, C8D8, C9D1, C9D8, C10D1, C10D8, C11D1, C11D8, C12D1, C12D8, C13D1, C13D8, C14D1, C14D8, C15D1, C15D8, C16D1, C16D8, C17D1, C17D8, C18D1, C18D8. Range columns were not used for in-person visits.","Day 0 is Cycle 1 Day 1 (C1D1), the first dose administration/randomization.; The 'Screening (Visit 1)' column represents one in-person contact day for all listed procedures.; For Gemcitabine, IV infusion occurs on Day 1 and Day 8 of each cycle, making both in-person 'core_treatment' days.; Tumor Imaging is performed at Screening (Day 0 for categorization) and then every 6 weeks (C3D1, C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1) as per footnote 'k' on Page 28.; Other specific lab/assessment schedules (e.g., Urinalysis, TSH) are applied as per footnotes on Pages 28-29.; The precedence rule for categorization (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to each unique contact day."
36535566,Standard Chemotherapy (Docetaxel),control,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until disease progression,"Screening (Visit 1), C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1. Range columns were not used for in-person visits.","Day 0 is Cycle 1 Day 1 (C1D1), the first dose administration/randomization.; The 'Screening (Visit 1)' column represents one in-person contact day for all listed procedures.; For Docetaxel, IV infusion occurs on Day 1 of each cycle, making it an in-person 'core_treatment' day.; Tumor Imaging is performed at Screening (Day 0 for categorization) and then every 6 weeks (C3D1, C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1) as per footnote 'k' on Page 28.; Other specific lab/assessment schedules (e.g., Urinalysis, TSH) are applied as per footnotes on Pages 28-29.; The precedence rule for categorization (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to each unique contact day."
36541957,Ibrutinib + Chemoimmunotherapy (RICE or RVICI) followed by Ibrutinib Monotherapy,intervention,2,5,10,13,14,15,0,2,3,3,3,3,1,1,2,3,4,5,0,1,3,3,3,3,1,1,2,4,4,4,28,"3 cycles of combination therapy, then 3 cycles of ibrutinib monotherapy (if PR or better), followed by follow-up until PD or 3 years after C1D1.","Screening Day -14 (clinic_visits), Screening Day -7 (imaging_diagnostics), C1D1 (core_treatment), C1D7 (clinic_visits), C1D14 (imaging_diagnostics), C1D22 (labs), C2D1 (core_treatment), C2D14 (labs), C3D1 (core_treatment), C3D14 (labs), EoT (Day 84, imaging_diagnostics), Mono C1D1 (Day 85, clinic_visits), Mono C2D1 (Day 113, clinic_visits), Mono C3D1 (Day 141, clinic_visits), EoM (Day 169, imaging_diagnostics), 9-month FU (Day 270, imaging_diagnostics), 12-month FU (Day 365, imaging_diagnostics). All range-columns were mapped to one nominal date.","Assumed 2 distinct in-person days for screening due to the breadth of procedures (consent, PE, labs, multiple imaging modalities, biopsies, lumbar puncture). One day for initial clinical/consent/basic labs (clinic_visits), another for more invasive/complex diagnostics (imaging_diagnostics).; Assumed 'Day 7 or 8' and 'Day 14 (±1 day)' visits are distinct in-person contact days, mapped to Day 7 and Day 14 respectively.; Assumed weekly hematology and chemistry labs in Cycle 1 (per footnote k, Table 1) imply an in-person visit on Day 22.; Assumed mid-cycle hematology and chemistry labs in Cycles 2 and 3 (per footnote k, Table 1) imply an in-person visit on Day 14 of those cycles (C2D14, C3D14).; Assumed bone marrow aspirate/biopsy and CSF evaluations on C2D1 and C3D1 are 'clinically indicated' for counting purposes, as per protocol instruction to include conditional visits if drug continues.; Assumed ECG and Echocardiogram/MUGA on C2D1 and C3D1 are required (assuming RVICI regimen for counting purposes).; Assumed the End-of-Treatment (EoT) visit occurs on Day 84 (after completion of 3 combination cycles) and is a comprehensive in-person visit.; Assumed Ibrutinib monotherapy starts on Day 85 (Mono C1D1), immediately following the EoT visit.; Assumed the End-of-Monotherapy (EoM) visit occurs on Day 169 (after completion of 3 monotherapy cycles) and is a comprehensive in-person visit.; Assumed all specified follow-up visits in Tables 3 and 4 are in-person contact days.; Applied category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits for days with multiple procedures."
36541957,Chemoimmunotherapy (RICE or RVICI) alone,control,2,5,9,10,11,12,0,2,3,3,3,3,1,1,2,3,4,5,0,1,3,3,3,3,1,1,1,1,1,1,28,"3 cycles of combination therapy, followed by follow-up until PD or 3 years after C1D1.","Screening Day -14 (clinic_visits), Screening Day -7 (imaging_diagnostics), C1D1 (core_treatment), C1D7 (clinic_visits), C1D14 (imaging_diagnostics), C1D22 (labs), C2D1 (core_treatment), C2D14 (labs), C3D1 (core_treatment), C3D14 (labs), EoT (Day 84, imaging_diagnostics), 6-month FU (Day 180, imaging_diagnostics), 9-month FU (Day 270, imaging_diagnostics), 12-month FU (Day 365, imaging_diagnostics). All range-columns were mapped to one nominal date.","Assumed 2 distinct in-person days for screening due to the breadth of procedures (consent, PE, labs, multiple imaging modalities, biopsies, lumbar puncture). One day for initial clinical/consent/basic labs (clinic_visits), another for more invasive/complex diagnostics (imaging_diagnostics).; Assumed 'Day 7 or 8' and 'Day 14 (±1 day)' visits are distinct in-person contact days, mapped to Day 7 and Day 14 respectively.; Assumed weekly hematology and chemistry labs in Cycle 1 (per footnote k, Table 1) imply an in-person visit on Day 22.; Assumed mid-cycle hematology and chemistry labs in Cycles 2 and 3 (per footnote k, Table 1) imply an in-person visit on Day 14 of those cycles (C2D14, C3D14).; Assumed bone marrow aspirate/biopsy and CSF evaluations on C2D1 and C3D1 are 'clinically indicated' for counting purposes, as per protocol instruction to include conditional visits if drug continues.; Assumed ECG and Echocardiogram/MUGA on C2D1 and C3D1 are required (assuming RVICI regimen for counting purposes).; Assumed the End-of-Treatment (EoT) visit occurs on Day 84 (after completion of 3 combination cycles) and is a comprehensive in-person visit.; Assumed no ibrutinib monotherapy phase for this arm.; Assumed all specified follow-up visits in Tables 3 and 4 are in-person contact days.; Applied category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits for days with multiple procedures."
36623230,Arm A: 45 Gy twice daily for 3 weeks; concurrent cisplatin or carboplatin and etoposide chemotherapy,control,3,19,29,30,31,32,0,18,24,24,24,24,2,0,2,3,4,5,1,1,3,3,3,3,0,0,0,0,0,0,21,"fixed duration (4 cycles chemotherapy, 3 weeks radiotherapy)","Screening (Day -28, Day -16, Day -15), Cycle 1 (Day 0, Day 1, Day 2, Day 3, Day 4, Day 7, Day 8, Day 9, Day 10, Day 11, Day 14, Day 15, Day 16, Day 17, Day 18), Cycle 2 (Day 21, Day 22, Day 23, Day 28), Cycle 3 (Day 42, Day 43, Day 44, Day 49), Cycle 4 (Day 63, Day 64, Day 65, Day 70), Restaging after C4 (Day 84), Follow-up (Day 90, Day 180, Day 270, Day 365).","Radiotherapy for both arms is assumed to start on Cycle 1 Day 1 (Day 0) for calculation purposes, representing the earliest and most intensive scenario.; Radiotherapy is administered 5 days per week (Monday-Friday), with weekends off.; Pre-registration activities (screening) are assumed to occur on 3 distinct days: one for imaging (CT/PET/MRI), one for labs (blood work, pregnancy test, H&P), and one for pulmonary function tests (PFTs). Due to precedence rules, H&P is subsumed under labs/imaging.; The 'Time of Restaging (q 2 cycles)' visit after Cycle 2 is assumed to coincide with Cycle 3 Day 1 (Day 42), which is a chemotherapy day. Therefore, it does not add a unique contact day and is categorized as 'core_treatment' due to precedence.; Follow-up visits are assumed to occur at nominal 3, 6, 9, and 12-month marks (Day 90, Day 180, Day 270, Day 365) after Day 0, and include comprehensive assessments (imaging, labs, clinic visits), with imaging taking precedence for categorization."
36623230,Arm B: 70 Gy once daily for 7 weeks; concurrent cisplatin or carboplatin and etoposide chemotherapy,intervention,3,23,42,43,44,45,0,23,38,38,38,38,2,0,2,3,4,5,1,0,2,2,2,2,0,0,0,0,0,0,21,"fixed duration (4 cycles chemotherapy, 7 weeks radiotherapy)","Screening (Day -28, Day -16, Day -15), Cycle 1 (Day 0, Day 1, Day 2, Day 3, Day 4, Day 7, Day 8, Day 9, Day 10, Day 11, Day 14, Day 15, Day 16, Day 17, Day 18), Cycle 2 (Day 21, Day 22, Day 23, Day 24, Day 25, Day 28, Day 29, Day 30, Day 31, Day 32, Day 35, Day 36, Day 37, Day 38, Day 39), Cycle 3 (Day 42, Day 43, Day 44, Day 45, Day 46, Day 49), Cycle 4 (Day 63, Day 64, Day 65, Day 70), Restaging after C4 (Day 84), Follow-up (Day 90, Day 180, Day 270, Day 365).","Radiotherapy for both arms is assumed to start on Cycle 1 Day 1 (Day 0) for calculation purposes, representing the earliest and most intensive scenario.; Radiotherapy is administered 5 days per week (Monday-Friday), with weekends off.; Pre-registration activities (screening) are assumed to occur on 3 distinct days: one for imaging (CT/PET/MRI), one for labs (blood work, pregnancy test, H&P), and one for pulmonary function tests (PFTs). Due to precedence rules, H&P is subsumed under labs/imaging.; The 'Time of Restaging (q 2 cycles)' visit after Cycle 2 is assumed to coincide with Cycle 3 Day 1 (Day 42), which is a chemotherapy and radiotherapy day. Therefore, it does not add a unique contact day and is categorized as 'core_treatment' due to precedence.; Follow-up visits are assumed to occur at nominal 3, 6, 9, and 12-month marks (Day 90, Day 180, Day 270, Day 365) after Day 0, and include comprehensive assessments (imaging, labs, clinic visits), with imaging taking precedence for categorization."
36669140,Regimen A (VDC/IE),control,1,11,30,58,70,71,0,9,22,44,54,54,1,0,1,1,2,3,0,2,7,13,14,14,0,0,0,0,0,0,14,until progression,"Screening (Day -7), Induction (Days 0, 1, 7, 14-18, 21, 28, 29, 35, 42-46, 49, 56, 57, 63, 70-74, 77, 83), Consolidation (Days 84, 85, 91, 98-102, 105, 112, 113, 119, 126-130, 133, 140, 141, 147, 154-158, 161, 168, 169, 175, 182-186, 189, 195), Metastatic Site Radiation (Days 203-207), Follow-up (Day 285). Range-columns for drug administration were mapped to individual nominal dates.","Regimen B is considered identical to Regimen A for contact days. The protocol (Version 05/01/19) states that ganitumab administration was discontinued for all patients on Regimen B as of March 20, 2019, and that they 'instead receive the same therapy as patients on Regimen A.'; The 'Week Day' columns in the Therapy Delivery Maps (e.g., Page 27) represent the absolute day from Cycle 1 Day 1 (Day 0) of that phase (Induction or Consolidation).; Drug administration days (e.g., 'Days 1-5' for Ifosfamide/Etoposide) are counted as individual contact days for each day within the specified range.; Visits explicitly marked with an asterisk (e.g., 'b*') in the 'Studies' column (e.g., CBC, differential, platelets) are counted as in-person contact days.; Local Control (surgery/XRT) is variable. Fixed evaluations at 'End of Induction / Pre-Local Control' (Day 83) are counted. If radiation is performed for local control, it is concurrent with Consolidation chemotherapy.; Metastatic Site Radiation (SBRT) is 5 days, starting no earlier than 3 weeks from the start of Week 15 of Consolidation (Day 182 + 21 days = Day 203).; Follow-up visits are timed from the End of Consolidation therapy (Day 195).; Optional visits or samples (e.g., 'Optional BMA submission', 'Optional sample in Streck', 'PK blood sample (ONLY for 1st 10 patients < 21 yo)') were excluded.; Category precedence was applied as: core_treatment > imaging_diagnostics > labs > clinic_visits."
36669140,Regimen B (VDC/IE plus ganitumab),intervention,1,11,30,58,70,71,0,9,22,44,54,54,1,0,1,1,2,3,0,2,7,13,14,14,0,0,0,0,0,0,14,until progression,"Screening (Day -7), Induction (Days 0, 1, 7, 14-18, 21, 28, 29, 35, 42-46, 49, 56, 57, 63, 70-74, 77, 83), Consolidation (Days 84, 85, 91, 98-102, 105, 112, 113, 119, 126-130, 133, 140, 141, 147, 154-158, 161, 168, 169, 175, 182-186, 189, 195), Metastatic Site Radiation (Days 203-207), Follow-up (Day 285). Range-columns for drug administration were mapped to individual nominal dates.","Regimen B is considered identical to Regimen A for contact days. The protocol (Version 05/01/19) states that ganitumab administration was discontinued for all patients on Regimen B as of March 20, 2019, and that they 'instead receive the same therapy as patients on Regimen A.' Therefore, the ganitumab-specific visits and procedures are excluded from the count.; The 'Week Day' columns in the Therapy Delivery Maps (e.g., Page 41) represent the absolute day from Cycle 1 Day 1 (Day 0) of that phase (Induction or Consolidation).; Drug administration days (e.g., 'Days 1-5' for Ifosfamide/Etoposide) are counted as individual contact days for each day within the specified range.; Visits explicitly marked with an asterisk (e.g., 'b*') in the 'Studies' column (e.g., CBC, differential, platelets) are counted as in-person contact days.; Local Control (surgery/XRT) is variable. Fixed evaluations at 'End of Induction / Pre-Local Control' (Day 83) are counted. If radiation is performed for local control, it is concurrent with Consolidation chemotherapy.; Metastatic Site Radiation (SBRT) is 5 days, starting no earlier than 3 weeks from the start of Week 15 of Consolidation (Day 182 + 21 days = Day 203).; Follow-up visits are timed from the End of Consolidation therapy (Day 195).; Optional visits or samples (e.g., 'Optional BMA submission', 'Optional sample in Streck', 'PK blood sample (ONLY for 1st 10 patients < 21 yo)') were excluded.; Category precedence was applied as: core_treatment > imaging_diagnostics > labs > clinic_visits."
36764316,AMG 510 (960 mg once daily orally),intervention,5,5,11,19,27,37,1,3,3,3,3,3,2,0,2,4,6,8,1,0,1,3,5,8,1,2,5,9,13,18,21,until progression (calculated up to Day +365 for maximum scheduled visits),"Screening (5 days), C1D1, C1D5, C1D8, C2D1, C2D5, C3D1 (with imaging), C3D5, C4D1, C4D5, C5D1 (with imaging), C5D5, ..., C17D1 (with imaging), C17D5, C18D1, C18D5. Range-columns were mapped to one nominal date (e.g., 'Day 14–21' to Day 14, though no such ranges were present in treatment cycles).","Cycle length is 21 days for both arms.; Day 0 is defined as Cycle 1 Day 1 (C1D1).; Treatment duration is calculated up to Day +365 (12 months) to capture all scheduled visits within the horizon. Safety Follow-up (SFU) is assumed to occur after Day +365 if treatment continues for the full 12 months, and thus not counted in the 12-month window.; Screening visits are counted as 5 distinct days: 1 for general clinic assessments/PRO/QOL, 1 for ECG, 1 for all screening labs, 1 for CT/MRI imaging, and 1 for mandatory tumor biopsy (if required for eligibility).; For AMG 510, in-clinic dosing occurs on C1D1, C1D8, and C2D1. For subsequent cycles (C3D1 onwards), AMG 510 is administered at home. Therefore, C1D1, C1D8, and C2D1 are categorized as 'core_treatment'.; For Docetaxel, intravenous infusion occurs on all CxD1. Therefore, all CxD1 are categorized as 'core_treatment'.; Tumor assessments (CT/MRI) are scheduled every 6 weeks from C1D1 (at weeks 7, 13, 19, 25, 31, 37, 43, and 49). These correspond to Day 42, 84, 126, 168, 210, 252, 294, and 336, which are C3D1, C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, and C17D1, respectively.; For AMG 510, since dosing is at home from C3D1 onwards, the coinciding imaging assessment on these CxD1 days makes 'imaging_diagnostics' the primary category.; For Docetaxel, since IV infusion occurs on all CxD1, 'core_treatment' remains the primary category for these days, with imaging being a secondary activity.; CxD5 visits for both arms primarily involve clinic visits (physical exam, vitals, PRO/QOL) and routine labs, with 'clinic_visits' being the primary category.; CxD1 visits for AMG 510 from C4D1 onwards (where no dosing or imaging is primary) are categorized as 'labs' due to the extensive PK/biomarker and safety lab collections."
36764316,Docetaxel (75 mg/m2 intravenously every 3 weeks),control,5,4,10,18,26,36,1,2,5,9,13,18,2,0,0,0,0,0,1,0,0,0,0,0,1,2,5,9,13,18,21,until progression (calculated up to Day +365 for maximum scheduled visits),"Screening (5 days), C1D1, C1D5, C2D1, C2D5, C3D1 (with imaging), C3D5, C4D1, C4D5, C5D1 (with imaging), C5D5, ..., C17D1 (with imaging), C17D5, C18D1, C18D5. Range-columns were mapped to one nominal date (e.g., 'Day 14–21' to Day 14, though no such ranges were present in treatment cycles).","Cycle length is 21 days for both arms.; Day 0 is defined as Cycle 1 Day 1 (C1D1).; Treatment duration is calculated up to Day +365 (12 months) to capture all scheduled visits within the horizon. Safety Follow-up (SFU) is assumed to occur after Day +365 if treatment continues for the full 12 months, and thus not counted in the 12-month window.; Screening visits are counted as 5 distinct days: 1 for general clinic assessments/PRO/QOL, 1 for ECG, 1 for all screening labs, 1 for CT/MRI imaging, and 1 for mandatory tumor biopsy (if required for eligibility).; For AMG 510, in-clinic dosing occurs on C1D1, C1D8, and C2D1. For subsequent cycles (C3D1 onwards), AMG 510 is administered at home. Therefore, C1D1, C1D8, and C2D1 are categorized as 'core_treatment'.; For Docetaxel, intravenous infusion occurs on all CxD1. Therefore, all CxD1 are categorized as 'core_treatment'.; Tumor assessments (CT/MRI) are scheduled every 6 weeks from C1D1 (at weeks 7, 13, 19, 25, 31, 37, 43, and 49). These correspond to Day 42, 84, 126, 168, 210, 252, 294, and 336, which are C3D1, C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, and C17D1, respectively.; For AMG 510, since dosing is at home from C3D1 onwards, the coinciding imaging assessment on these CxD1 days makes 'imaging_diagnostics' the primary category.; For Docetaxel, since IV infusion occurs on all CxD1, 'core_treatment' remains the primary category for these days, with imaging being a secondary activity.; CxD5 visits for both arms primarily involve clinic visits (physical exam, vitals, PRO/QOL) and routine labs, with 'clinic_visits' being the primary category.; CxD1 visits for AMG 510 from C4D1 onwards (where no dosing or imaging is primary) are categorized as 'labs' due to the extensive PK/biomarker and safety lab collections."
36795891,Rucaparib / Physician's Choice (Abiraterone Acetate or Enzalutamide),intervention,2,3,7,14,20,27,0,2,4,7,10,14,1,0,0,0,0,0,1,1,3,7,10,13,0,0,0,0,0,0,28,until progression,"Screening: Day -28, Day -14. Treatment: Day 1, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141, Day 155, Day 169, Day 183, Day 197, Day 211, Day 225, Day 239, Day 253, Day 267, Day 281, Day 295, Day 309, Day 323, Day 337, Day 351, Day 365. Range-columns were mapped to one nominal date.","The 'Pre-screening Phase' column is considered an optional visit outside the defined 'screening_window' (Day -28 to Day -1) and is not counted.; The 'Day -28 to Day -1' and 'Day -14 to Day -1' columns in the Screening Phase are treated as two distinct in-person visits.; For the Rucaparib and Abiraterone/Enzalutamide arms, the treatment phase follows a 28-day cycle with in-person visits on Day 1 and Day 15 of each cycle, continuing until Day 365.; Study Drug Dispensation is categorized as 'core_treatment'.; Tumor Assessment/CT/MRI/Bone Scan and 12-lead ECG are categorized as 'imaging_diagnostics'.; Blood samples for plasma ctDNA analysis, Pharmacogenomic blood sample, Clinical Laboratory Assessments, PSA Measurement, and Serum Testosterone are categorized as 'labs'.; Physical Examination, Weight, Height, Vital Signs, Prior/Concomitant Medications/Procedures, Patient-reported outcome, ECOG Performance Status, and Adverse Events are categorized as 'clinic_visits'.; Precedence for categorization of a single day with multiple activities: core_treatment > imaging_diagnostics > labs > clinic_visits."
36795891,Physician's Choice (Docetaxel),control,2,2,6,11,13,14,0,2,5,9,10,10,1,0,1,2,3,4,1,0,0,0,0,0,0,0,0,0,0,0,21,"maximum 10 cycles for docetaxel, assessments continue until progression","Screening: Day -28, Day -14. Treatment: Day 1, Day 22, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 127, Day 148, Day 169, Day 190, Day 253, Day 337. Range-columns were mapped to one nominal date.","The 'Pre-screening Phase' column is considered an optional visit outside the defined 'screening_window' (Day -28 to Day -1) and is not counted.; The 'Day -28 to Day -1' and 'Day -14 to Day -1' columns in the Screening Phase are treated as two distinct in-person visits.; Docetaxel administration occurs every 21 days for a maximum of 10 cycles. Other assessments (e.g., tumor assessments, PROs) follow a schedule of every 8 weeks for 24 weeks, then every 12 weeks thereafter.; Study Drug Dispensation/Docetaxel Administration is categorized as 'core_treatment'.; Tumor Assessment/CT/MRI/Bone Scan and 12-lead ECG are categorized as 'imaging_diagnostics'.; Blood samples for plasma ctDNA analysis, Clinical Laboratory Assessments, and PSA Measurement are categorized as 'labs'.; Physical Examination, Weight, Height, Vital Signs, Prior/Concomitant Medications/Procedures, Patient-reported outcome, ECOG Performance Status, and Adverse Events are categorized as 'clinic_visits'.; Precedence for categorization of a single day with multiple activities: core_treatment > imaging_diagnostics > labs > clinic_visits."
36952634,Niraparib + AAP (Cohorts 1 & 2 Randomized),intervention,2,3,7,10,13,17,0,2,3,4,6,9,2,0,1,3,4,5,0,1,3,3,3,3,0,0,0,0,0,0,28,until progression,"Prescreening (Day -28), Screening (Day -1), Cycle 1 Day 1 (Day 0), Cycle 1 Day 15 (Day 14), Cycle 2 Day 1 (Day 28), Cycle 2 Day 15 (Day 42), Cycle 3 Day 1 (Day 56), Cycle 3 Day 15 (Day 70), Cycle 4 Day 1 (Day 84), Cycle 5 Day 1 (Day 112), Cycle 6 Day 1 (Day 140), Cycle 7 Day 1 (Day 168), Cycle 8 Day 1 (Day 196), Cycle 9 Day 1 (Day 224), Cycle 10 Day 1 (Day 252), Cycle 11 Day 1 (Day 280), Cycle 12 Day 1 (Day 308), Cycle 13 Day 1 (Day 336), Cycle 15 Day 1 (Day 364). Imaging is performed at C3D1, C5D1, C7D1, C10D1, C13D1. PK samples are collected at C2D1, C3D1, C4D1, C5D1, C6D1, C7D1. All range-columns were mapped to one nominal date.","Treatment is assumed to continue for the full 12-month duration for calculation purposes, as the protocol states 'Treatment continues until disease progression, unacceptable toxicity, death, or study termination' and does not specify a fixed shorter duration for all subjects.; Prescreening and Screening are considered two distinct in-person contact days, as they appear in separate columns in the Schedule of Events (SoE) and involve distinct in-person procedures.; The 'Day 15' column in the SoE is interpreted as Day 14 relative to Cycle 1 Day 1 (Day 0) for calendarization.; Patient-Reported Outcomes (PROs) and weekly blood pressure monitoring (if not coinciding with other mandatory in-person visits) are assumed to be conducted remotely or do not constitute a separate in-person contact day, based on protocol text (e.g., 'Collection by phone can be done for any ePRO collection', 'BP monitoring can occur at clinic visit or can be reported to the site by the subject, by home nurse, or by other method deemed reliable by the investigator').; Pharmacokinetic (PK) sampling visits (C2D1, C3D1, C4D1, C5D1, C6D1, C7D1) coincide with other scheduled in-person visits and do not add additional unique contact days.; For Cohort 2, the main Schedule of Events (Table 1) is used for the treatment phase, as the 'minimal collection schedule' in Attachment 7 (Table 12) is primarily for data collection for unblinded subjects, and the protocol indicates subjects move to the Long-term Extension (LTE) phase only after database lock, implying the main SoE applies until then. The 'dispense study drugs' in Table 1 implies an in-person visit for drug collection.; For Cohort 3, the protocol explicitly states subjects 'undergo the same study procedures as Cohort 1', so the same schedule of events applies."
36952634,Placebo + AAP (Cohorts 1 & 2 Randomized),control,2,3,7,10,13,17,0,2,3,4,6,9,2,0,1,3,4,5,0,1,3,3,3,3,0,0,0,0,0,0,28,until progression,"Prescreening (Day -28), Screening (Day -1), Cycle 1 Day 1 (Day 0), Cycle 1 Day 15 (Day 14), Cycle 2 Day 1 (Day 28), Cycle 2 Day 15 (Day 42), Cycle 3 Day 1 (Day 56), Cycle 3 Day 15 (Day 70), Cycle 4 Day 1 (Day 84), Cycle 5 Day 1 (Day 112), Cycle 6 Day 1 (Day 140), Cycle 7 Day 1 (Day 168), Cycle 8 Day 1 (Day 196), Cycle 9 Day 1 (Day 224), Cycle 10 Day 1 (Day 252), Cycle 11 Day 1 (Day 280), Cycle 12 Day 1 (Day 308), Cycle 13 Day 1 (Day 336), Cycle 15 Day 1 (Day 364). Imaging is performed at C3D1, C5D1, C7D1, C10D1, C13D1. PK samples are collected at C2D1, C3D1, C4D1, C5D1, C6D1, C7D1. All range-columns were mapped to one nominal date.","Treatment is assumed to continue for the full 12-month duration for calculation purposes, as the protocol states 'Treatment continues until disease progression, unacceptable toxicity, death, or study termination' and does not specify a fixed shorter duration for all subjects.; Prescreening and Screening are considered two distinct in-person contact days, as they appear in separate columns in the Schedule of Events (SoE) and involve distinct in-person procedures.; The 'Day 15' column in the SoE is interpreted as Day 14 relative to Cycle 1 Day 1 (Day 0) for calendarization.; Patient-Reported Outcomes (PROs) and weekly blood pressure monitoring (if not coinciding with other mandatory in-person visits) are assumed to be conducted remotely or do not constitute a separate in-person contact day, based on protocol text (e.g., 'Collection by phone can be done for any ePRO collection', 'BP monitoring can occur at clinic visit or can be reported to the site by the subject, by home nurse, or by other method deemed reliable by the investigator').; Pharmacokinetic (PK) sampling visits (C2D1, C3D1, C4D1, C5D1, C6D1, C7D1) coincide with other scheduled in-person visits and do not add additional unique contact days. Note that abiraterone PK is only collected at C2D1 and C3D1.; For Cohort 2, the main Schedule of Events (Table 1) is used for the treatment phase, as the 'minimal collection schedule' in Attachment 7 (Table 12) is primarily for data collection for unblinded subjects, and the protocol indicates subjects move to the Long-term Extension (LTE) phase only after database lock, implying the main SoE applies until then. The 'dispense study drugs' in Table 1 implies an in-person visit for drug collection.; For Cohort 3, the protocol explicitly states subjects 'undergo the same study procedures as Cohort 1', so the same schedule of events applies."
36952634,Niraparib + AA FDC + Prednisone (Cohort 3 Open-Label),intervention,2,3,7,10,13,17,0,2,3,4,6,9,2,0,1,3,4,5,0,1,3,3,3,3,0,0,0,0,0,0,28,until progression,"Prescreening (Day -28), Screening (Day -1), Cycle 1 Day 1 (Day 0), Cycle 1 Day 15 (Day 14), Cycle 2 Day 1 (Day 28), Cycle 2 Day 15 (Day 42), Cycle 3 Day 1 (Day 56), Cycle 3 Day 15 (Day 70), Cycle 4 Day 1 (Day 84), Cycle 5 Day 1 (Day 112), Cycle 6 Day 1 (Day 140), Cycle 7 Day 1 (Day 168), Cycle 8 Day 1 (Day 196), Cycle 9 Day 1 (Day 224), Cycle 10 Day 1 (Day 252), Cycle 11 Day 1 (Day 280), Cycle 12 Day 1 (Day 308), Cycle 13 Day 1 (Day 336), Cycle 15 Day 1 (Day 364). Imaging is performed at C3D1, C5D1, C7D1, C10D1, C13D1. PK samples are collected at C2D1, C3D1, C4D1, C5D1, C6D1, C7D1. All range-columns were mapped to one nominal date.","Treatment is assumed to continue for the full 12-month duration for calculation purposes, as the protocol states 'Treatment continues until disease progression, unacceptable toxicity, death, or study termination' and does not specify a fixed shorter duration for all subjects.; Prescreening and Screening are considered two distinct in-person contact days, as they appear in separate columns in the Schedule of Events (SoE) and involve distinct in-person procedures.; The 'Day 15' column in the SoE is interpreted as Day 14 relative to Cycle 1 Day 1 (Day 0) for calendarization.; Patient-Reported Outcomes (PROs) and weekly blood pressure monitoring (if not coinciding with other mandatory in-person visits) are assumed to be conducted remotely or do not constitute a separate in-person contact day, based on protocol text (e.g., 'Collection by phone can be done for any ePRO collection', 'BP monitoring can occur at clinic visit or can be reported to the site by the subject, by home nurse, or by other method deemed reliable by the investigator').; Pharmacokinetic (PK) sampling visits (C2D1, C3D1, C4D1, C5D1, C6D1, C7D1) coincide with other scheduled in-person visits and do not add additional unique contact days. Note that abiraterone PK is only collected at C2D1 and C3D1.; For Cohort 2, the main Schedule of Events (Table 1) is used for the treatment phase, as the 'minimal collection schedule' in Attachment 7 (Table 12) is primarily for data collection for unblinded subjects, and the protocol indicates subjects move to the Long-term Extension (LTE) phase only after database lock, implying the main SoE applies until then. The 'dispense study drugs' in Table 1 implies an in-person visit for drug collection.; For Cohort 3, the protocol explicitly states subjects 'undergo the same study procedures as Cohort 1', so the same schedule of events applies."
36969338,BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1),intervention,4,4,10,20,30,40,2,4,10,20,30,40,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (Day -14, Day -3), Run-in (Day -2, Day -1 for Arm 1 only), then Cycle 1 Day 1, Day 8, Day 15, and subsequent cycles on Day 1, Day 8, Day 15 (e.g., C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, etc.) through Day +365. Range-columns (e.g., 'Day 14–21') were mapped to one nominal date (e.g., Day 14).","Day 0 is defined as Cycle 1 Day 1 (C1D1).; The 'Baseline evaluations' (<14 days prior to randomization) are considered a single in-person visit (e.g., Day -14).; The 'Additional testing' (<72 hours prior to randomization) is considered a distinct single in-person visit (e.g., Day -3).; For Arm 1, 'Run-in Day 1' and 'Run-in Day 2' (BBI-608 administration 2 days prior to C1D1) are considered two distinct in-person visits (Day -2, Day -1).; All assessments (Physical Exam, Vitals, ECOG PS, Concurrent Medication List, Weight, Adverse Event Assessment, Hematology, Biochemistry, Urinalysis, ECG, Quality of Life, Radiology/Imaging, Sparse PK, Pregnancy Test) occurring on days with IV infusions or oral BBI-608 administration are subsumed under 'core_treatment' due to precedence.; Treatment is assumed to continue for the full 365-day horizon, as per 'until progression' rule, unless a specific discontinuation date within this period is stated. The February 28th, 2020 completion date is a study-level completion, not a per-patient treatment duration limit within the 365-day horizon.; The 'After Permanent Treatment Discontinuation' schedule is not applied within the 365-day horizon, as treatment is assumed to continue."
36969338,nab-paclitaxel with gemcitabine (Arm 2),control,2,4,10,20,30,40,0,4,10,20,30,40,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (Day -14, Day -3), then Cycle 1 Day 1, Day 8, Day 15, and subsequent cycles on Day 1, Day 8, Day 15 (e.g., C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, etc.) through Day +365. Range-columns (e.g., 'Day 14–21') were mapped to one nominal date (e.g., Day 14).","Day 0 is defined as Cycle 1 Day 1 (C1D1).; The 'Baseline evaluations' (<14 days prior to randomization) are considered a single in-person visit (e.g., Day -14).; The 'Additional testing' (<72 hours prior to randomization) is considered a distinct single in-person visit (e.g., Day -3).; For Arm 2, there are no 'Run-in' days as BBI-608 is not administered.; All assessments (Physical Exam, Vitals, ECOG PS, Concurrent Medication List, Weight, Adverse Event Assessment, Hematology, Biochemistry, Urinalysis, ECG, Quality of Life, Radiology/Imaging, Pregnancy Test) occurring on days with IV infusions are subsumed under 'core_treatment' due to precedence.; Treatment is assumed to continue for the full 365-day horizon, as per 'until progression' rule, unless a specific discontinuation date within this period is stated. The February 28th, 2020 completion date is a study-level completion, not a per-patient treatment duration limit within the 365-day horizon.; The 'After Permanent Treatment Discontinuation' schedule is not applied within the 365-day horizon, as treatment is assumed to continue."
37069359,BL-8040 + G-CSF,intervention,1,9,33,35,36,37,0,8,9,9,9,9,1,1,1,2,2,2,0,0,23,24,25,26,0,0,0,0,0,0,28,until progression,"Screening (Day -28 to -1), Baseline (Day 0), Day 1, Day 2, Day 3, Day 4 (morning & evening), Day 5, Day 6 (morning & evening), Day 7, Day 8, Visit 9 (Conditioning, Day +35), Visit 10 (Transplant, Day +36), Daily Engraftment (Day +37 to Day +57), Visit 11 (Day 30 post-transplant, Day +66), Visit 12 (Day 60 post-transplant, Day +96), Visit 13 (Day 100 post-transplant, Day +136), Visit 14 (Day 180 post-transplant, Day +216), Visit 15 (Day 270 post-transplant, Day +306).","Part 2 arms (BL-8040 + G-CSF and Placebo + G-CSF) have identical visit schedules and procedures for calculating contact days.; A single Screening Visit day is assumed to occur within Day -28 to Day -1, including a Bone Marrow Biopsy for relevant patients, classifying it as an imaging_diagnostics day.; Baseline Visit (Day 0) is a distinct in-person contact day, including an ECG, classifying it as an imaging_diagnostics day.; The maximum mobilization/apheresis schedule (up to Day 8) is assumed to occur, including the second BL-8040/Placebo dose on Day 6 and apheresis sessions on Day 5, 6, 7, and 8, as this represents the maximum patient burden for this phase. These days are primarily classified as core_treatment due to drug administration and apheresis.; Conditioning (Visit 9) is assumed to occur on Day +35 (within 5 weeks after Day 8), primarily involving labs.; Transplantation (Visit 10) is assumed to occur on Day +36 (24 hours after conditioning), classified as a core_treatment day.; The engraftment period is assumed to be 21 days of daily in-patient visits following transplantation (Day +37 to Day +57), primarily for labs.; Bone Marrow Biopsy is assumed to be performed at Screening and Visit 13 (Day 100 post-transplant) for relevant patients, driving the category to imaging_diagnostics for those days.; Phone calls for long-term follow-up (Visits 17+) are not counted as in-person healthcare contact days.; For visits with multiple procedures, category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to assign a single primary category for the day."
37069359,Placebo + G-CSF,control,1,9,33,35,36,37,0,8,9,9,9,9,1,1,1,2,2,2,0,0,23,24,25,26,0,0,0,0,0,0,28,until progression,"Screening (Day -28 to -1), Baseline (Day 0), Day 1, Day 2, Day 3, Day 4 (morning & evening), Day 5, Day 6 (morning & evening), Day 7, Day 8, Visit 9 (Conditioning, Day +35), Visit 10 (Transplant, Day +36), Daily Engraftment (Day +37 to Day +57), Visit 11 (Day 30 post-transplant, Day +66), Visit 12 (Day 60 post-transplant, Day +96), Visit 13 (Day 100 post-transplant, Day +136), Visit 14 (Day 180 post-transplant, Day +216), Visit 15 (Day 270 post-transplant, Day +306).","Part 2 arms (BL-8040 + G-CSF and Placebo + G-CSF) have identical visit schedules and procedures for calculating contact days.; A single Screening Visit day is assumed to occur within Day -28 to Day -1, including a Bone Marrow Biopsy for relevant patients, classifying it as an imaging_diagnostics day.; Baseline Visit (Day 0) is a distinct in-person contact day, including an ECG, classifying it as an imaging_diagnostics day.; The maximum mobilization/apheresis schedule (up to Day 8) is assumed to occur, including the second BL-8040/Placebo dose on Day 6 and apheresis sessions on Day 5, 6, 7, and 8, as this represents the maximum patient burden for this phase. These days are primarily classified as core_treatment due to drug administration and apheresis.; Conditioning (Visit 9) is assumed to occur on Day +35 (within 5 weeks after Day 8), primarily involving labs.; Transplantation (Visit 10) is assumed to occur on Day +36 (24 hours after conditioning), classified as a core_treatment day.; The engraftment period is assumed to be 21 days of daily in-patient visits following transplantation (Day +37 to Day +57), primarily for labs.; Bone Marrow Biopsy is assumed to be performed at Screening and Visit 13 (Day 100 post-transplant) for relevant patients, driving the category to imaging_diagnostics for those days.; Phone calls for long-term follow-up (Visits 17+) are not counted as in-person healthcare contact days.; For visits with multiple procedures, category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to assign a single primary category for the day."
37071094,mFOLFOX6 + panitumumab group,intervention,1,9,21,39,60,80,0,9,21,39,60,80,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,until discontinuation criteria are met (guided duration of 12 months),"Screening (Day -28 to Day -1), then for each 14-day cycle: Day 1 (drug administration, labs, clinical findings, ECOG PS, plus imaging/tumor markers on C1D1, C5D1, C9D1, C13D1, C17D1, C21D1, C25D1), Day 2 (5-FU civ), Day 3 (5-FU civ).","Treatment is assumed to continue for the full 365 days to cover the 12-month window, as the protocol states a 'guided duration of 12 months' and 'continuing until discontinuation criteria are met'.; 5-FU continuous intravenous infusion (civ) for 46 hours (Day 1-3) is counted as three distinct in-person contact days per cycle (Day 1 for initiation, Day 2 for ongoing monitoring/infusion, Day 3 for discontinuation/monitoring).; All 'At enrollment' activities (ICF, patient background, RAS status, clinical findings, height/body weight, ECOG PS, laboratory tests, immunological tests, tumor markers, and imaging tests) are assumed to be performed on a single in-person screening day within the Day -28 to Day -1 window. Imaging (CT/MRI) has the highest precedence among these screening activities.; During protocol treatment, imaging and tumor marker assessments (scheduled every 8 weeks on Day 1 of specific cycles) fall on days already designated for core treatment (drug administration). Therefore, these do not add new contact days but are subsumed under the 'core_treatment' category due to precedence.; Category precedence applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
37071094,mFOLFOX6 + bevacizumab group,control,1,9,21,39,60,80,0,9,21,39,60,80,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,until discontinuation criteria are met (guided duration of 12 months),"Screening (Day -28 to Day -1), then for each 14-day cycle: Day 1 (drug administration, labs, clinical findings, ECOG PS, plus imaging/tumor markers on C1D1, C5D1, C9D1, C13D1, C17D1, C21D1, C25D1), Day 2 (5-FU civ), Day 3 (5-FU civ).","Treatment is assumed to continue for the full 365 days to cover the 12-month window, as the protocol states a 'guided duration of 12 months' and 'continuing until discontinuation criteria are met'.; 5-FU continuous intravenous infusion (civ) for 46 hours (Day 1-3) is counted as three distinct in-person contact days per cycle (Day 1 for initiation, Day 2 for ongoing monitoring/infusion, Day 3 for discontinuation/monitoring).; All 'At enrollment' activities (ICF, patient background, RAS status, clinical findings, height/body weight, ECOG PS, laboratory tests, immunological tests, tumor markers, and imaging tests) are assumed to be performed on a single in-person screening day within the Day -28 to Day -1 window. Imaging (CT/MRI) has the highest precedence among these screening activities.; During protocol treatment, imaging and tumor marker assessments (scheduled every 8 weeks on Day 1 of specific cycles) fall on days already designated for core treatment (drug administration). Therefore, these do not add new contact days but are subsumed under the 'core_treatment' category due to precedence.; Category precedence applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
37075781,Arm A: Pembrolizumab plus Gemcitabine and Cisplatin,intervention,2,4,9,18,26,36,1,4,9,18,26,36,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,Pembrolizumab and Gemcitabine until progression/unacceptable toxicity (assumed 365 days for calculation); Cisplatin for up to 8 cycles (168 days).,"Screening Day 1 (core_treatment), Screening Day 2 (imaging_diagnostics), C1D1, C1D8, C2D1, C2D8, C3D1, C3D8, C4D1, C4D8, C5D1, C5D8, C6D1, C6D8, C7D1, C7D8, C8D1, C8D8, C9D1, C9D8, C10D1, C10D8, C11D1, C11D8, C12D1, C12D8, C13D1, C13D8, C14D1, C14D8, C15D1, C15D8, C16D1, C16D8, C17D1, C17D8, C18D1, C18D8 (up to Day 365). All intervention phase D1/D8 visits involve drug administration.","Cycle length is 21 days (Q3W) as indicated by 'Study Intervention Phase 21-Day Cycles' in the SoA table.; Pembrolizumab and Gemcitabine are assumed to continue for the full 365-day horizon for calculation purposes, as their duration is 'until PD or unacceptable toxicity' and 'up to 35 administrations' (Pembrolizumab, approx. 2 years) respectively, exceeding the 12-month window.; Cisplatin is administered for a maximum of 8 cycles (8 cycles * 21 days/cycle = 168 days).; Day 1 and Day 8 of each cycle are considered in-person healthcare contact days due to required drug administration and multiple assessments.; D8 visits continue as long as Gemcitabine is administered, even after Cisplatin is discontinued, because notes specify D8 assessments are not required only if *both* chemotherapy agents are permanently discontinued.; Tumor imaging assessments (every 6 weeks through Week 54, then every 12 weeks) coincide with Day 1 of cycles 3, 5, 7, 9, 11, 13, 15, 17, and therefore do not add unique contact days.; PK/ADA and TSH/T3/FT4 assessments on specific cycle days coincide with existing D1 or D8 visits and do not add unique contact days.; Screening phase is assumed to have 2 distinct in-person visits to accommodate procedures with different timing requirements (e.g., tissue collection, imaging, physical exam, and various labs).; For screening, one day is primarily for tissue collection (biopsy, classified as core_treatment) and initial labs, and another day is primarily for tumor imaging, ECG, audiometry, and other labs (classified as imaging_diagnostics)."
37075781,Arm B: Placebo plus Gemcitabine and Cisplatin,control,2,4,9,18,26,36,1,4,9,18,26,36,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,Placebo and Gemcitabine until progression/unacceptable toxicity (assumed 365 days for calculation); Cisplatin for up to 8 cycles (168 days).,"Screening Day 1 (core_treatment), Screening Day 2 (imaging_diagnostics), C1D1, C1D8, C2D1, C2D8, C3D1, C3D8, C4D1, C4D8, C5D1, C5D8, C6D1, C6D8, C7D1, C7D8, C8D1, C8D8, C9D1, C9D8, C10D1, C10D8, C11D1, C11D8, C12D1, C12D8, C13D1, C13D8, C14D1, C14D8, C15D1, C15D8, C16D1, C16D8, C17D1, C17D8, C18D1, C18D8 (up to Day 365). All intervention phase D1/D8 visits involve drug administration.","Cycle length is 21 days (Q3W) as indicated by 'Study Intervention Phase 21-Day Cycles' in the SoA table.; Placebo and Gemcitabine are assumed to continue for the full 365-day horizon for calculation purposes, as their duration is 'until PD or unacceptable toxicity' and 'up to 35 administrations' (Placebo, approx. 2 years) respectively, exceeding the 12-month window.; Cisplatin is administered for a maximum of 8 cycles (8 cycles * 21 days/cycle = 168 days).; Day 1 and Day 8 of each cycle are considered in-person healthcare contact days due to required drug administration and multiple assessments.; D8 visits continue as long as Gemcitabine is administered, even after Cisplatin is discontinued, because notes specify D8 assessments are not required only if *both* chemotherapy agents are permanently discontinued.; Tumor imaging assessments (every 6 weeks through Week 54, then every 12 weeks) coincide with Day 1 of cycles 3, 5, 7, 9, 11, 13, 15, 17, and therefore do not add unique contact days.; PK/ADA and TSH/T3/FT4 assessments on specific cycle days coincide with existing D1 or D8 visits and do not add unique contact days.; Screening phase is assumed to have 2 distinct in-person visits to accommodate procedures with different timing requirements (e.g., tissue collection, imaging, physical exam, and various labs).; For screening, one day is primarily for tissue collection (biopsy, classified as core_treatment) and initial labs, and another day is primarily for tumor imaging, ECG, audiometry, and other labs (classified as imaging_diagnostics)."
37080222,Arm A (Tislelizumab + chemotherapy doublet),intervention,1,13,31,51,71,96,1,10,25,45,65,90,0,0,0,0,0,0,0,3,6,6,6,6,0,0,0,0,0,0,21,until progression,"Screening: 1 day (core_treatment for biopsy). Cycles 1-3: Day 1 (core_treatment), Day 2-5 (core_treatment), Day 8 (labs), Day 15 (labs). Cycles 4-18 (up to Day 365): Day 1 (core_treatment), Day 2-5 (core_treatment). Range-columns (e.g., 'Day 1-5') were mapped to individual nominal dates.","Day 0 is the day of randomization, and Cycle 1 Day 1 (C1D1) is the first day of treatment.; The most intensive chemotherapy doublet (Platinum + 5-FU) is assumed for calculating contact days, as it involves 5 consecutive days of IV infusion per cycle, maximizing contact days for the arm.; Treatment is assumed to continue for the full 365-day horizon for calculation purposes, as per 'until progression' rule.; The 'Fresh tumor tissue' assessment (biopsy) during screening is considered a mandatory in-person procedure, categorizing the screening day as 'core_treatment' due to precedence.; For Day 1 of each cycle, IV infusions (Tislelizumab/Placebo, Platinum, 5-FU) categorize the day as 'core_treatment', taking precedence over other assessments like imaging, labs, and clinic visits.; For Day 2-5 of cycles with 5-FU, the 5-FU IV infusion categorizes these days as 'core_treatment'.; For Day 8 and Day 15 of Cycles 1-3, the primary in-person activities are laboratory assessments (Hematology, Serum Chemistry, Coagulation), categorizing these days as 'labs'. Note 25 regarding telephone calls for AEs/conmeds is overridden by the explicit 'X' for labs in Appendix 1 and text on page 35 (Section 7.4.4) requiring weekly labs for the first 3 cycles.; Platinum therapy stopping after 6 cycles (Day 105) does not reduce contact days, as the non-platinum agent (5-FU) continues with the same schedule, and the Schedule of Assessments remains unchanged."
37080222,Arm B (Placebo + chemotherapy doublet),control,1,13,31,51,71,96,1,10,25,45,65,90,0,0,0,0,0,0,0,3,6,6,6,6,0,0,0,0,0,0,21,until progression,"Screening: 1 day (core_treatment for biopsy). Cycles 1-3: Day 1 (core_treatment), Day 2-5 (core_treatment), Day 8 (labs), Day 15 (labs). Cycles 4-18 (up to Day 365): Day 1 (core_treatment), Day 2-5 (core_treatment). Range-columns (e.g., 'Day 1-5') were mapped to individual nominal dates.","Day 0 is the day of randomization, and Cycle 1 Day 1 (C1D1) is the first day of treatment.; The most intensive chemotherapy doublet (Platinum + 5-FU) is assumed for calculating contact days, as it involves 5 consecutive days of IV infusion per cycle, maximizing contact days for the arm.; Treatment is assumed to continue for the full 365-day horizon for calculation purposes, as per 'until progression' rule.; The 'Fresh tumor tissue' assessment (biopsy) during screening is considered a mandatory in-person procedure, categorizing the screening day as 'core_treatment' due to precedence.; For Day 1 of each cycle, IV infusions (Tislelizumab/Placebo, Platinum, 5-FU) categorize the day as 'core_treatment', taking precedence over other assessments like imaging, labs, and clinic visits.; For Day 2-5 of cycles with 5-FU, the 5-FU IV infusion categorizes these days as 'core_treatment'.; For Day 8 and Day 15 of Cycles 1-3, the primary in-person activities are laboratory assessments (Hematology, Serum Chemistry, Coagulation), categorizing these days as 'labs'. Note 25 regarding telephone calls for AEs/conmeds is overridden by the explicit 'X' for labs in Appendix 1 and text on page 35 (Section 7.4.4) requiring weekly labs for the first 3 cycles.; Platinum therapy stopping after 6 cycles (Day 105) does not reduce contact days, as the non-platinum agent (5-FU) continues with the same schedule, and the Schedule of Assessments remains unchanged."
37080223,Arm A - Control Arm,control,4,23,37,41,42,43,0,23,35,35,35,35,3,0,0,3,3,3,1,0,1,2,2,2,0,0,1,1,2,3,28,"6 weeks of chemoradiation, then follow-up for 5 years","Screening: Baseline clinic/bloods, Baseline CT, Baseline PET, Baseline MRI. Chemoradiation Phase: EBRT (5 days/week for 6 weeks), 5 weekly Cisplatin infusions (overlapping with EBRT), 5 Brachytherapy fractions. Follow-up Phase: End of Treatment visit, 3-month, 6-month, 9-month, 12-month follow-up visits with imaging (CT, PET, MRI) at 6-month.","Baseline assessments (clinic, bloods, imaging) are assumed to occur over 4 distinct days in the screening window: 1 day for clinic/bloods, 1 day for CT, 1 day for PET, 1 day for MRI.; External Beam Radiation Therapy (EBRT) is assumed to be 5 days/week for 6 weeks, totaling 30 days.; Cisplatin (5 weekly doses) is administered on 5 of the EBRT days; these days are not counted as additional contact days.; Brachytherapy is assumed to be 5 fractions, each on a separate day, immediately following EBRT completion, within the 8-week total treatment window (Day 42, 44, 46, 48, 50).; The End of Treatment visit (Day 56) includes clinic assessments, QoL, and bloods, categorized as a 'labs' day due to precedence.; The 3-month (Day 90), 9-month (Day 270), and 12-month (Day 365) follow-up visits are assumed to be single clinic contact days, categorized as 'clinic_visits'.; The 6-month follow-up visit (Day 180) is assumed to involve 1 day for clinic assessments/QoL/bloods (categorized as 'labs') and 3 separate days for imaging (CT, PET, MRI, categorized as 'imaging_diagnostics').; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
37080223,Arm B - Intervention Arm,intervention,4,23,36,43,44,45,0,23,36,39,39,39,3,0,0,3,3,3,1,0,0,1,1,1,0,0,0,0,1,2,21,"6 weeks of chemoradiation + 4 cycles of adjuvant chemotherapy, then follow-up for 5 years","Screening: Baseline clinic/bloods, Baseline CT, Baseline PET, Baseline MRI. Chemoradiation Phase: EBRT (5 days/week for 6 weeks), 5 weekly Cisplatin infusions (overlapping with EBRT), 5 Brachytherapy fractions. Adjuvant Chemotherapy Phase: 4 cycles of 3-weekly Carboplatin/Paclitaxel infusions (Day 1 of each cycle). Follow-up Phase: Consolidated End of Treatment/6-month visit with imaging, 9-month, 12-month follow-up visits.","Baseline assessments (clinic, bloods, imaging) are assumed to occur over 4 distinct days in the screening window: 1 day for clinic/bloods, 1 day for CT, 1 day for PET, 1 day for MRI.; External Beam Radiation Therapy (EBRT) is assumed to be 5 days/week for 6 weeks, totaling 30 days.; Cisplatin (5 weekly doses) is administered on 5 of the EBRT days; these days are not counted as additional contact days.; Brachytherapy is assumed to be 5 fractions, each on a separate day, immediately following EBRT completion, within the 8-week total treatment window (Day 42, 44, 46, 48, 50).; Adjuvant chemotherapy starts 4 weeks after completion of chemoradiation (around Day 83). Each of the 4 cycles (Day 83, 104, 125, 146) is a core_treatment day, including concurrent assessments.; For Arm B, the 3-month follow-up is covered by the first adjuvant chemotherapy visit (C1D1) as per protocol footnote A.; The End of Treatment visit and 6-month follow-up are consolidated into one set of assessments around Day 180, assumed to involve 1 day for clinic assessments/QoL/bloods (categorized as 'labs') and 3 separate days for imaging (CT, PET, MRI, categorized as 'imaging_diagnostics'), per protocol footnote I.; The 9-month (Day 270) and 12-month (Day 365) follow-up visits are assumed to be single clinic contact days, categorized as 'clinic_visits'.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
37086745,Trastuzumab deruxtecan (DS-8201a),intervention,2,4,7,11,15,20,0,2,5,9,13,18,2,0,0,0,0,0,0,2,2,2,2,2,0,0,0,0,0,0,21,until progression,"Screening: Day -28 (Tissue Screening/Biopsy), Day -14 (Main Screening). Treatment: Day 1 of each 21-day cycle (C1D1, C2D1, C3D1, etc.), Cycle 1 Day 8, Cycle 1 Day 15. All range-based columns were mapped to one nominal date.","The 'Tissue Screening' column (Day -28 to Day -1) is counted as one in-person day, assuming a fresh biopsy is required for some subjects as per footnote 'b' of Table 17.1.; All procedures listed under the 'Screening' column (Day -14 to Day -1) are consolidated into one in-person day.; All procedures listed under 'Day 1' columns for treatment cycles are consolidated into one in-person day.; Q6W (Every 6 Weeks) tumor assessments (CT/MRI, Brain CT/MRI) are assumed to coincide with Day 1 of cycles (C3D1, C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1) and therefore do not add new contact days but contribute to the 'core_treatment' category due to precedence.; Echo/MUGA and HEOR assessments (every 2 or 4 cycles) are assumed to coincide with Day 1 of cycles and do not add new contact days.; Treatment is assumed to continue for at least 365 days ('until progression') for the purpose of calculating visits within the fixed time windows. End of Treatment (EOT) and Follow-up visits are therefore considered to occur after the 12-month window.; For category classification, 'core_treatment' takes precedence over 'imaging_diagnostics', 'imaging_diagnostics' over 'labs', and 'labs' over 'clinic_visits'."
37086745,Investigator's Choice,control,2,4,7,11,15,20,0,2,5,9,13,18,2,0,0,0,0,0,0,2,2,2,2,2,0,0,0,0,0,0,21,until progression,"Screening: Day -28 (Tissue Screening/Biopsy), Day -14 (Main Screening). Treatment: Day 1 of each 21-day cycle (C1D1, C2D1, C3D1, etc.), Cycle 1 Day 8, Cycle 1 Day 15. All range-based columns were mapped to one nominal date.","The 'Tissue Screening' column (Day -28 to Day -1) is counted as one in-person day, assuming a fresh biopsy is required for some subjects as per footnote 'b' of Table 17.1.; All procedures listed under the 'Screening' column (Day -14 to Day -1) are consolidated into one in-person day.; All procedures listed under 'Day 1' columns for treatment cycles are consolidated into one in-person day.; Q6W (Every 6 Weeks) tumor assessments (CT/MRI, Brain CT/MRI) are assumed to coincide with Day 1 of cycles (C3D1, C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1) and therefore do not add new contact days but contribute to the 'core_treatment' category due to precedence.; Echo/MUGA and HEOR assessments (every 2 or 4 cycles) are assumed to coincide with Day 1 of cycles and do not add new contact days.; Treatment is assumed to continue for at least 365 days ('until progression') for the purpose of calculating visits within the fixed time windows. End of Treatment (EOT) and Follow-up visits are therefore considered to occur after the 12-month window.; For category classification, 'core_treatment' takes precedence over 'imaging_diagnostics', 'imaging_diagnostics' over 'labs', and 'labs' over 'clinic_visits'.; For Investigator's Choice, both Trastuzumab IV infusion and Lapatinib/Capecitabine oral administration on Day 1 of each cycle are considered 'core_treatment' days. Although Capecitabine and Lapatinib are taken on multiple days, only the in-person visit day is counted as a healthcare contact day."
37104748,Arm 1: Dose-escalated RT alone,control,2,23,44,45,46,47,0,23,44,44,44,44,1,0,0,0,0,0,1,0,0,1,2,3,0,0,0,0,0,0,28,RT is fixed duration (~9 weeks); follow-up is long-term.,"Screening (Day -28, Day -21), RT treatment days (Day 0 to Day 62, 44 days), Follow-up visits (Day 152, Day 242, Day 332).","Assumed EBRT alone as the representative RT modality for both arms, consisting of 44 fractions over 9 weeks (Day 0 to Day 62, 5 days/week).; Assumed 2 distinct in-person screening visits: one for clinical assessments/labs/QOL/blood/tissue (Day -28, categorized as Labs due to precedence) and one for imaging (Day -21, categorized as Imaging).; Assumed weekly during-RT assessments (AE evaluation, CBC in Weeks 1 & 5, QOL/Blood in Week 3 & last week) coincide with RT treatment days, thus not adding unique contact days and falling under 'core_treatment' by precedence.; Follow-up visits (3, 6, 9 months post RT) are assumed to be single in-person days including physical exam, DRE, PSA, performance status, AE evaluation, and QOL when indicated. These are categorized as 'labs' due to mandatory PSA collection."
37104748,Arm 2: Dose-escalated RT combined with short-term (6 months) androgen blockade (LHRH agonist + antiandrogen),intervention,2,23,46,50,51,53,0,23,46,49,49,49,1,0,0,0,0,0,1,0,0,1,2,4,0,0,0,0,0,0,28,RT is fixed duration (~9 weeks); ADT is fixed duration (6 months); follow-up is long-term.,"Screening (Day -28, Day -21), LHRH injections (Day -56, -26, 4, 34, 64, 94, 124, 154), RT treatment days (Day 0 to Day 62, 44 days), Serum testosterone only visits (Day 180, Day 360), Follow-up visits (Day 242, Day 332).","Assumed EBRT alone as the representative RT modality for both arms, consisting of 44 fractions over 9 weeks (Day 0 to Day 62, 5 days/week).; Assumed 2 distinct in-person screening visits: one for clinical assessments/labs/QOL/blood/tissue (Day -28, categorized as Labs due to precedence) and one for imaging (Day -21, categorized as Imaging).; Assumed weekly during-RT assessments (AE evaluation, CBC in Weeks 1 & 5, QOL/Blood in Week 3 & last week) coincide with RT treatment days, thus not adding unique contact days and falling under 'core_treatment' by precedence.; LHRH agonist injections are monthly for 6 months, starting 8 weeks prior to RT (Day -56, -26, 4, 34, 64, 94). These are categorized as 'core_treatment'.; Monthly AST/ALT/ALP during ADT (Day -56, -26, 4, 34, 64, 94) coincide with LHRH injection days and are thus categorized as 'core_treatment' by precedence.; Serum testosterone is collected at RT start (Day 0) and then every 6 months (Day 180, Day 360). Day 0 coincides with RT. Day 180 and Day 360 are additional 'labs' days.; Follow-up visits (6, 9 months post RT) are assumed to be single in-person days including physical exam, DRE, PSA, performance status, AE evaluation, QOL, and serum testosterone when indicated. These are categorized as 'labs' due to mandatory PSA/Serum Test collection."
37141294,Pembrolizumab (MK-3475) 2 mg/kg Q3W,intervention,4,2,5,9,13,18,1,2,5,9,13,18,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,until progression (or up to 35 administrations/2 years),"Screening (4 distinct days: Clinic/ECG/PROs, Labs, Biopsy, Imaging), followed by Day 1 of each 21-day cycle (C1D1, C2D1, C3D1, ..., C18D1). Each Day 1 visit includes core treatment (IV infusion) and other assessments.","Screening procedures are assumed to occur over 4 distinct in-person days: one day for initial clinic assessments/ECG/PROs, one day for blood/urine labs, one day for tumor biopsy, and one day for tumor imaging, based on the nature of the procedures and specified timing windows (e.g., 'within 10 days prior to first dose' for labs, 'within 28 days prior to randomization' for imaging).; For the treatment phase, all procedures on Day 1 of each cycle (including drug administration, clinic assessments, labs, and imaging where scheduled) are consolidated into a single 'core_treatment' day due to the highest precedence of active treatment delivery (IV infusion).; Optional biopsies (e.g., Week 6, 12, 24) mentioned in Note 17 (Page 27) are excluded from contact day counts.; Treatment is assumed to continue as scheduled up to the 12-month (Day 365) horizon, as the protocol states 'up to two years or 35 administrations' (735 days), which extends beyond 12 months. Post-treatment follow-up visits are therefore outside the 12-month window.; The 'End of Treatment' and 'Discontinuation Visit' columns are not counted as separate days within the fixed 12-month window, as treatment is assumed to continue through Day 365."
37141294,Docetaxel 75 mg/m² Q3W,control,4,2,5,9,13,18,1,2,5,9,13,18,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening (4 distinct days: Clinic/ECG/PROs, Labs, Biopsy, Imaging), followed by Day 1 of each 21-day cycle (C1D1, C2D1, C3D1, ..., C18D1). Each Day 1 visit includes core treatment (IV infusion) and other assessments.","Screening procedures are assumed to occur over 4 distinct in-person days: one day for initial clinic assessments/ECG/PROs, one day for blood/urine labs, one day for tumor biopsy, and one day for tumor imaging, based on the nature of the procedures and specified timing windows (e.g., 'within 10 days prior to first dose' for labs, 'within 28 days prior to randomization' for imaging).; For the treatment phase, all procedures on Day 1 of each cycle (including drug administration, clinic assessments, labs, and imaging where scheduled) are consolidated into a single 'core_treatment' day due to the highest precedence of active treatment delivery (IV infusion).; Optional biopsies (e.g., Week 6, 12, 24) mentioned in Note 17 (Page 27) are excluded from contact day counts.; Treatment is assumed to continue as scheduled up to the 12-month (Day 365) horizon, as the protocol states 'multiple cycles... per local standard of care' and for consistency with the intervention arm. Post-treatment follow-up visits are therefore outside the 12-month window.; The 'End of Treatment' and 'Discontinuation Visit' columns are not counted as separate days within the fixed 12-month window, as treatment is assumed to continue through Day 365."
37257422,Arm A (SS) - Standard Steroids,intervention,1,23,38,44,51,57,0,23,37,43,50,56,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,28,until progression (up to 12 cycles for Adjuvant Phase),"Screening, Chemoradiation Phase (Day 0, 1, 2, 3, 4, 7, 8, 9, 10, 11, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25, 28, 29, 30, 31, 32, 35, 36, 37, 38, 39, 42, 43, 44, 45, 46), Week 9 Day 1 (Day 56), Adjuvant Phase (C1D1, C1D15, C2D1, C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C5D15, C6D1, C6D15, C7D1, C7D15, C8D1, C8D15, C9D1, C9D15, C10D1, C10D15, C11D1).","Day 0 is defined as Chemoradiation Phase Week 1 Day 1.; The Chemoradiation Phase is assumed to last 7 weeks (Day 0 to Day 48 inclusive), with focal radiation therapy (RT) occurring 5 days per week (Monday-Friday), totaling 35 in-person RT days.; Depatuxizumab mafodotin IV infusions on Week 1 Day 1, Week 3 Day 1, and Week 5 Day 1 of the Chemoradiation Phase are assumed to coincide with RT days and do not add unique contact days.; Other scheduled in-person assessments (Ophthalmology, Labs, Physical Exam, Vitals) during the Chemoradiation Phase (Week 1 Day 1, Week 3 Day 1, Week 5 Day 1, Week 7 Day 1) are assumed to coincide with RT days and do not add unique contact days.; Oral Temozolomide (TMZ) administration is not considered an in-person contact day unless combined with other in-person procedures.; The Adjuvant Phase is assumed to start on Day 76 (28 days after the end of the 7-week Chemoradiation Phase on Day 48).; The 'Week 9 Day 1' visit (Day 56) is counted as an in-person visit between the Chemoradiation and Adjuvant Phases.; All three treatment arms (Arm A, Arm B, Arm C) have identical in-person visit schedules, as the prophylactic eye treatments are self-administered or integrated into existing visits without requiring additional in-person contact days.; Optional activities (e.g., Archival Tumor Sample) are not counted as mandatory in-person contact days.; Long-Term Follow-Up visits 'Until Symptom Resolution' are not counted as fixed visits within the 365-day horizon.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits was applied for days with multiple activities."
37257422,Arm B (SS/VC) - Standard Steroids + Vasoconstrictor + Cold Compress,intervention,1,23,38,44,51,57,0,23,37,43,50,56,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,28,until progression (up to 12 cycles for Adjuvant Phase),"Screening, Chemoradiation Phase (Day 0, 1, 2, 3, 4, 7, 8, 9, 10, 11, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25, 28, 29, 30, 31, 32, 35, 36, 37, 38, 39, 42, 43, 44, 45, 46), Week 9 Day 1 (Day 56), Adjuvant Phase (C1D1, C1D15, C2D1, C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C5D15, C6D1, C6D15, C7D1, C7D15, C8D1, C8D15, C9D1, C9D15, C10D1, C10D15, C11D1).","Day 0 is defined as Chemoradiation Phase Week 1 Day 1.; The Chemoradiation Phase is assumed to last 7 weeks (Day 0 to Day 48 inclusive), with focal radiation therapy (RT) occurring 5 days per week (Monday-Friday), totaling 35 in-person RT days.; Depatuxizumab mafodotin IV infusions on Week 1 Day 1, Week 3 Day 1, and Week 5 Day 1 of the Chemoradiation Phase are assumed to coincide with RT days and do not add unique contact days.; Other scheduled in-person assessments (Ophthalmology, Labs, Physical Exam, Vitals) during the Chemoradiation Phase (Week 1 Day 1, Week 3 Day 1, Week 5 Day 1, Week 7 Day 1) are assumed to coincide with RT days and do not add unique contact days.; Oral Temozolomide (TMZ) administration is not considered an in-person contact day unless combined with other in-person procedures.; The Adjuvant Phase is assumed to start on Day 76 (28 days after the end of the 7-week Chemoradiation Phase on Day 48).; The 'Week 9 Day 1' visit (Day 56) is counted as an in-person visit between the Chemoradiation and Adjuvant Phases.; All three treatment arms (Arm A, Arm B, Arm C) have identical in-person visit schedules, as the prophylactic eye treatments are self-administered or integrated into existing visits without requiring additional in-person contact days.; Optional activities (e.g., Archival Tumor Sample) are not counted as mandatory in-person contact days.; Long-Term Follow-Up visits 'Until Symptom Resolution' are not counted as fixed visits within the 365-day horizon.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits was applied for days with multiple activities."
37257422,Arm C (ES/VC) - Enhanced Steroids + Vasoconstrictor + Cold Compress,intervention,1,23,38,44,51,57,0,23,37,43,50,56,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,28,until progression (up to 12 cycles for Adjuvant Phase),"Screening, Chemoradiation Phase (Day 0, 1, 2, 3, 4, 7, 8, 9, 10, 11, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25, 28, 29, 30, 31, 32, 35, 36, 37, 38, 39, 42, 43, 44, 45, 46), Week 9 Day 1 (Day 56), Adjuvant Phase (C1D1, C1D15, C2D1, C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C5D15, C6D1, C6D15, C7D1, C7D15, C8D1, C8D15, C9D1, C9D15, C10D1, C10D15, C11D1).","Day 0 is defined as Chemoradiation Phase Week 1 Day 1.; The Chemoradiation Phase is assumed to last 7 weeks (Day 0 to Day 48 inclusive), with focal radiation therapy (RT) occurring 5 days per week (Monday-Friday), totaling 35 in-person RT days.; Depatuxizumab mafodotin IV infusions on Week 1 Day 1, Week 3 Day 1, and Week 5 Day 1 of the Chemoradiation Phase are assumed to coincide with RT days and do not add unique contact days.; Other scheduled in-person assessments (Ophthalmology, Labs, Physical Exam, Vitals) during the Chemoradiation Phase (Week 1 Day 1, Week 3 Day 1, Week 5 Day 1, Week 7 Day 1) are assumed to coincide with RT days and do not add unique contact days.; Oral Temozolomide (TMZ) administration is not considered an in-person contact day unless combined with other in-person procedures.; The Adjuvant Phase is assumed to start on Day 76 (28 days after the end of the 7-week Chemoradiation Phase on Day 48).; The 'Week 9 Day 1' visit (Day 56) is counted as an in-person visit between the Chemoradiation and Adjuvant Phases.; All three treatment arms (Arm A, Arm B, Arm C) have identical in-person visit schedules, as the prophylactic eye treatments are self-administered or integrated into existing visits without requiring additional in-person contact days.; Optional activities (e.g., Archival Tumor Sample) are not counted as mandatory in-person contact days.; Long-Term Follow-Up visits 'Until Symptom Resolution' are not counted as fixed visits within the 365-day horizon.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits was applied for days with multiple activities."
37272516,Vorasidenib (AG-881),intervention,2,3,6,9,12,16,0,2,4,7,10,14,1,1,2,2,2,2,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (MRI/ECHO/ECG), Screening (Labs/Clinical/Randomization), C1D1, C1D15, C2D1, C2D15, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1. Range-columns (e.g., 'D1 ±2 Days') were mapped to one nominal date (e.g., Day 1).","The 'Screening' period (D -28 to D -1) is assumed to involve two distinct in-person visits: one dedicated to imaging (MRI, ECHO, ECG) and another for all other clinical assessments, labs, and randomization. This is based on the volume and nature of assessments.; Activities listed under 'Pre-screening (D -84 to D -28)' are considered outside the defined 'screening_window' (Day -28 to Day -1) and are therefore not counted in the specified time intervals.; PK blood sampling and ECGs listed in Table 2 are considered part of the main visit for that day and do not add new contact days, but influence the category assignment based on precedence.; For days with multiple in-person assessments, the category is assigned based on the defined precedence: core_treatment > imaging_diagnostics > labs > clinic_visits.; The 'Buccal swab for germline mutation analyses (optional)' is excluded as it is explicitly marked as optional.; Assessments like 'Adverse events' and 'Prior and concomitant medications/procedures' are considered data collection activities and only contribute to a contact day if they are part of another mandatory in-person assessment on that day.; The 'Cycle 37+ (Odd Cycles Only)' rule for visits is not applicable within the 365-day horizon, as the last D1 visit within this period is C14D1 (Day 364)."
37272516,Placebo,control,2,3,6,9,12,16,0,2,4,7,10,14,1,1,2,2,2,2,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (MRI/ECHO/ECG), Screening (Labs/Clinical/Randomization), C1D1, C1D15, C2D1, C2D15, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1. Range-columns (e.g., 'D1 ±2 Days') were mapped to one nominal date (e.g., Day 1).","The 'Screening' period (D -28 to D -1) is assumed to involve two distinct in-person visits: one dedicated to imaging (MRI, ECHO, ECG) and another for all other clinical assessments, labs, and randomization. This is based on the volume and nature of assessments.; Activities listed under 'Pre-screening (D -84 to D -28)' are considered outside the defined 'screening_window' (Day -28 to Day -1) and are therefore not counted in the specified time intervals.; PK blood sampling and ECGs listed in Table 2 are considered part of the main visit for that day and do not add new contact days, but influence the category assignment based on precedence.; For days with multiple in-person assessments, the category is assigned based on the defined precedence: core_treatment > imaging_diagnostics > labs > clinic_visits.; The 'Buccal swab for germline mutation analyses (optional)' is excluded as it is explicitly marked as optional.; Assessments like 'Adverse events' and 'Prior and concomitant medications/procedures' are considered data collection activities and only contribute to a contact day if they are part of another mandatory in-person assessment on that day.; The 'Cycle 37+ (Odd Cycles Only)' rule for visits is not applicable within the 365-day horizon, as the last D1 visit within this period is C14D1 (Day 364)."
37276510,SGI-110,intervention,1,11,27,45,61,79,0,8,19,32,47,64,1,0,1,3,4,5,0,3,7,10,10,10,0,0,0,0,0,0,28,until progression,"Screening (1 day); Cycles 1-2: Day 1, 2, 3, 4, 5 (treatment), Day 8, 15, 22 (labs); Cycles 3-6: Day 1, 2, 3, 4, 5 (treatment), Day 15 (labs); Cycles ≥7: Day 1, 2, 3, 4, 5 (treatment). BM aspirate/biopsy on C3D1, C5D1, C7D1, Day 258, Day 348. Range-columns (e.g., 'Day 14–21') were not present, and multi-day treatment blocks were counted as individual days.","Day 0 is Cycle 1 Day 1 (C1D1).; A single in-person screening visit is assumed within the Day -28 to Day -1 window, encompassing all screening procedures including BM aspirate/biopsy, molecular genetics/cytogenetics, and ECG. This day is categorized as 'imaging_diagnostics' due to the precedence rule.; Treatment is assumed to continue for the full 365-day horizon, as the protocol states 'at least 6 cycles, continuing as long as the subject benefits'.; For SGI-110, Cycle 1 Day 1 and Cycle 1 Day 5 include PK sampling. C1D1 also includes ECG. These days are categorized as 'core_treatment' due to drug administration having higher precedence than labs/imaging, except when BM aspirate/biopsy is performed on a treatment day.; BM aspirate/biopsy on C3D1, C5D1, C7D1 are considered 'imaging_diagnostics' days, overriding 'core_treatment' due to precedence.; Additional BM aspirate/biopsy visits on Day 258 (Day 168 + 90 days) and Day 348 (Day 258 + 90 days) are counted as separate 'imaging_diagnostics' contact days, as they are not explicitly tied to a cycle Day 1 visit in Cycles >6 where only treatment days are required.; For Cycles >6, only treatment days (Days 1-5) are required, with hematology blood draws only on Day 1. Thus, mid-cycle lab visits (Day 15, 22) are not counted after Cycle 6."
37276510,Treatment Choice (TC),control,1,15,42,78,109,142,0,13,36,67,97,129,1,0,1,3,4,5,0,2,5,8,8,8,0,0,0,0,0,0,28,until progression,"Screening (1 day); Cycles 1-2: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 (treatment), Day 15, 22 (labs); Cycles 3-6: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 (treatment), Day 15 (labs); Cycles ≥7: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 (treatment). BM aspirate/biopsy on C3D1, C5D1, C7D1, Day 258, Day 348. Range-columns (e.g., 'Day 14–21') were not present, and multi-day treatment blocks were counted as individual days.","Day 0 is Cycle 1 Day 1 (C1D1).; A single in-person screening visit is assumed within the Day -28 to Day -1 window, encompassing all screening procedures including BM aspirate/biopsy, molecular genetics/cytogenetics, and ECG. This day is categorized as 'imaging_diagnostics' due to the precedence rule.; Treatment is assumed to continue for the full 365-day horizon, as the protocol implies ongoing treatment for AML.; For the TC arm, calculations are based on the regimen with the maximum number of in-person contact days (Cytarabine: Days 1-10 treatment) to represent the highest participant burden.; For Decitabine IV, PK sampling occurs on C1D1 and C1D5. These days are categorized as 'core_treatment' due to drug administration having higher precedence than labs/imaging, except when BM aspirate/biopsy is performed on a treatment day.; BM aspirate/biopsy on C3D1, C5D1, C7D1 are considered 'imaging_diagnostics' days, overriding 'core_treatment' due to precedence.; Additional BM aspirate/biopsy visits on Day 258 (Day 168 + 90 days) and Day 348 (Day 258 + 90 days) are counted as separate 'imaging_diagnostics' contact days, as they are not explicitly tied to a cycle Day 1 visit in Cycles >6 where only treatment days are required.; For Cycles >6, only treatment days (Days 1-10 for Cytarabine) are required, with hematology blood draws only on Day 1. Thus, mid-cycle lab visits (Day 15, 22) are not counted after Cycle 6."
37284847,"Group 1: Olanzapine, Fosaprepitant/Aprepitant, 5-HT3 Receptor Antagonist, Dexamethasone",intervention,1,19,19,19,19,19,0,4,4,4,4,4,0,0,0,0,0,0,1,0,0,0,0,0,0,15,15,15,15,15,6,up to 4 cycles (24 days total),"Screening, C1D1, C2D1, C2D2, C2D3, C2D4, C2D5, C2D6, C3D1, C3D2, C3D3, C3D4, C3D5, C3D6, C4D1, C4D2, C4D3, C4D4, C4D5, C4D6. No range-columns were mapped to a single nominal date; 'Days 2-6' in continuation cycles are counted as 5 distinct in-person days.","The statement 'Protocol therapy will be instituted for single day chemotherapy for one cycle only' (Page 6, Section 2.0) is interpreted as referring to the type of chemotherapy (single-day administration) rather than the number of cycles, as other sections clearly indicate up to four cycles of chemotherapy (initial + three continuation cycles).; All 'Prior to Registration' assessments (History and physical, Height/Weight/ECOG PS, Baseline Nausea and Vomiting Questionnaire, Serum or Urine HCG, Creatinine/AST or ALT) are assumed to occur on a single in-person screening visit within the Day -28 to Day -1 window.; IV administration of Palonosetron/Ondansetron and Fosaprepitant/Aprepitant (or Placebo) on Day 1 of each cycle constitutes an in-person core treatment activity.; Oral medications (Olanzapine, Dexamethasone) are considered self-administered and do not count as in-person contact days.; Daily Nurse Telephone Contact for Cycle 1 Days 2-6 (Page 9, footnote 1) is explicitly a phone call and does not count as an in-person contact day.; Adverse event assessments for continuation phase (Cycles 2-4, Days 2-6) are explicitly stated as 'done during chemotherapy cycle visits' (Page 9, footnote 4), implying in-person visits.; The optional blood draw for pharmacogenomic studies (Page 54) is excluded as it is optional.; The Day 21 Nurse/Research Coordinator Contact (Page 73) is a telephone contact and does not count as an in-person contact day.; The total study duration is a maximum of 24 days (initial 6 days + 3 additional 6-day cycles), meaning all on-treatment visits occur within Day 0 to Day 23."
37284847,"Group 2: Olanzapine, Placebo, 5-HT3 Receptor Antagonist, Dexamethasone",control,1,19,19,19,19,19,0,4,4,4,4,4,0,0,0,0,0,0,1,0,0,0,0,0,0,15,15,15,15,15,6,up to 4 cycles (24 days total),"Screening, C1D1, C2D1, C2D2, C2D3, C2D4, C2D5, C2D6, C3D1, C3D2, C3D3, C3D4, C3D5, C3D6, C4D1, C4D2, C4D3, C4D4, C4D5, C4D6. No range-columns were mapped to a single nominal date; 'Days 2-6' in continuation cycles are counted as 5 distinct in-person days.","The statement 'Protocol therapy will be instituted for single day chemotherapy for one cycle only' (Page 6, Section 2.0) is interpreted as referring to the type of chemotherapy (single-day administration) rather than the number of cycles, as other sections clearly indicate up to four cycles of chemotherapy (initial + three continuation cycles).; All 'Prior to Registration' assessments (History and physical, Height/Weight/ECOG PS, Baseline Nausea and Vomiting Questionnaire, Serum or Urine HCG, Creatinine/AST or ALT) are assumed to occur on a single in-person screening visit within the Day -28 to Day -1 window.; IV administration of Palonosetron/Ondansetron and Placebo on Day 1 of each cycle constitutes an in-person core treatment activity.; Oral medications (Olanzapine, Dexamethasone) are considered self-administered and do not count as in-person contact days.; Daily Nurse Telephone Contact for Cycle 1 Days 2-6 (Page 9, footnote 1) is explicitly a phone call and does not count as an in-person contact day.; Adverse event assessments for continuation phase (Cycles 2-4, Days 2-6) are explicitly stated as 'done during chemotherapy cycle visits' (Page 9, footnote 4), implying in-person visits.; The optional blood draw for pharmacogenomic studies (Page 54) is excluded as it is optional.; The Day 21 Nurse/Research Coordinator Contact (Page 73) is a telephone contact and does not count as an in-person contact day.; The total study duration is a maximum of 24 days (initial 6 days + 3 additional 6-day cycles), meaning all on-treatment visits occur within Day 0 to Day 23."
37285865,Talazoparib in combination with enzalutamide,intervention,2,2,6,11,14,17,0,2,6,11,14,17,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,Not applicable; fixed visit schedule.,until progression,"Prescreening (optional), Screening, and scheduled visits at Week 1, 3, 5, 7, 9, 11, 13, 15, 17, 21, 25, 29, 33, 37, 41, 45, 49. Week-based visits are mapped to nominal days (Week X = Day X*7).","An optional Prescreening visit is assumed to occur as a distinct in-person day for initial genomic testing (categorized as 'labs').; The Screening visit is assumed to be a distinct in-person day, including ECG and radiographic assessments (categorized as 'imaging_diagnostics').; Day 0 is the day of randomization for Part 2, and Day 1 is the first treatment visit (Week 1).; All 'Study Week' columns in Table 2 represent a single in-person visit on the nominal day (e.g., Week X = Day X*7).; All scheduled visits during the 'Treatment Period' (Table 2) involve 'Study treatment dispensing' (oral daily medication), which takes precedence for categorization as 'core_treatment', even if other assessments (labs, imaging, clinic visits) also occur on that day.; Treatment is assumed to continue up to Day 365 for the 12-month window, as per 'until progression' rule.; Safety Follow-Up and Long-Term Follow-Up visits are outside the 12-month window or are covered by the treatment period imaging schedule, or can be conducted remotely if imaging is not required, thus not adding new in-person days within the 12-month treatment period beyond the scheduled treatment visits."
37285865,Placebo in combination with enzalutamide,control,2,2,6,11,14,17,0,2,6,11,14,17,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,Not applicable; fixed visit schedule.,until progression,"Prescreening (optional), Screening, and scheduled visits at Week 1, 3, 5, 7, 9, 11, 13, 15, 17, 21, 25, 29, 33, 37, 41, 45, 49. Week-based visits are mapped to nominal days (Week X = Day X*7).","An optional Prescreening visit is assumed to occur as a distinct in-person day for initial genomic testing (categorized as 'labs').; The Screening visit is assumed to be a distinct in-person day, including ECG and radiographic assessments (categorized as 'imaging_diagnostics').; Day 0 is the day of randomization for Part 2, and Day 1 is the first treatment visit (Week 1).; All 'Study Week' columns in Table 2 represent a single in-person visit on the nominal day (e.g., Week X = Day X*7).; All scheduled visits during the 'Treatment Period' (Table 2) involve 'Study treatment dispensing' (oral daily medication), which takes precedence for categorization as 'core_treatment', even if other assessments (labs, imaging, clinic visits) also occur on that day.; Treatment is assumed to continue up to Day 365 for the 12-month window, as per 'until progression' rule.; Safety Follow-Up and Long-Term Follow-Up visits are outside the 12-month window or are covered by the treatment period imaging schedule, or can be conducted remotely if imaging is not required, thus not adding new in-person days within the 12-month treatment period beyond the scheduled treatment visits."
37290035,Arm 1 (pembrolizumab 200 mg IV Q3W plus olaparib 300 mg PO BID),intervention,3,2,5,9,13,18,0,2,5,9,13,18,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,21,until progression,"Screening (Day -28, Day -10, Day -1), C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1. All cycle Day 1 columns represent a single nominal date.","Cycle length is 21 days based on 'Q3W' and 'Day 1 of each 21-day cycle'.; Treatment duration is 'until progression' but capped at Day 365 for this analysis.; Second Course Phase is excluded per Amendment 06, as it is no longer an option for participants.; ePRO, biomarker sample collection (except specified labs), and central tumor response assessments are discontinued per Amendment 06. Local tumor imaging continues per SOC.; Screening involves three distinct in-person visits: Day -28 (imaging), Day -10 (labs/ECG/physical exam), and Day -1 (randomization/final screen).; The 'Telephone contact or visit on Cycle 1 Day 8' is assumed to be a phone call or optional visit, not a mandatory in-person contact day, following the 'most conservative lower estimate' rule for ambiguity.; All Day 1 visits for treatment cycles are categorized as 'core_treatment' due to drug administration/dispensing, applying the precedence rule.; For screening, Day -10 is categorized as 'imaging_diagnostics' due to the presence of 12-lead ECG and precedence rules."
37290035,"Arm 2 (abiraterone acetate 1000 mg PO QD plus prednisone/prednisolone 5 mg PO BID, or enzalutamide 160 mg PO QD)",control,3,2,5,9,13,18,0,2,5,9,13,18,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,21,until progression,"Screening (Day -28, Day -10, Day -1), C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1. All cycle Day 1 columns represent a single nominal date.","Cycle length is 21 days based on 'Q3W' and 'Day 1 of each 21-day cycle'.; Treatment duration is 'until progression' but capped at Day 365 for this analysis.; Second Course Phase is excluded per Amendment 06, as it is no longer an option for participants.; ePRO, biomarker sample collection (except specified labs), and central tumor response assessments are discontinued per Amendment 06. Local tumor imaging continues per SOC.; Screening involves three distinct in-person visits: Day -28 (imaging), Day -10 (labs/ECG/physical exam), and Day -1 (randomization/final screen).; The 'Telephone contact or visit on Cycle 1 Day 8' is assumed to be a phone call or optional visit, not a mandatory in-person contact day, following the 'most conservative lower estimate' rule for ambiguity.; All Day 1 visits for treatment cycles are categorized as 'core_treatment' due to drug administration/dispensing, applying the precedence rule.; For screening, Day -10 is categorized as 'imaging_diagnostics' due to the presence of 12-lead ECG and precedence rules."
37290461,Atezolizumab + Cabozantinib,intervention,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening (Day -7 nominal), Day 0 (C1D1), Day 21 (C2D1), Day 42 (C3D1), Day 63 (C4D1), Day 84 (C5D1), Day 105 (C6D1), Day 126 (C7D1), Day 147 (C8D1), Day 168 (C9D1), Day 189 (C10D1), Day 210 (C11D1), Day 231 (C12D1), Day 252 (C13D1), Day 273 (C14D1), Day 294 (C15D1), Day 315 (C16D1), Day 336 (C17D1), Day 357 (C18D1). All visits are nominal Day 1 of each cycle; no range-columns were mapped to one nominal date.","A single in-person screening visit is counted, encompassing all listed screening activities (physical exam, vitals, labs, ECG, tumor assessment). Fresh biopsy is conditional ('if clinically feasible') and thus not counted as a mandatory contact day.; Treatment continues for the full 365 days for the purpose of counting visits within the 12-month window.; The Treatment Discontinuation Visit and Follow-Up visits are assumed to occur after Day 365 if treatment continues for a full year, and thus are not included in the 12-month window count.; Cabozantinib daily oral doses taken at home are not in-person contact days, except for the initial dispensing on C1D1.; For category breakdown, the highest precedence activity on a given day determines the day's category (core_treatment > imaging_diagnostics > labs > clinic_visits)."
37290461,Cabozantinib,control,1,2,5,9,13,18,0,1,1,1,1,1,1,1,3,4,7,9,0,0,1,4,5,8,0,0,0,0,0,0,21,until progression,"Screening (Day -7 nominal), Day 0 (C1D1), Day 21 (C2D1), Day 42 (C3D1), Day 63 (C4D1), Day 84 (C5D1), Day 105 (C6D1), Day 126 (C7D1), Day 147 (C8D1), Day 168 (C9D1), Day 189 (C10D1), Day 210 (C11D1), Day 231 (C12D1), Day 252 (C13D1), Day 273 (C14D1), Day 294 (C15D1), Day 315 (C16D1), Day 336 (C17D1), Day 357 (C18D1). All visits are nominal Day 1 of each cycle; no range-columns were mapped to one nominal date.","A single in-person screening visit is counted, encompassing all listed screening activities (physical exam, vitals, labs, ECG, tumor assessment). Fresh biopsy is conditional ('if clinically feasible') and thus not counted as a mandatory contact day.; Treatment continues for the full 365 days for the purpose of counting visits within the 12-month window.; The Treatment Discontinuation Visit and Follow-Up visits are assumed to occur after Day 365 if treatment continues for a full year, and thus are not included in the 12-month window count.; Cabozantinib daily oral doses taken at home are not in-person contact days, except for the initial dispensing on C1D1.; For category breakdown, the highest precedence activity on a given day determines the day's category (core_treatment > imaging_diagnostics > labs > clinic_visits)."
37315297,Arm 1: Combined External Beam Radiation (EBRT) and Transperineal Interstitial Permanent Brachytherapy,intervention,2,23,27,29,30,31,0,23,26,26,26,26,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,2,3,4,,"fixed treatment course, then until progression for follow-up (capped at Day 365 for this analysis)","Screening (Day -28, Day -27), EBRT (Day 0-4, 7-11, 14-18, 21-25, 28-32), Brachytherapy Implant (Day 46), Post-Implant CT/X-rays (Day 67), Follow-up (Day 120, Day 180, Day 270, Day 365). Range-columns for EBRT are counted as individual treatment days.","Screening involves 2 distinct in-person days: one for initial clinic visit/labs/questionnaires (Day -28) and one for TRUS/CT/MRI for lymph node assessment (Day -27).; Weekly radiation oncologist visits during EBRT are subsumed into the 25 EBRT core treatment days, as they occur on one of the treatment days.; Brachytherapy implant for Arm 1 is nominally scheduled for Day 46 (mid-point of 2-4 weeks after EBRT completion on Day 32).; Post-implant CT/X-rays for Arm 1 are nominally scheduled for Day 67 (mid-point of 3-5 weeks after implant). This visit also includes follow-up assessments (H&P, labs, questionnaires), with imaging taking precedence for categorization.; Follow-up visits at Months 4, 6, 9, and 12 are distinct in-person contact days, including H&P, labs, and questionnaires (where applicable), with clinic visits taking precedence for categorization."
37315297,Arm 2: Brachytherapy Alone,control,2,1,2,4,5,6,0,1,1,1,1,1,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,2,3,4,,"fixed treatment course, then until progression for follow-up (capped at Day 365 for this analysis)","Screening (Day -28, Day -27), Brachytherapy Implant (Day 14), Post-Implant CT/X-rays (Day 35), Follow-up (Day 120, Day 180, Day 270, Day 365).","Screening involves 2 distinct in-person days: one for initial clinic visit/labs/questionnaires (Day -28) and one for TRUS/CT/MRI for lymph node assessment (Day -27).; Brachytherapy implant for Arm 2 is nominally scheduled for Day 14 (mid-point of 2-4 weeks after study enrollment).; Post-implant CT/X-rays for Arm 2 are nominally scheduled for Day 35 (mid-point of 3-5 weeks after implant). This visit also includes follow-up assessments (H&P, labs, questionnaires), with imaging taking precedence for categorization.; Follow-up visits at Months 4, 6, 9, and 12 are distinct in-person contact days, including H&P, labs, and questionnaires (where applicable), with clinic visits taking precedence for categorization."
37331369,Fruquintinib plus BSC,intervention,1,3,7,10,13,17,0,3,7,10,13,17,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (Day -28), C1D1 (Day 0), C1D21 (Day 21), C2D1 (Day 28), C2D21 (Day 49), C3D1 (Day 56), C3D21 (Day 77), and then CkD1 for Cycles 4 through 14 (Day 84, 112, 140, 168, 196, 224, 252, 280, 308, 336, 364). Day 21 visits are not scheduled from Cycle 4 onwards per Table 1 and SAP Table 4. Range-columns (e.g., 'Visit Window (days)') were mapped to one nominal date.","Treatment duration is assumed to continue for the full 365-day horizon for the purpose of counting scheduled cycle visits.; End of Treatment (EOT) and Safety Follow-Up visits are not included as they occur after the last dose and would fall outside the 365-day window if treatment continues for the full year.; Survival Follow-Up is conducted by telephone and is therefore not counted as an in-person healthcare contact day.; The 'Screening' visit (Day -28) is categorized as 'imaging_diagnostics' due to the comprehensive nature of diagnostic procedures (e.g., baseline tumor evaluation, ECG, echocardiogram) performed prior to active treatment. The initial drug dispense at screening is considered an administrative/logistical task rather than 'active treatment delivery'.; All Cycle Day 1 (CkD1) and Cycle Day 21 (CkD21) visits are categorized as 'core_treatment' due to study drug administration/dispensing and/or mandatory PK sampling on drug administration days, which requires in-person attendance."
37331369,Placebo plus BSC,control,1,3,7,10,13,17,0,3,7,10,13,17,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (Day -28), C1D1 (Day 0), C1D21 (Day 21), C2D1 (Day 28), C2D21 (Day 49), C3D1 (Day 56), C3D21 (Day 77), and then CkD1 for Cycles 4 through 14 (Day 84, 112, 140, 168, 196, 224, 252, 280, 308, 336, 364). Day 21 visits are not scheduled from Cycle 4 onwards per Table 1 and SAP Table 4. Range-columns (e.g., 'Visit Window (days)') were mapped to one nominal date.","Treatment duration is assumed to continue for the full 365-day horizon for the purpose of counting scheduled cycle visits.; End of Treatment (EOT) and Safety Follow-Up visits are not included as they occur after the last dose and would fall outside the 365-day window if treatment continues for the full year.; Survival Follow-Up is conducted by telephone and is therefore not counted as an in-person healthcare contact day.; The 'Screening' visit (Day -28) is categorized as 'imaging_diagnostics' due to the comprehensive nature of diagnostic procedures (e.g., baseline tumor evaluation, ECG, echocardiogram) performed prior to active treatment. The initial drug dispense at screening is considered an administrative/logistical task rather than 'active treatment delivery'.; All Cycle Day 1 (CkD1) and Cycle Day 21 (CkD21) visits are categorized as 'core_treatment' due to study drug administration/dispensing and/or mandatory PK sampling on drug administration days, which requires in-person attendance."
37342922,Tacrolimus/Methotrexate (Tac/MTX),intervention,3,9,17,19,20,21,0,5,5,5,5,5,1,0,0,1,1,2,2,4,12,13,14,14,0,0,0,0,0,0,28,Patients will be followed for 1 year post-PBSC transplant (up to Day 365).,"Screening: Day -28 (imaging/diagnostics), Day -14 (labs), Day -1 (labs). Post-transplant: Day 0 (core treatment), Day +1 (core treatment), Day +3 (core treatment), Day +6 (core treatment), Day +7 (labs), Day +11 (core treatment), Day +14 (labs), Day +21 (labs), Day +28 (labs), Day +35 (labs), Day +42 (labs), Day +49 (labs), Day +56 (labs), Day +63 (labs), Day +70 (labs), Day +77 (labs), Day +84 (labs), Day +98 (imaging/diagnostics), Day +180 (labs), Day +270 (labs), Day +365 (imaging/diagnostics).","Day 0 is the anchor point (first PBSC infusion).; Pre-Conditioning assessments (History, PE, KPS, HCT-CI, DRI, ID titers, EKG/LVEF, PFTs, Chest X-ray/CT, Pregnancy test, Chimerism) are assumed to occur on a single dedicated visit day (Day -28) within the screening window, with imaging/diagnostics taking precedence.; Pre-conditioning Mi-Immune samples and CBC (Day -14 to -7) are assumed to occur on a single day (Day -14) within the screening window, with labs taking precedence.; Pre-infusion CBC and Mi-Immune samples (Day -1 to 0) are assumed to occur on Day -1, with labs taking precedence.; Disease evaluation requiring bone marrow biopsy/imaging prior to conditioning (e.g., Day -44) is assumed to fall outside the Day -28 to Day -1 screening window, as conditioning regimens are listed with negative days (e.g., Days -5 to -3).; Oral drug administration (e.g., MMF, oral Tacrolimus if no other procedures) does not constitute an in-person contact day unless other in-person procedures are scheduled for that day.; Patient Reported Outcomes (PRO) are excluded as they can be collected remotely.; All listed assessments in Table 1 (Page 196) with an 'X' are considered mandatory in-person procedures unless explicitly stated otherwise (e.g., PRO).; For days with multiple in-person activities, the highest precedence category is assigned: core_treatment > imaging_diagnostics > labs > clinic_visits."
37342922,PTCy/Tac/MMF,intervention,3,7,15,17,18,19,0,3,3,3,3,3,1,0,0,1,1,2,2,4,12,13,14,14,0,0,0,0,0,0,28,Patients will be followed for 1 year post-PBSC transplant (up to Day 365).,"Screening: Day -28 (imaging/diagnostics), Day -14 (labs), Day -1 (labs). Post-transplant: Day 0 (core treatment), Day +3 (core treatment), Day +4 (core treatment), Day +7 (labs), Day +14 (labs), Day +21 (labs), Day +28 (labs), Day +35 (labs), Day +42 (labs), Day +49 (labs), Day +56 (labs), Day +63 (labs), Day +70 (labs), Day +77 (labs), Day +84 (labs), Day +98 (imaging/diagnostics), Day +180 (labs), Day +270 (labs), Day +365 (imaging/diagnostics).","Day 0 is the anchor point (first PBSC infusion).; Pre-Conditioning assessments (History, PE, KPS, HCT-CI, DRI, ID titers, EKG/LVEF, PFTs, Chest X-ray/CT, Pregnancy test, Chimerism) are assumed to occur on a single dedicated visit day (Day -28) within the screening window, with imaging/diagnostics taking precedence.; Pre-conditioning Mi-Immune samples and CBC (Day -14 to -7) are assumed to occur on a single day (Day -14) within the screening window, with labs taking precedence.; Pre-infusion CBC and Mi-Immune samples (Day -1 to 0) are assumed to occur on Day -1, with labs taking precedence.; Disease evaluation requiring bone marrow biopsy/imaging prior to conditioning (e.g., Day -44) is assumed to fall outside the Day -28 to Day -1 screening window, as conditioning regimens are listed with negative days (e.g., Days -5 to -3).; Oral drug administration (e.g., MMF, oral Tacrolimus if no other procedures) does not constitute an in-person contact day unless other in-person procedures are scheduled for that day.; Patient Reported Outcomes (PRO) are excluded as they can be collected remotely.; All listed assessments in Table 1 (Page 196) with an 'X' are considered mandatory in-person procedures unless explicitly stated otherwise (e.g., PRO).; For days with multiple in-person activities, the highest precedence category is assigned: core_treatment > imaging_diagnostics > labs > clinic_visits."
37379502,Lazertinib (240 mg once daily),intervention,1,4,7,9,11,13,0,2,5,7,9,11,1,0,0,0,0,0,0,2,2,2,2,2,0,0,0,0,0,0,21,until progression,"Screening, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1. All range-columns were mapped to one nominal date.","The 'Screening' column in Table 5 represents a single in-person visit for all marked procedures within the screening window (Day -28 to Day -1).; Randomization occurs on Day 0 (C1D1) and is combined with the first treatment visit.; PK blood samples are not taken during screening, only from C1D1 onwards as specified in footnote 19 of Table 5.; 'Dispense study treatment' is considered an in-person activity for drug collection, thus categorized as 'core_treatment'.; 'Study treatment return' is an in-person activity but coincides with 'Dispense study treatment' (core_treatment) and therefore does not add a unique contact day due to precedence.; 'Every 6 weeks' for RECIST, cfDNA, questionnaires, HRU module, and 'Every 12 weeks' for Echocardiography/MUGA, are relative to randomization (Day 0).; 'Day 1 of every other cycle from Cycle 5 onwards' (footnote 1 of Table 5) means C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1, which correspond to Days 84, 126, 168, 210, 252, 294, 336 respectively, based on a 21-day cycle length.; The 'Visit window' row indicates flexibility, but the nominal day is used for counting unique contact days.; Follow-up visits (28-day Safety F/U, Progression F/U, Survival F/U) are not included as they occur after treatment discontinuation.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits was applied."
37379502,Gefitinib (250 mg once daily),control,1,4,7,9,11,13,0,2,5,7,9,11,1,0,0,0,0,0,0,2,2,2,2,2,0,0,0,0,0,0,21,until progression,"Screening, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1. All range-columns were mapped to one nominal date.","The 'Screening' column in Table 5 represents a single in-person visit for all marked procedures within the screening window (Day -28 to Day -1).; Randomization occurs on Day 0 (C1D1) and is combined with the first treatment visit.; PK blood samples are not taken during screening, only from C1D1 onwards as specified in footnote 19 of Table 5.; 'Dispense study treatment' is considered an in-person activity for drug collection, thus categorized as 'core_treatment'.; 'Study treatment return' is an in-person activity but coincides with 'Dispense study treatment' (core_treatment) and therefore does not add a unique contact day due to precedence.; 'Every 6 weeks' for RECIST, cfDNA, questionnaires, HRU module, and 'Every 12 weeks' for Echocardiography/MUGA, are relative to randomization (Day 0).; 'Day 1 of every other cycle from Cycle 5 onwards' (footnote 1 of Table 5) means C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1, which correspond to Days 84, 126, 168, 210, 252, 294, 336 respectively, based on a 21-day cycle length.; The 'Visit window' row indicates flexibility, but the nominal day is used for counting unique contact days.; Follow-up visits (28-day Safety F/U, Progression F/U, Survival F/U) are not included as they occur after treatment discontinuation.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits was applied."
37423228,Atezolizumab,intervention,2,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening (Day -28, Day -14), C1D1, C2D1, C3D1, ..., C18D1. Range columns (e.g., 'Day 1 ± 5 days') were mapped to one nominal date (Day 1).","Assumed 2 distinct screening days: one for general check-up/labs (Day -28), and one for tumor tissue biopsy/imaging (Day -14), due to the comprehensive nature of the procedures, even though the SoE lists them in one 'Screening Period' column.; For the Atezolizumab arm, all tumor assessments (every 6 weeks) and TSH/plasma biomarker collections fall on a Cycle Day 1 visit due to the 21-day cycle length, thus not adding unique contact days beyond the core treatment days.; All 'Day X ± Y days' intervals are counted on the nominal Day X."
37423228,Single Agent Chemotherapy,control,2,2,5,9,13,18,0,2,4,7,10,14,1,0,1,2,3,4,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (Day -28, Day -14), C1D1, C2D1, C3D1, ..., C14D1, plus additional imaging days at Day 42, 126, 210, 294. Range columns (e.g., 'Day 1 ± 5 days') were mapped to one nominal date (Day 1).","Assumed 2 distinct screening days: one for general check-up/labs (Day -28), and one for tumor tissue biopsy/imaging (Day -14), due to the comprehensive nature of the procedures, even though the SoE lists them in one 'Screening Period' column.; For the Chemotherapy arm, a 28-day cycle length was assumed based on the protocol stating '3-weekly or 4-weekly' and the default cycle length of 28 days, representing a common conservative choice for a fixed schedule.; Tumor assessments (every 6 weeks) and plasma biomarker collections (Week 7) for the Chemotherapy arm sometimes fall on days separate from the Cycle Day 1 treatment visits, creating additional unique contact days.; All 'Day X ± Y days' intervals are counted on the nominal Day X."
37478390,Arm A (Zanubrutinib),intervention,1,4,11,21,30,40,0,2,4,7,10,14,1,0,0,0,0,0,0,2,7,14,20,26,0,0,0,0,0,0,28,until progression,"Screening (Day -X), CkD1 (Day 0, 28, 56, ...), CkD4 (Day 4, 32, 60, ...), CkD7 (Day 7, 35, 63, ...), CkD28 (Day 28, 56, 84, ...). CkD28 and C(k+1)D1 are consolidated into a single contact day.","Cycle length is 28 days.; Treatment is assumed to continue for at least 365 days for calculation purposes, as per 'until progressive disease' rule.; The 'Screening' column represents one in-person visit for initial assessments (e.g., bone marrow biopsy, ECG, ECHO/MUGA, labs, physical exam). This day is categorized as 'imaging_diagnostics' due to the biopsy and imaging.; Day 1 of each cycle (CkD1) is a mandatory in-person visit for study drug administration, CBC, vital signs, physical exam, ECOG, weight, B symptoms, patient diary review, chemistry, β2-microglobulin, and urinalysis. This day is categorized as 'core_treatment' due to drug administration.; The 'D1±4' column represents a mandatory in-person visit on Day 4 of Cycles 1-13 for CBC, Chemistry, β2-microglobulin, and Urinalysis. This day is categorized as 'labs'.; The 'D1+7' column represents a mandatory in-person visit on Day 7 of Cycles 1-13 for Pharmacokinetics (Arms A & C only). This day is categorized as 'labs'.; The 'Every 4 weeks (Day 28 of each cycle)' for pregnancy test implies a mandatory in-person visit on Day 28 of each cycle. This day is categorized as 'labs'.; When CkD28 and C(k+1)D1 fall on the same calendar day (e.g., Day 28, Day 56), they are counted as a single unique healthcare contact day. Per precedence rules, this day is categorized as 'core_treatment' due to C(k+1)D1 drug administration.; Additional assessments (e.g., ECG, Imaging, QOL, Serum immunoglobulins, Response Assessment, SPEP/immunofixation, Cold agglutinins, Cryoglobulin, Anti-MAG, Serum viscosity) that fall on CkD1 visits are subsumed under the 'core_treatment' category for that day.; The header 'C16, C19, C22+ (every 3 cycles) Subjects must come every cycle for CBC, study drug, and patient diary review (D1+7)' is interpreted as confirming a mandatory Day 1 visit for every cycle (CkD1) for the listed procedures, with the 'every 3 cycles' applying to specific assessments on those Day 1 visits. The '(D1+7)' in this header is disregarded as a separate visit for these later cycles, as PK is only for C1-C13.; EOT and Safety Follow-up visits occur after Day 365 and are not included in the 12-month window. Follow-up via phone contact is not counted as an in-person visit."
37478390,Arm B (Ibrutinib),intervention,1,3,8,14,20,27,0,2,4,7,10,14,1,0,0,0,0,0,0,1,4,7,10,13,0,0,0,0,0,0,28,until progression,"Screening (Day -X), CkD1 (Day 0, 28, 56, ...), CkD4 (Day 4, 32, 60, ...), CkD28 (Day 28, 56, 84, ...). CkD28 and C(k+1)D1 are consolidated into a single contact day.","Cycle length is 28 days.; Treatment is assumed to continue for at least 365 days for calculation purposes, as per 'until progressive disease' rule.; The 'Screening' column represents one in-person visit for initial assessments (e.g., bone marrow biopsy, ECG, ECHO/MUGA, labs, physical exam). This day is categorized as 'imaging_diagnostics' due to the biopsy and imaging.; Day 1 of each cycle (CkD1) is a mandatory in-person visit for study drug administration, CBC, vital signs, physical exam, ECOG, weight, B symptoms, patient diary review, chemistry, β2-microglobulin, and urinalysis. This day is categorized as 'core_treatment' due to drug administration.; The 'D1±4' column represents a mandatory in-person visit on Day 4 of Cycles 1-13 for CBC, Chemistry, β2-microglobulin, and Urinalysis. This day is categorized as 'labs'.; Arm B does not have mandatory PK visits on Day 7 of cycles.; The 'Every 4 weeks (Day 28 of each cycle)' for pregnancy test implies a mandatory in-person visit on Day 28 of each cycle. This day is categorized as 'labs'.; When CkD28 and C(k+1)D1 fall on the same calendar day (e.g., Day 28, Day 56), they are counted as a single unique healthcare contact day. Per precedence rules, this day is categorized as 'core_treatment' due to C(k+1)D1 drug administration.; Additional assessments (e.g., ECG, Imaging, QOL, Serum immunoglobulins, Response Assessment, SPEP/immunofixation, Cold agglutinins, Cryoglobulin, Anti-MAG, Serum viscosity) that fall on CkD1 visits are subsumed under the 'core_treatment' category for that day.; The header 'C16, C19, C22+ (every 3 cycles) Subjects must come every cycle for CBC, study drug, and patient diary review (D1+7)' is interpreted as confirming a mandatory Day 1 visit for every cycle (CkD1) for the listed procedures, with the 'every 3 cycles' applying to specific assessments on those Day 1 visits. The '(D1+7)' in this header is disregarded as a separate visit for these later cycles, as PK is only for C1-C13.; EOT and Safety Follow-up visits occur after Day 365 and are not included in the 12-month window. Follow-up via phone contact is not counted as an in-person visit."
37478390,Arm C (Zanubrutinib),intervention,1,4,11,21,30,40,0,2,4,7,10,14,1,0,0,0,0,0,0,2,7,14,20,26,0,0,0,0,0,0,28,until progression,"Screening (Day -X), CkD1 (Day 0, 28, 56, ...), CkD4 (Day 4, 32, 60, ...), CkD7 (Day 7, 35, 63, ...), CkD28 (Day 28, 56, 84, ...). CkD28 and C(k+1)D1 are consolidated into a single contact day.","Cycle length is 28 days.; Treatment is assumed to continue for at least 365 days for calculation purposes, as per 'until progressive disease' rule.; The 'Screening' column represents one in-person visit for initial assessments (e.g., bone marrow biopsy, ECG, ECHO/MUGA, labs, physical exam). This day is categorized as 'imaging_diagnostics' due to the biopsy and imaging.; Day 1 of each cycle (CkD1) is a mandatory in-person visit for study drug administration, CBC, vital signs, physical exam, ECOG, weight, B symptoms, patient diary review, chemistry, β2-microglobulin, and urinalysis. This day is categorized as 'core_treatment' due to drug administration.; The 'D1±4' column represents a mandatory in-person visit on Day 4 of Cycles 1-13 for CBC, Chemistry, β2-microglobulin, and Urinalysis. This day is categorized as 'labs'.; The 'D1+7' column represents a mandatory in-person visit on Day 7 of Cycles 1-13 for Pharmacokinetics (Arms A & C only). This day is categorized as 'labs'.; The 'Every 4 weeks (Day 28 of each cycle)' for pregnancy test implies a mandatory in-person visit on Day 28 of each cycle. This day is categorized as 'labs'.; When CkD28 and C(k+1)D1 fall on the same calendar day (e.g., Day 28, Day 56), they are counted as a single unique healthcare contact day. Per precedence rules, this day is categorized as 'core_treatment' due to C(k+1)D1 drug administration.; Additional assessments (e.g., ECG, Imaging, QOL, Serum immunoglobulins, Response Assessment, SPEP/immunofixation, Cold agglutinins, Cryoglobulin, Anti-MAG, Serum viscosity) that fall on CkD1 visits are subsumed under the 'core_treatment' category for that day.; The header 'C16, C19, C22+ (every 3 cycles) Subjects must come every cycle for CBC, study drug, and patient diary review (D1+7)' is interpreted as confirming a mandatory Day 1 visit for every cycle (CkD1) for the listed procedures, with the 'every 3 cycles' applying to specific assessments on those Day 1 visits. The '(D1+7)' in this header is disregarded as a separate visit for these later cycles, as PK is only for C1-C13.; EOT and Safety Follow-up visits occur after Day 365 and are not included in the 12-month window. Follow-up via phone contact is not counted as an in-person visit."
37524096,Everolimus (daily),intervention,2,1,3,5,7,9,0,0,0,0,0,0,1,0,0,1,2,2,1,1,3,4,5,7,0,0,0,0,0,0,42,54 weeks (378 days),"Pre-study (2 distinct days), then Week 1 of each 6-week cycle for 9 cycles (Day 0, 42, 84, 126, 168, 210, 252, 294, 336). CT scans for recurrence assessment are integrated into the Week 1 visits of Cycle 4 (Day 126) and Cycle 7 (Day 252).","The 'PRE STUDY' column in the Study Calendar represents screening visits. The physical exam/labs and CT scan are considered two distinct in-person contact days during screening, as they involve different primary activities (labs vs. imaging).; Weekly toxicity assessments in Cycle 1 (WK 2-6) are assumed to be phone calls, not in-person visits, as per footnote Ω and the absence of other in-person procedures on those days.; Oral daily drug administration does not count as a 'core_treatment' contact day for the visits, as the drug is self-administered at home. The visits are primarily for monitoring, assessment, and drug review/dispensing, thus categorized under 'labs' or 'imaging_diagnostics' based on precedence.; The 'Everolimus/Placebo' 'X' in the SoE table for Week 1 of each cycle signifies the continuation of the treatment period and drug review/dispensing, not direct in-person administration of the oral drug.; When multiple activities occur on a single day, the category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) is applied to assign the day to a single primary category.; The SoE table columns 'WK 1', 'WK 7', 'WK 13', etc., are interpreted as the nominal start day of the cycle/week (Day 0, Day 42, Day 84, etc.).; CT scans for recurrence assessment (Week 18, 36, 54) are integrated into the Week 1 visits of Cycle 4 (Day 126) and Cycle 7 (Day 252). The CT scan at Week 54 (Day 378) falls outside the 12-month window (Day +365) and is not counted."
37524096,Placebo (daily),control,2,1,3,5,7,9,0,0,0,0,0,0,1,0,0,1,2,2,1,1,3,4,5,7,0,0,0,0,0,0,42,54 weeks (378 days),"Pre-study (2 distinct days), then Week 1 of each 6-week cycle for 9 cycles (Day 0, 42, 84, 126, 168, 210, 252, 294, 336). CT scans for recurrence assessment are integrated into the Week 1 visits of Cycle 4 (Day 126) and Cycle 7 (Day 252).","The 'PRE STUDY' column in the Study Calendar represents screening visits. The physical exam/labs and CT scan are considered two distinct in-person contact days during screening, as they involve different primary activities (labs vs. imaging).; Weekly toxicity assessments in Cycle 1 (WK 2-6) are assumed to be phone calls, not in-person visits, as per footnote Ω and the absence of other in-person procedures on those days.; Oral daily drug administration does not count as a 'core_treatment' contact day for the visits, as the drug is self-administered at home. The visits are primarily for monitoring, assessment, and drug review/dispensing, thus categorized under 'labs' or 'imaging_diagnostics' based on precedence.; The 'Everolimus/Placebo' 'X' in the SoE table for Week 1 of each cycle signifies the continuation of the treatment period and drug review/dispensing, not direct in-person administration of the oral drug.; When multiple activities occur on a single day, the category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) is applied to assign the day to a single primary category.; The SoE table columns 'WK 1', 'WK 7', 'WK 13', etc., are interpreted as the nominal start day of the cycle/week (Day 0, Day 42, Day 84, etc.).; CT scans for recurrence assessment (Week 18, 36, 54) are integrated into the Week 1 visits of Cycle 4 (Day 126) and Cycle 7 (Day 252). The CT scan at Week 54 (Day 378) falls outside the 12-month window (Day +365) and is not counted."
37604981,Intensive Chemotherapy: Glasdegib + Cytarabine/Daunorubicin,intervention,1,5,14,22,25,29,0,2,7,11,14,18,1,1,1,1,1,1,0,2,6,10,10,10,0,0,0,0,0,0,28,up to 2 years post randomization,"Screening (Day -28), Induction 1 (Day 0, Day 6, Day 13, Day 20), Consolidation Cycles 1-4 (Day 1, Day 5, Day 10, Day 21 of each 28-day cycle), Following Consolidation (Day 1 of each 28-day cycle, monthly). Range-columns were mapped to one nominal date (e.g., Day 14 for 'Day 14-21').","Assumed a single Induction cycle (Induction 2 is conditional and not included in fixed schedule).; Assumed 4 Consolidation cycles (maximum specified) to calculate contact days within 365 days.; Assumed 'Following Consolidation' monthly visits continue until Day 365 after the 4 consolidation cycles are complete.; HSCT is an optional procedure and not included in the fixed schedule.; PK/ECG '0, 1, 4 hour' timepoints on a given Day 1 are considered measurements taken during a single in-person visit for that day.; Oral Glasdegib/Placebo administration is daily, but only days with explicit 'X' in the Glasdegib/Placebo row in the SoE table are counted as 'core_treatment' contact days (representing dispensing/monitoring in clinic). Other in-person visit days are categorized by the highest precedence non-drug activity."
37604981,Intensive Chemotherapy: Placebo + Cytarabine/Daunorubicin,control,1,5,14,22,25,29,0,2,7,11,14,18,1,1,1,1,1,1,0,2,6,10,10,10,0,0,0,0,0,0,28,up to 2 years post randomization,"Screening (Day -28), Induction 1 (Day 0, Day 6, Day 13, Day 20), Consolidation Cycles 1-4 (Day 1, Day 5, Day 10, Day 21 of each 28-day cycle), Following Consolidation (Day 1 of each 28-day cycle, monthly). Range-columns were mapped to one nominal date (e.g., Day 14 for 'Day 14-21').","Assumed a single Induction cycle (Induction 2 is conditional and not included in fixed schedule).; Assumed 4 Consolidation cycles (maximum specified) to calculate contact days within 365 days.; Assumed 'Following Consolidation' monthly visits continue until Day 365 after the 4 consolidation cycles are complete.; HSCT is an optional procedure and not included in the fixed schedule.; PK/ECG '0, 1, 4 hour' timepoints on a given Day 1 are considered measurements taken during a single in-person visit for that day.; Oral Glasdegib/Placebo administration is daily, but only days with explicit 'X' in the Glasdegib/Placebo row in the SoE table are counted as 'core_treatment' contact days (representing dispensing/monitoring in clinic). Other in-person visit days are categorized by the highest precedence non-drug activity."
37604981,Non-Intensive Chemotherapy: Glasdegib + Azacitidine,intervention,1,4,10,20,30,39,0,3,7,14,20,26,1,0,0,0,0,0,0,1,3,6,10,13,0,0,0,0,0,0,28,up to 2 years post randomization,"Screening (Day -28), Cycles 1-13 (Day 1, Day 7, Day 15 of each 28-day cycle).","Assumed treatment continues for 13 cycles (364 days) to cover the 365-day window, as 'at least 6 cycles' is a minimum and 'up to 2 years' is the maximum.; HSCT is an optional procedure and not included in the fixed schedule.; PK/ECG '0, 1, 4 hour' timepoints on a given Day 1 are considered measurements taken during a single in-person visit for that day.; Oral Glasdegib/Placebo administration is daily, but only days with explicit 'X' in the Glasdegib/Placebo row in the SoE table are counted as 'core_treatment' contact days (representing dispensing/monitoring in clinic). Other in-person visit days are categorized by the highest precedence non-drug activity."
37604981,Non-Intensive Chemotherapy: Placebo + Azacitidine,control,1,4,10,20,30,39,0,3,7,14,20,26,1,0,0,0,0,0,0,1,3,6,10,13,0,0,0,0,0,0,28,up to 2 years post randomization,"Screening (Day -28), Cycles 1-13 (Day 1, Day 7, Day 15 of each 28-day cycle).","Assumed treatment continues for 13 cycles (364 days) to cover the 365-day window, as 'at least 6 cycles' is a minimum and 'up to 2 years' is the maximum.; HSCT is an optional procedure and not included in the fixed schedule.; PK/ECG '0, 1, 4 hour' timepoints on a given Day 1 are considered measurements taken during a single in-person visit for that day.; Oral Glasdegib/Placebo administration is daily, but only days with explicit 'X' in the Glasdegib/Placebo row in the SoE table are counted as 'core_treatment' contact days (representing dispensing/monitoring in clinic). Other in-person visit days are categorized by the highest precedence non-drug activity."
37646660,Arm A: Melflufen + Daratumumab + Dexamethasone,intervention,1,5,13,26,39,53,0,5,13,26,39,53,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (Day -28 to -1), Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 22, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, Cycle 2 Day 22, Cycle 3 Day 1, Cycle 3 Day 8, Cycle 3 Day 15, Cycle 3 Day 22, Cycle 4 Day 1, Cycle 4 Day 8, Cycle 4 Day 15, Cycle 4 Day 22, Cycle 5 Day 1, Cycle 5 Day 8, Cycle 5 Day 15, Cycle 5 Day 22, Cycle 6 Day 1, Cycle 6 Day 8, Cycle 6 Day 15, Cycle 6 Day 22, Cycle 7 Day 1, Cycle 7 Day 8, Cycle 7 Day 15, Cycle 7 Day 22, Cycle 8 Day 1, Cycle 8 Day 8, Cycle 8 Day 15, Cycle 8 Day 22, Cycle 9 Day 1, Cycle 9 Day 8, Cycle 9 Day 15, Cycle 9 Day 22, Cycle 10 Day 1, Cycle 10 Day 8, Cycle 10 Day 15, Cycle 10 Day 22, Cycle 11 Day 1, Cycle 11 Day 8, Cycle 11 Day 15, Cycle 11 Day 22, Cycle 12 Day 1, Cycle 12 Day 8, Cycle 12 Day 15, Cycle 12 Day 22, Cycle 13 Day 1, Cycle 13 Day 8, Cycle 13 Day 15, Cycle 13 Day 22, Cycle 14 Day 1.","Treatment is assumed to continue for the full 365-day horizon, as per 'until progression' rule.; End of Treatment (EOT) and all subsequent follow-up visits (8 weeks after last dose, PFS-FU, OS/PFS-2-FU) are assumed to occur after Day +365 and are therefore not included in the 1-month to 12-month windows.; The 'Screening Day -21 to -1' column in Table 1-2 represents a single in-person contact day.; Assessments marked with '(X)' (e.g., Physical Examination on Day 8/15/22) are considered 'only if indicated' and are excluded as non-mandatory in-person visits, unless a footnote explicitly mandates them (e.g., Vital Signs, Hematology).; Vital Signs and Hematology on Day 8, 15, and 22 for all cycles are considered mandatory in-person assessments based on footnotes e and i on page 17-18.; Dexamethasone administration for Arm A is weekly (Day 1, 8, 15, 22 for all cycles, per Table 6-4) and is considered a core treatment activity requiring an in-person visit for administration and compliance review.; Category precedence applied: core_treatment > imaging_diagnostics > labs > clinic_visits.; For Arm A, all treatment days (Day 1, 8, 15, 22 of each cycle) involve administration of Melflufen, Daratumumab, and/or Dexamethasone, thus all are categorized as 'core_treatment'."
37646660,Arm B: Daratumumab Monotherapy,control,1,5,13,26,39,53,0,5,11,17,20,24,1,0,0,0,0,0,0,0,2,9,19,29,0,0,0,0,0,0,28,until progression,"Screening (Day -28 to -1), Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 22, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, Cycle 2 Day 22, Cycle 3 Day 1, Cycle 3 Day 8, Cycle 3 Day 15, Cycle 3 Day 22, Cycle 4 Day 1, Cycle 4 Day 8, Cycle 4 Day 15, Cycle 4 Day 22, Cycle 5 Day 1, Cycle 5 Day 8, Cycle 5 Day 15, Cycle 5 Day 22, Cycle 6 Day 1, Cycle 6 Day 8, Cycle 6 Day 15, Cycle 6 Day 22, Cycle 7 Day 1, Cycle 7 Day 8, Cycle 7 Day 15, Cycle 7 Day 22, Cycle 8 Day 1, Cycle 8 Day 8, Cycle 8 Day 15, Cycle 8 Day 22, Cycle 9 Day 1, Cycle 9 Day 8, Cycle 9 Day 15, Cycle 9 Day 22, Cycle 10 Day 1, Cycle 10 Day 8, Cycle 10 Day 15, Cycle 10 Day 22, Cycle 11 Day 1, Cycle 11 Day 8, Cycle 11 Day 15, Cycle 11 Day 22, Cycle 12 Day 1, Cycle 12 Day 8, Cycle 12 Day 15, Cycle 12 Day 22, Cycle 13 Day 1, Cycle 13 Day 8, Cycle 13 Day 15, Cycle 13 Day 22, Cycle 14 Day 1.","Treatment is assumed to continue for the full 365-day horizon, as per 'until progression' rule.; End of Treatment (EOT) and all subsequent follow-up visits (8 weeks after last dose, PFS-FU, OS/PFS-2-FU) are assumed to occur after Day +365 and are therefore not included in the 1-month to 12-month windows.; The 'Screening Day -21 to -1' column in Table 1-2 represents a single in-person contact day.; Assessments marked with '(X)' (e.g., Physical Examination on Day 8/15/22) are considered 'only if indicated' and are excluded as non-mandatory in-person visits, unless a footnote explicitly mandates them (e.g., Vital Signs, Hematology).; Vital Signs and Hematology on Day 8, 15, and 22 for all cycles are considered mandatory in-person assessments based on footnotes e and i on page 17-18.; For Arm B, Daratumumab is administered on Day 1 (all cycles) and Day 8, 15, 22 (Cycles 1-2) or Day 15 (Cycles 3-6). These days are categorized as 'core_treatment'.; For Arm B, on Day 8 and Day 22 of Cycles 3-6 and 7+, Daratumumab is NOT administered. However, mandatory Vital Signs and Hematology assessments occur. As Hematology (labs) takes precedence over Vital Signs (clinic visits), these days are categorized as 'labs'.; Category precedence applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
37647576,Nimotuzumab combined with gemcitabine,intervention,2,5,13,26,39,52,0,5,13,26,39,52,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression or intolerable toxicity,"Screening: Day -28 (Screening I), Day -14 (Screening II). Treatment Cycles (28-day cycle): Day 0 (C1D1), Day 7 (C1D8), Day 14 (C1D15), Day 21 (C1D22). This pattern repeats for 13 cycles up to Day 357. Efficacy Evaluation visits occur on Day 56 (C3D1), Day 112 (C5D1), Day 168 (C7D1), Day 224 (C9D1), Day 280 (C11D1), Day 336 (C13D1) and are included in the treatment cycle count.","Screening period check (I) and Screening period examination (II) are considered two distinct in-person contact days (nominal Day -28 and Day -14, respectively) within the screening window.; The 'Baseline period' column in the Schedule of Events table (Appendix 1) represents assessments that can be fulfilled by 'Screening period examination (II)' if timed appropriately. Day 0 (C1D1) is the first treatment day and is not counted as a separate 'Baseline visit' day distinct from the first treatment.; Treatment is assumed to continue up to Day 365 for calculation purposes, based on the 'until disease progression or intolerable toxicity' rule.; The 'Every 3 months Follow up' visits are not counted as in-person contact days, as the Schedule of Events table indicates 'Keep a record' and there is no explicit mention of mandatory in-person procedures for these follow-ups.; Efficacy evaluation visits ('Every 8 weeks') coincide with the first day of certain treatment cycles (C3D1, C5D1, C7D1, C9D1, C11D1, C13D1). Since these days involve drug administration (core_treatment), they are categorized under 'core_treatment' due to the specified precedence rule, even though they also include imaging diagnostics.; The 'Final cancer visit assessment' is assumed to occur after Day 365 or upon treatment termination, and therefore no contact days for this visit are included within the 12-month window."
37647576,Placebo plus gemcitabine,control,2,5,13,26,39,52,0,5,13,26,39,52,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression or intolerable toxicity,"Screening: Day -28 (Screening I), Day -14 (Screening II). Treatment Cycles (28-day cycle): Day 0 (C1D1), Day 7 (C1D8), Day 14 (C1D15), Day 21 (C1D22). This pattern repeats for 13 cycles up to Day 357. Efficacy Evaluation visits occur on Day 56 (C3D1), Day 112 (C5D1), Day 168 (C7D1), Day 224 (C9D1), Day 280 (C11D1), Day 336 (C13D1) and are included in the treatment cycle count.","Screening period check (I) and Screening period examination (II) are considered two distinct in-person contact days (nominal Day -28 and Day -14, respectively) within the screening window.; The 'Baseline period' column in the Schedule of Events table (Appendix 1) represents assessments that can be fulfilled by 'Screening period examination (II)' if timed appropriately. Day 0 (C1D1) is the first treatment day and is not counted as a separate 'Baseline visit' day distinct from the first treatment.; Treatment is assumed to continue up to Day 365 for calculation purposes, based on the 'until disease progression or intolerable toxicity' rule.; The 'Every 3 months Follow up' visits are not counted as in-person contact days, as the Schedule of Events table indicates 'Keep a record' and there is no explicit mention of mandatory in-person procedures for these follow-ups.; Efficacy evaluation visits ('Every 8 weeks') coincide with the first day of certain treatment cycles (C3D1, C5D1, C7D1, C9D1, C11D1, C13D1). Since these days involve drug administration (core_treatment), they are categorized under 'core_treatment' due to the specified precedence rule, even though they also include imaging diagnostics.; The 'Final cancer visit assessment' is assumed to occur after Day 365 or upon treatment termination, and therefore no contact days for this visit are included within the 12-month window."
37704166,Experimental Arm A: OSE2101,intervention,1,3,6,10,13,18,0,2,5,7,8,9,1,0,0,2,4,7,0,1,1,1,1,2,0,0,0,0,0,0,21,until progression,"Screening/Randomization (Day -1), C1D1 (Day 0), C1D15 (Day 15), C2D1 (Day 21), C3D1 (Day 42), C4D1 (Day 63), C5D1 (Day 84), C6D1 (Day 105), C7D1 (Day 161), C8D1 (Day 217), C9D1 (Day 273), C10D1 (Day 329). Additional scan-only days: Day 126, Day 168, Day 210, Day 252, Day 294, Day 336. End of Treatment visit (Day 357). Range-columns (e.g., 'Day 15 (±2)') were mapped to one nominal date (Day 15).","Pre-screening HLA-A2 determination (Day -35) is assumed to occur outside the defined screening window (Day -28 to Day -1) and is therefore not counted.; The 'Screening and randomization' visit is counted as one in-person day (Day -1). Tumor assessments (scans) are present on this day, making it an 'imaging_diagnostics' day by precedence.; Treatment continues until progression; for the purpose of the 12-month horizon, it is assumed no progression occurs, and treatment continues as scheduled.; The 'End of treatment' visit is scheduled 4 weeks (28 days) after the last treatment administration. For Arm A, the last treatment dose within 365 days is on Day 329 (C10D1), so the EOT visit is on Day 357. For Arm B, the last treatment dose within 365 days is on Day 357 (C18D1), so the EOT visit on Day 385 falls outside the 12-month window and is not counted.; Optional biomarker blood/tumor samples are not counted as separate contact days as they are either explicitly optional or coincide with other mandatory visits.; Tumor assessments (scans) are scheduled every 6 weeks (42 days) from Day 0. If a scan day coincides with a treatment day, the day is categorized as 'core_treatment' due to precedence. If it falls on a non-treatment day, it is categorized as 'imaging_diagnostics'."
37704166,Control Arm B: Docetaxel or Pemetrexed,control,1,3,6,10,14,19,0,2,5,9,13,18,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,21,until progression,"Screening/Randomization (Day -1), C1D1 (Day 0), C1D15 (Day 15), C2D1 (Day 21), C3D1 (Day 42), C4D1 (Day 63), C5D1 (Day 84), C6D1 (Day 105), C7D1 (Day 126), C8D1 (Day 147), C9D1 (Day 168), C10D1 (Day 189), C11D1 (Day 210), C12D1 (Day 231), C13D1 (Day 252), C14D1 (Day 273), C15D1 (Day 294), C16D1 (Day 315), C17D1 (Day 336), C18D1 (Day 357). Range-columns (e.g., 'Day 15 (±2)') were mapped to one nominal date (Day 15).","Pre-screening HLA-A2 determination (Day -35) is assumed to occur outside the defined screening window (Day -28 to Day -1) and is therefore not counted.; The 'Screening and randomization' visit is counted as one in-person day (Day -1). Tumor assessments (scans) are present on this day, making it an 'imaging_diagnostics' day by precedence.; Treatment continues until progression; for the purpose of the 12-month horizon, it is assumed no progression occurs, and treatment continues as scheduled.; The 'End of treatment' visit is scheduled 4 weeks (28 days) after the last treatment administration. For Arm B, the last treatment dose within 365 days is on Day 357 (C18D1), so the EOT visit on Day 385 falls outside the 12-month window and is not counted.; Optional biomarker blood/tumor samples are not counted as separate contact days as they are either explicitly optional or coincide with other mandatory visits.; Tumor assessments (scans) are scheduled every 6 weeks (42 days) from Day 0. All scan days coincide with treatment days for Arm B, so these days are categorized as 'core_treatment' due to precedence."
37708904,Arm 1: irinotecan liposome injection+oxaliplatin+5-FU/LV,intervention,2,5,15,30,45,65,0,3,9,18,27,39,1,0,0,0,0,0,1,2,6,12,18,26,0,0,0,0,0,0,28,until progression,"Screening (2 days), Cycle 1 Day 1, Cycle 1 Day 3, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 17. For subsequent cycles (C2-C13), the pattern repeats for Day 1, Day 3, Day 8, Day 15, Day 17. All listed day-ranges (e.g., 'Day 14–21') were interpreted as a single nominal date if present, but this protocol uses specific days.","Screening period (Day -28 to Day -1) is assumed to require 2 distinct in-person visits: one for initial comprehensive workup (e.g., CT/MRI, ECG, DPD, UGT1A1*28, consent) and another for final pre-randomization checks (e.g., vital signs, labs, pregnancy test).; For screening days, category precedence was applied: Day -7 (Imaging/Diagnostics), Day -1 (Labs).; Treatment is assumed to continue until Day +365, completing 13 full 28-day cycles (C1D1 to C13D17).; The 'Q8W after randomisation' disease evaluations (CT/MRI) fall on Cycle Day 1 of odd-numbered cycles (C3D1, C5D1, etc.). Since these days also involve core treatment administration, they are categorized as 'core_treatment' due to precedence and do not add new unique contact days.; Optional PK sampling (C1 Days 4-14) is not counted as a mandatory in-person visit.; The End of Treatment (EoT) visit is assumed to fall outside the Day +365 window if treatment continues for 13 cycles."
37708904,Arm 2: nab-paclitaxel+gemcitabine,control,2,3,9,18,27,39,0,3,9,18,27,39,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (2 days), Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15. For subsequent cycles (C2-C13), the pattern repeats for Day 1, Day 8, Day 15. All listed day-ranges (e.g., 'Day 14–21') were interpreted as a single nominal date if present, but this protocol uses specific days.","Screening period (Day -28 to Day -1) is assumed to require 2 distinct in-person visits: one for initial comprehensive workup (e.g., CT/MRI, ECG, DPD, UGT1A1*28, consent) and another for final pre-randomization checks (e.g., vital signs, labs, pregnancy test).; For screening days, category precedence was applied: Day -7 (Imaging/Diagnostics), Day -1 (Labs).; Treatment is assumed to continue until Day +365, completing 13 full 28-day cycles (C1D1 to C13D15).; The 'Q8W after randomisation' disease evaluations (CT/MRI) fall on Cycle Day 1 of odd-numbered cycles (C3D1, C5D1, etc.). Since these days also involve core treatment administration, they are categorized as 'core_treatment' due to precedence and do not add new unique contact days.; The End of Treatment (EoT) visit is assumed to fall outside the Day +365 window if treatment continues for 13 cycles."
37722354,Placebo + Bendamustine and Rituximab (BR),control,2,4,8,13,14,16,0,4,8,12,12,12,2,0,0,1,1,2,0,0,0,0,1,2,0,0,0,0,0,0,28,until progression,"Screening Day 1 (Day -28), Screening Day 2 (Day -21), Cycle 1 Day 1 (Day 0), Cycle 1 Day 2 (Day 1), Cycle 2 Day 1 (Day 28), Cycle 2 Day 2 (Day 29), Cycle 3 Day 1 (Day 56), Cycle 3 Day 2 (Day 57), Cycle 4 Day 1 (Day 84), Cycle 4 Day 2 (Day 85), Cycle 5 Day 1 (Day 112), Cycle 5 Day 2 (Day 113), Cycle 6 Day 1 (Day 140), Cycle 6 Day 2 (Day 141), Post-Chemotherapy Period visits every 8 weeks starting at Cycle 7 Day 1 (Day 168, Day 224, Day 280, Day 336).","Screening procedures are assumed to occur over 2 distinct in-person days: one for initial clinic assessments (Day -28) and another for imaging/biopsy (Day -21), as these can be performed up to 60 days prior to randomization.; Ibrutinib/placebo is administered orally once daily and is self-administered, so its administration itself does not count as a healthcare contact day. Visits for dispensing and accountability are counted.; Prednisone (oral) for R-CHOP is self-administered on Days 1-5; only Day 1 is counted as an in-person visit due to co-occurring IV treatments and other assessments.; Pharmacokinetic (PK) and biomarker samples, and PRO questionnaires, are collected on existing visit days and do not add new contact days.; The End-of-Treatment (EOT) visit is not included within the 365-day horizon, as study drug continues until disease progression, and no progression is assumed within this period.; For days with multiple activities, the category precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied."
37722354,"Placebo + Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)",control,2,2,5,8,9,11,0,2,5,6,6,6,2,0,0,1,1,2,0,0,0,1,2,3,0,0,0,0,0,0,21,until progression,"Screening Day 1 (Day -28), Screening Day 2 (Day -21), Cycle 1 Day 1 (Day 0), Cycle 2 Day 1 (Day 21), Cycle 3 Day 1 (Day 42), Cycle 4 Day 1 (Day 63), Cycle 5 Day 1 (Day 84), Cycle 6 Day 1 (Day 105), Post-Chemotherapy Period visits every 8 weeks starting at Cycle 7 Day 1 (Day 126, Day 182, Day 238, Day 294, Day 350).","Screening procedures are assumed to occur over 2 distinct in-person days: one for initial clinic assessments (Day -28) and another for imaging/biopsy (Day -21), as these can be performed up to 60 days prior to randomization.; Ibrutinib/placebo is administered orally once daily and is self-administered, so its administration itself does not count as a healthcare contact day. Visits for dispensing and accountability are counted.; Prednisone (oral) for R-CHOP is self-administered on Days 1-5; only Day 1 is counted as an in-person visit due to co-occurring IV treatments and other assessments.; Pharmacokinetic (PK) and biomarker samples, and PRO questionnaires, are collected on existing visit days and do not add new contact days.; The End-of-Treatment (EOT) visit is not included within the 365-day horizon, as study drug continues until disease progression, and no progression is assumed within this period.; For days with multiple activities, the category precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied."
37722354,Ibrutinib + Bendamustine and Rituximab (BR),intervention,2,4,8,13,14,16,0,4,8,12,12,12,2,0,0,1,1,2,0,0,0,0,1,2,0,0,0,0,0,0,28,until progression,"Screening Day 1 (Day -28), Screening Day 2 (Day -21), Cycle 1 Day 1 (Day 0), Cycle 1 Day 2 (Day 1), Cycle 2 Day 1 (Day 28), Cycle 2 Day 2 (Day 29), Cycle 3 Day 1 (Day 56), Cycle 3 Day 2 (Day 57), Cycle 4 Day 1 (Day 84), Cycle 4 Day 2 (Day 85), Cycle 5 Day 1 (Day 112), Cycle 5 Day 2 (Day 113), Cycle 6 Day 1 (Day 140), Cycle 6 Day 2 (Day 141), Post-Chemotherapy Period visits every 8 weeks starting at Cycle 7 Day 1 (Day 168, Day 224, Day 280, Day 336).","Screening procedures are assumed to occur over 2 distinct in-person days: one for initial clinic assessments (Day -28) and another for imaging/biopsy (Day -21), as these can be performed up to 60 days prior to randomization.; Ibrutinib/placebo is administered orally once daily and is self-administered, so its administration itself does not count as a healthcare contact day. Visits for dispensing and accountability are counted.; Prednisone (oral) for R-CHOP is self-administered on Days 1-5; only Day 1 is counted as an in-person visit due to co-occurring IV treatments and other assessments.; Pharmacokinetic (PK) and biomarker samples, and PRO questionnaires, are collected on existing visit days and do not add new contact days.; The End-of-Treatment (EOT) visit is not included within the 365-day horizon, as study drug continues until disease progression, and no progression is assumed within this period.; For days with multiple activities, the category precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied."
37722354,"Ibrutinib + Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)",intervention,2,2,5,8,9,11,0,2,5,6,6,6,2,0,0,1,1,2,0,0,0,1,2,3,0,0,0,0,0,0,21,until progression,"Screening Day 1 (Day -28), Screening Day 2 (Day -21), Cycle 1 Day 1 (Day 0), Cycle 2 Day 1 (Day 21), Cycle 3 Day 1 (Day 42), Cycle 4 Day 1 (Day 63), Cycle 5 Day 1 (Day 84), Cycle 6 Day 1 (Day 105), Post-Chemotherapy Period visits every 8 weeks starting at Cycle 7 Day 1 (Day 126, Day 182, Day 238, Day 294, Day 350).","Screening procedures are assumed to occur over 2 distinct in-person days: one for initial clinic assessments (Day -28) and another for imaging/biopsy (Day -21), as these can be performed up to 60 days prior to randomization.; Ibrutinib/placebo is administered orally once daily and is self-administered, so its administration itself does not count as a healthcare contact day. Visits for dispensing and accountability are counted.; Prednisone (oral) for R-CHOP is self-administered on Days 1-5; only Day 1 is counted as an in-person visit due to co-occurring IV treatments and other assessments.; Pharmacokinetic (PK) and biomarker samples, and PRO questionnaires, are collected on existing visit days and do not add new contact days.; The End-of-Treatment (EOT) visit is not included within the 365-day horizon, as study drug continues until disease progression, and no progression is assumed within this period.; For days with multiple activities, the category precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied."
37748693,Arm A: Avelumab 10 mg/kg IV once every 2 weeks,intervention,1,3,7,13,20,26,0,3,7,13,20,26,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,until progression,"Screening/Baseline visit, then Avelumab infusions every 14 days (W1 Day 1, W3 Day 15, W5 Day 29, etc.). Tumor evaluations and other assessments coincide with these infusion visits.","Day 0 is defined as W1 Day 1, the first on-treatment visit.; The 'Screening/Baseline' column represents a single in-person visit day within the Day -28 to Day -1 window.; For Arm A, all in-person assessments (physical exams, labs, vital signs, tumor evaluations) are performed on the same day as the Avelumab infusion, so they do not add separate contact days.; Treatment is assumed to continue until Day 365 for counting purposes, as per 'until progression' rule."
37748693,Arm B: Investigator's choice platinum-containing chemotherapy,control,2,4,9,14,16,18,1,4,9,12,12,12,1,0,0,2,4,6,0,0,0,0,0,0,0,0,0,0,0,0,21,"maximum 6 cycles of chemotherapy, followed by tumor assessments until progression","Screening/Baseline visit (including Pemetrexed premedication for non-squamous histology), then Chemotherapy infusions on Day 1 and Day 8 of each 21-day cycle (W1 Day 1, W2 Day 8, W4 Day 22, W5 Day 29, etc.) for up to 6 cycles. Post-treatment tumor evaluations every 6 weeks.","Day 0 is defined as W1 Day 1, the first on-treatment visit.; The 'Screening/Baseline' column represents a single in-person visit day within the Day -28 to Day -1 window.; For Arm B, the most burdensome chemotherapy schedule (Gemcitabine with Day 1 and Day 8 visits per cycle) was used for treatment phase calculations.; An additional in-person visit for Pemetrexed premedication (oral folic acid, vitamin B12 intramuscular injection) is assumed to occur during the screening window for subjects receiving Pemetrexed, making the screening period 2 days for this arm.; All other in-person assessments (physical exams, labs, vital signs) are performed on the same day as chemotherapy infusions, so they do not add separate contact days.; Tumor evaluations are performed every 6 weeks for the first 12 months. Those coinciding with chemotherapy visits are counted as core_treatment; those occurring after the maximum 6 cycles of chemotherapy are counted as separate imaging_diagnostics days."
37748693,"Arm C: Avelumab 10 mg/kg IV once weekly for 12 weeks, followed by 10 mg/kg once every 2 weeks",intervention,1,5,13,19,26,32,0,5,13,19,26,32,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,7,until progression,"Screening/Baseline visit, then Avelumab infusions weekly for 12 weeks (W1 Day 1, W2 Day 8, ..., W12 Day 78), followed by Avelumab infusions every 14 days (W13 Day 85, W15 Day 99, etc.). Tumor evaluations and other assessments coincide with these infusion visits.","Day 0 is defined as W1 Day 1, the first on-treatment visit.; The 'Screening/Baseline' column represents a single in-person visit day within the Day -28 to Day -1 window.; For Arm C, all in-person assessments (physical exams, labs, vital signs, tumor evaluations) are performed on the same day as the Avelumab infusion, so they do not add separate contact days.; Treatment is assumed to continue until Day 365 for counting purposes, as per 'until progression' rule."
37788412,Canakinumab 200 mg s.c.,intervention,1,4,13,26,39,53,0,2,5,9,13,18,1,0,0,0,0,0,0,2,8,17,26,35,0,0,0,0,0,0,21,18 cycles (378 days),"Screening (1 day), C1D1, C1D8, C1D15, and then repeating CkD1, CkD8, CkD15 for subsequent cycles up to C18. Range-columns were mapped to one nominal date (e.g., 'Day 14–21' is Day 14, but in this protocol, all visits are specific days).","All screening activities (including consent, history, physical exam, ECOG, vitals, weight, height, EORTC, EQ-5D, tuberculosis status, HIV/HBsAg/HCV, hematology, biochemistry, coagulation, urinalysis, pregnancy tests, CT/MRI chest/abdomen/pelvis, MRI brain, ECG, Immunogenicity, PK, IL-1β) are consolidated into one in-person visit during the screening window (Day -28 to Day -1). This visit is categorized as 'imaging_diagnostics' due to the mandated imaging assessments.; Imaging assessments scheduled 'every 12 weeks for the first year (treatment phase) following Cycle 1 Day 1' (Day 84, 168, 252, 336) coincide with Day 1 of Cycles 5, 9, 13, and 17, respectively. As drug administration occurs on Day 1 of each cycle, these days are categorized as 'core_treatment' and do not add additional contact days.; An 'X' or 'S' in the Schedule of Events table (Table 7-1) indicates a mandatory in-person assessment.; Post-treatment surveillance and survival follow-up visits are beyond the 365-day horizon and are not included in the counts."
37788412,Placebo s.c.,intervention,1,4,13,26,39,53,0,2,5,9,13,18,1,0,0,0,0,0,0,2,8,17,26,35,0,0,0,0,0,0,21,18 cycles (378 days),"Screening (1 day), C1D1, C1D8, C1D15, and then repeating CkD1, CkD8, CkD15 for subsequent cycles up to C18. Range-columns were mapped to one nominal date (e.g., 'Day 14–21' is Day 14, but in this protocol, all visits are specific days).","All screening activities (including consent, history, physical exam, ECOG, vitals, weight, height, EORTC, EQ-5D, tuberculosis status, HIV/HBsAg/HCV, hematology, biochemistry, coagulation, urinalysis, pregnancy tests, CT/MRI chest/abdomen/pelvis, MRI brain, ECG, Immunogenicity, PK, IL-1β) are consolidated into one in-person visit during the screening window (Day -28 to Day -1). This visit is categorized as 'imaging_diagnostics' due to the mandated imaging assessments.; Imaging assessments scheduled 'every 12 weeks for the first year (treatment phase) following Cycle 1 Day 1' (Day 84, 168, 252, 336) coincide with Day 1 of Cycles 5, 9, 13, and 17, respectively. As drug administration occurs on Day 1 of each cycle, these days are categorized as 'core_treatment' and do not add additional contact days.; An 'X' or 'S' in the Schedule of Events table (Table 7-1) indicates a mandatory in-person assessment.; Post-treatment surveillance and survival follow-up visits are beyond the 365-day horizon and are not included in the counts."
37792130,MYL-1402O + Carboplatin/Paclitaxel then MYL-1402O Monotherapy,intervention,2,5,13,25,38,48,0,2,5,9,13,17,1,0,0,0,0,0,0,3,8,16,25,31,1,0,0,0,0,0,21,until progression or up to 47 weeks maximum study participation,"Screening (Day -28), Randomization (Day -1), CkD0 (Day 0, 21, 42, ...), CkD5 (Day 5, 26, 47, ...), CkD14 (Day 14, 35, 56, ...), Safety Follow-Up (Day 322). Range-columns for mid-cycle samples were mapped to one nominal date.","The 'Screening' column in Table 1-1 represents one in-person visit day (e.g., Day -28), primarily for initial assessments and imaging.; The 'Randomization' column in Table 1-1 represents a separate in-person visit day (e.g., Day -1), distinct from the main screening visit and Day 0, for randomization and final eligibility checks.; Mid-cycle PK/Immunogenicity samples (between Days 3-8 and Days 10-18 of each cycle) are counted as two separate in-person lab visits per cycle, using nominal days Day 5 and Day 14 (or equivalent offsets in subsequent cycles).; Tumor assessments at Weeks 6, 12, 18, 30, and 42 coincide with Day 0 of the respective cycles (C3D0, C5D0, C7D0, C11D0, C15D0) and are not counted as additional visit days. The imaging procedures are performed as part of the core treatment visit.; BSA calculation is assumed to be done at every Day 0 visit, as it is a routine measurement requiring in-person contact.; The Safety Follow-Up Visit occurs 28 days after the last dose at Week 42 (Day 294), placing it on Day 322, and is counted as a distinct in-person lab visit.; Optional tumor assessments at the Safety Follow-Up Visit are excluded from the count.; The maximum study participation is capped at approximately 47 weeks (Day 329) as stated in the protocol, which limits the number of cycles and mid-cycle visits counted within the 12-month window."
37792130,Avastin + Carboplatin/Paclitaxel then Avastin Monotherapy,control,2,5,13,25,38,48,0,2,5,9,13,17,1,0,0,0,0,0,0,3,8,16,25,31,1,0,0,0,0,0,21,until progression or up to 47 weeks maximum study participation,"Screening (Day -28), Randomization (Day -1), CkD0 (Day 0, 21, 42, ...), CkD5 (Day 5, 26, 47, ...), CkD14 (Day 14, 35, 56, ...), Safety Follow-Up (Day 322). Range-columns for mid-cycle samples were mapped to one nominal date.","The 'Screening' column in Table 1-1 represents one in-person visit day (e.g., Day -28), primarily for initial assessments and imaging.; The 'Randomization' column in Table 1-1 represents a separate in-person visit day (e.g., Day -1), distinct from the main screening visit and Day 0, for randomization and final eligibility checks.; Mid-cycle PK/Immunogenicity samples (between Days 3-8 and Days 10-18 of each cycle) are counted as two separate in-person lab visits per cycle, using nominal days Day 5 and Day 14 (or equivalent offsets in subsequent cycles).; Tumor assessments at Weeks 6, 12, 18, 30, and 42 coincide with Day 0 of the respective cycles (C3D0, C5D0, C7D0, C11D0, C15D0) and are not counted as additional visit days. The imaging procedures are performed as part of the core treatment visit.; BSA calculation is assumed to be done at every Day 0 visit, as it is a routine measurement requiring in-person contact.; The Safety Follow-Up Visit occurs 28 days after the last dose at Week 42 (Day 294), placing it on Day 322, and is counted as a distinct in-person lab visit.; Optional tumor assessments at the Safety Follow-Up Visit are excluded from the count.; The maximum study participation is capped at approximately 47 weeks (Day 329) as stated in the protocol, which limits the number of cycles and mid-cycle visits counted within the 12-month window."
37845511,Nivolumab 480 mg Q4W,intervention,1,2,4,7,11,15,0,2,4,7,10,13,1,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,28,maximum of 12 months from the first dose of study treatment,"Screening Visit (1 day), Cycle 1 Day 1, Cycle 2 Day 1, ..., Cycle 13 Day 1 (infusions every 28 days), Week 26 Body Imaging, Week 52 Body Imaging. All range-columns were mapped to one nominal date (e.g., 'Screening Visit' as one day, 'Every 26 weeks' as Day 182 and Day 364).","All screening procedures (Informed Consent, Medical History, Physical Exam, Vital Signs, ECG, Labs, Pregnancy Test, Body Imaging, Brain Imaging, Tumor Tissue Samples, etc.) listed under the single 'Screening Visit' column in Table 2-1 are assumed to occur on one in-person day.; Body Imaging at Week 26 and Week 52 are considered distinct in-person visits separate from the Day 1 infusion visits, as they are scheduled 'Every 26 weeks (± 14 days)' and not explicitly part of the 'Day 1 of Each Cycle' procedures.; Brain Imaging during the treatment phase is conditional ('if signs or symptoms consistent with brain metastases') and therefore not counted as a routine contact day.; The maximum treatment duration of 12 months (365 days) is applied for calculating the number of cycles and imaging visits.; The category precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied for days with multiple activities."
37845511,Placebo Q4W,control,1,2,4,7,11,15,0,2,4,7,10,13,1,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,28,maximum of 12 months from the first dose of study treatment,"Screening Visit (1 day), Cycle 1 Day 1, Cycle 2 Day 1, ..., Cycle 13 Day 1 (infusions every 28 days), Week 26 Body Imaging, Week 52 Body Imaging. All range-columns were mapped to one nominal date (e.g., 'Screening Visit' as one day, 'Every 26 weeks' as Day 182 and Day 364).","All screening procedures (Informed Consent, Medical History, Physical Exam, Vital Signs, ECG, Labs, Pregnancy Test, Body Imaging, Brain Imaging, Tumor Tissue Samples, etc.) listed under the single 'Screening Visit' column in Table 2-1 are assumed to occur on one in-person day.; Body Imaging at Week 26 and Week 52 are considered distinct in-person visits separate from the Day 1 infusion visits, as they are scheduled 'Every 26 weeks (± 14 days)' and not explicitly part of the 'Day 1 of Each Cycle' procedures.; Brain Imaging during the treatment phase is conditional ('if signs or symptoms consistent with brain metastases') and therefore not counted as a routine contact day.; The maximum treatment duration of 12 months (365 days) is applied for calculating the number of cycles and imaging visits.; The category precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied for days with multiple activities."
37870976,Arm A (amivantamab plus chemotherapy),intervention,1,5,8,12,16,21,0,5,8,12,16,21,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening (Day -28 to -1), Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 1 Day 15, then Cycle Day 1 for all subsequent 21-day cycles (C2D1, C3D1, C4D1, C5D1, etc.).","Screening procedures (Day -28 to Day -1) are considered a single in-person healthcare contact day.; All procedures listed for a given 'Cycle Day' column in Table 1 occur on that single day.; Pre-infusion medications are administered on the same day as the main study drug infusions and do not add separate contact days.; PK/Immunogenicity sample collections are co-scheduled with infusion days and do not add separate contact days.; CT/MRI tumor imaging (every 6 weeks) and PRO assessments (every other cycle from C5) are co-scheduled with Cycle Day 1 visits and do not add separate contact days.; The highest precedence category for the Screening day is 'imaging_diagnostics' due to tumor biopsy, CT/MRI, Brain MRI, ECHO/MUGA, and ECG.; For all treatment days, the presence of drug administration (Pemetrexed, Carboplatin, Amivantamab) categorizes the day as 'core_treatment' due to precedence rules."
37870976,Arm B (chemotherapy),control,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening (Day -28 to -1), Cycle 1 Day 1, then Cycle Day 1 for all subsequent 21-day cycles (C2D1, C3D1, C4D1, C5D1, etc.).","Screening procedures (Day -28 to Day -1) are considered a single in-person healthcare contact day.; All procedures listed for a given 'Cycle Day' column in Table 1 occur on that single day.; Pre-infusion medications are administered on the same day as the main study drug infusions and do not add separate contact days.; CT/MRI tumor imaging (every 6 weeks) and PRO assessments (every other cycle from C5) are co-scheduled with Cycle Day 1 visits and do not add separate contact days.; The highest precedence category for the Screening day is 'imaging_diagnostics' due to tumor biopsy, CT/MRI, Brain MRI, ECHO/MUGA, and ECG.; For all treatment days, the presence of drug administration (Pemetrexed, Carboplatin) categorizes the day as 'core_treatment' due to precedence rules."
37875143,Pembrolizumab + Chemotherapy (FP or CAPOX),intervention,2,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,21,"until progression (up to 35 cycles, approx. 2 years)","Screening (Day -28, Day -1), then Day 0, Day 21, Day 42, Day 63, Day 84, Day 105, Day 126, Day 147, Day 168, Day 189, Day 210, Day 231, Day 252, Day 273, Day 294, Day 315, Day 336, Day 357. All cycle-specific columns (e.g., 'Day 14–21') were not present in the SoE, indicating a single nominal date per cycle for in-person visits.","The Schedule of Activities (SoA) in Table 1 (pages 7-14) is identical for both treatment arms, therefore, healthcare contact days are the same for both arms.; Cycle length is 21 days (Q3W) as explicitly stated.; Treatment duration for the initial treatment phase is up to 35 cycles (735 days); counts are capped at Day +365 for the 12-month window.; Screening procedures, though numerous, are consolidated into 2 distinct in-person days: one for initial consent and general assessments (Day -28, categorized as clinic_visits), and one for final eligibility, randomization, and key baseline diagnostics like tumor imaging and ECG (Day -1, categorized as imaging_diagnostics due to precedence).; For the intervention phase, any day with 'Pembrolizumab or Placebo Administration' or 'FP or CAPOX Administration' is categorized as 'core_treatment' due to precedence, even if other procedures (e.g., imaging, labs, ePROs, physical exams) also occur on that day.; Oral capecitabine administration (Days 1-14 for CAPOX) and continuous IV 5-FU infusion (Days 1-5 for FP) are not counted as separate in-person contact days beyond Day 1 of each cycle, as the SoA only marks 'X' for 'FP or CAPOX Administration' on Day 1, implying other days do not require physical clinic attendance for these specific drug administrations.; ePROs are considered in-person assessments when marked with 'X' in the SoA, but their category is superseded by 'core_treatment' on treatment days.; Tumor imaging occurs at Week 6 (Day 42) and then every 6 weeks (Day 84, 126, 168, 210, 252, 294, 336) during the intervention phase. These days are categorized as 'core_treatment' due to drug administration precedence.; TSH is performed every other cycle starting from Cycle 2 (Day 21, 63, 105, 147, 189, 231, 273, 315, 357). These days are categorized as 'core_treatment' due to drug administration precedence."
37875143,Placebo + Chemotherapy (FP or CAPOX),control,2,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,21,"until progression (up to 35 cycles, approx. 2 years)","Screening (Day -28, Day -1), then Day 0, Day 21, Day 42, Day 63, Day 84, Day 105, Day 126, Day 147, Day 168, Day 189, Day 210, Day 231, Day 252, Day 273, Day 294, Day 315, Day 336, Day 357. All cycle-specific columns (e.g., 'Day 14–21') were not present in the SoE, indicating a single nominal date per cycle for in-person visits.","The Schedule of Activities (SoA) in Table 1 (pages 7-14) is identical for both treatment arms, therefore, healthcare contact days are the same for both arms.; Cycle length is 21 days (Q3W) as explicitly stated.; Treatment duration for the initial treatment phase is up to 35 cycles (735 days); counts are capped at Day +365 for the 12-month window.; Screening procedures, though numerous, are consolidated into 2 distinct in-person days: one for initial consent and general assessments (Day -28, categorized as clinic_visits), and one for final eligibility, randomization, and key baseline diagnostics like tumor imaging and ECG (Day -1, categorized as imaging_diagnostics due to precedence).; For the intervention phase, any day with 'Pembrolizumab or Placebo Administration' or 'FP or CAPOX Administration' is categorized as 'core_treatment' due to precedence, even if other procedures (e.g., imaging, labs, ePROs, physical exams) also occur on that day.; Oral capecitabine administration (Days 1-14 for CAPOX) and continuous IV 5-FU infusion (Days 1-5 for FP) are not counted as separate in-person contact days beyond Day 1 of each cycle, as the SoA only marks 'X' for 'FP or CAPOX Administration' on Day 1, implying other days do not require physical clinic attendance for these specific drug administrations.; ePROs are considered in-person assessments when marked with 'X' in the SoA, but their category is superseded by 'core_treatment' on treatment days.; Tumor imaging occurs at Week 6 (Day 42) and then every 6 weeks (Day 84, 126, 168, 210, 252, 294, 336) during the intervention phase. These days are categorized as 'core_treatment' due to drug administration precedence.; TSH is performed every other cycle starting from Cycle 2 (Day 21, 63, 105, 147, 189, 231, 273, 315, 357). These days are categorized as 'core_treatment' due to drug administration precedence."
37935977,"Arm 1 (Standard Cytarabine plus Daunorubicin, 7+3)",intervention,1,12,34,45,46,47,0,9,16,19,19,19,1,2,2,2,3,4,0,1,12,16,16,16,0,0,4,8,8,8,28,until progression (up to 4 cycles of consolidation),"Pre-Tx (Day -1), Induction (C1D1-C1D7 mapped to Day 0-6, C1Wks 2-4 mapped to Day 13 and Day 27), Consolidation (CkD1-CkD7 mapped to Day 0-6 relative to start of cycle, CkWk2 mapped to Day 13 relative to start of cycle, CkWk3 mapped to Day 20 relative to start of cycle), Follow-up (Day 229, Day 319).","One Pre-Tx visit is assumed to occur on Day -1.; Cycle 1 Day 1 (C1D1) in the Schedule of Events (SoE) tables is mapped to calendar Day 0.; One Induction phase is assumed, Re-Induction is not included in the baseline count.; Consolidation starts on calendar Day 28 (immediately after the Day 27 BM exam) and includes 4 cycles.; Follow-up visits are assumed to occur at 3-month and 6-month intervals after the end of the 4th consolidation cycle (Day 139).; Range columns 'Wks 2-4' in Induction are mapped to nominal calendar Day 13 and Day 27 for BM exams.; Range columns 'Wk2' and 'Wk3' in Consolidation are mapped to nominal calendar Day 13 and Day 20 (relative to the start of each cycle) for weekly visits.; For days with multiple procedures, category precedence is applied (core_treatment > imaging_diagnostics > labs > clinic_visits)."
37935977,"Arm 2 (Idarubicin with High Dose Cytarabine, IA)",intervention,1,11,33,44,45,46,0,7,13,16,16,16,1,1,1,1,2,3,0,3,15,19,19,19,0,0,4,8,8,8,28,until progression (up to 4 cycles of consolidation),"Pre-Tx (Day -1), Induction (C1D1-C1D7 mapped to Day 0-6, C1Wks 2-4 mapped to Day 27), Consolidation (CkD1-CkD7 mapped to Day 0-6 relative to start of cycle, CkWk2 mapped to Day 13 relative to start of cycle, CkWk3 mapped to Day 20 relative to start of cycle), Follow-up (Day 229, Day 319).","One Pre-Tx visit is assumed to occur on Day -1.; Cycle 1 Day 1 (C1D1) in the Schedule of Events (SoE) tables is mapped to calendar Day 0.; One Induction phase is assumed, Re-Induction is not included in the baseline count.; Consolidation starts on calendar Day 28 (immediately after the Day 27 BM exam) and includes 4 cycles.; Follow-up visits are assumed to occur at 3-month and 6-month intervals after the end of the 4th consolidation cycle (Day 139).; Range columns 'Wks 2-4' in Induction are mapped to nominal calendar Day 27 for BM exams.; Range columns 'Wk2' and 'Wk3' in Consolidation are mapped to nominal calendar Day 13 and Day 20 (relative to the start of each cycle) for weekly visits.; For days with multiple procedures, category precedence is applied (core_treatment > imaging_diagnostics > labs > clinic_visits)."
37935977,Arm 3 (IA + Vorinostat),intervention,1,11,33,44,45,46,0,4,14,16,16,16,1,1,1,1,2,3,0,4,11,14,14,14,0,2,8,13,13,13,28,until progression (up to 4 cycles of consolidation),"Pre-Tx (Day -1), Induction (C1D1-C1D7 mapped to Day 0-6, C1Wks 2-4 mapped to Day 27), Consolidation (CkD1-CkD7 mapped to Day 0-6 relative to start of cycle, CkWk2 mapped to Day 13 relative to start of cycle, CkWk3 mapped to Day 20 relative to start of cycle), Follow-up (Day 229, Day 319).","One Pre-Tx visit is assumed to occur on Day -1.; Cycle 1 Day 1 (C1D1) in the Schedule of Events (SoE) tables is mapped to calendar Day 0.; One Induction phase is assumed, Re-Induction is not included in the baseline count.; Consolidation starts on calendar Day 28 (immediately after the Day 27 BM exam) and includes 4 cycles.; Follow-up visits are assumed to occur at 3-month and 6-month intervals after the end of the 4th consolidation cycle (Day 139).; Range columns 'Wks 2-4' in Induction are mapped to nominal calendar Day 27 for BM exams.; Range columns 'Wk2' and 'Wk3' in Consolidation are mapped to nominal calendar Day 13 and Day 20 (relative to the start of each cycle) for weekly visits.; Oral medication (Vorinostat) administration days are not counted as in-person contact days unless other in-person procedures (H&P, labs) are scheduled on those days.; For days with multiple procedures, category precedence is applied (core_treatment > imaging_diagnostics > labs > clinic_visits)."
37935977,Arm 3 (IA),intervention,1,11,33,44,45,46,0,7,13,16,16,16,1,1,1,1,2,3,0,3,15,19,19,19,0,0,4,8,8,8,28,until progression (up to 4 cycles of consolidation),"Pre-Tx (Day -1), Induction (C1D1-C1D7 mapped to Day 0-6, C1Wks 2-4 mapped to Day 27), Consolidation (CkD1-CkD7 mapped to Day 0-6 relative to start of cycle, CkWk2 mapped to Day 13 relative to start of cycle, CkWk3 mapped to Day 20 relative to start of cycle), Follow-up (Day 229, Day 319).","One Pre-Tx visit is assumed to occur on Day -1.; Cycle 1 Day 1 (C1D1) in the Schedule of Events (SoE) tables is mapped to calendar Day 0.; One Induction phase is assumed, Re-Induction is not included in the baseline count.; Consolidation starts on calendar Day 28 (immediately after the Day 27 BM exam) and includes 4 cycles.; Follow-up visits are assumed to occur at 3-month and 6-month intervals after the end of the 4th consolidation cycle (Day 139).; Range columns 'Wks 2-4' in Induction are mapped to nominal calendar Day 27 for BM exams.; Range columns 'Wk2' and 'Wk3' in Consolidation are mapped to nominal calendar Day 13 and Day 20 (relative to the start of each cycle) for weekly visits.; For days with multiple procedures, category precedence is applied (core_treatment > imaging_diagnostics > labs > clinic_visits)."
37980924,Apixaban Arm,intervention,1,6,7,7,7,7,0,1,1,1,1,1,0,1,1,1,1,1,1,4,4,4,4,4,0,0,1,1,1,1,28,fixed duration (approximately 28 days),"Screening (Day -7), Randomization/C1D1 (Day 0), C1D7 (Apixaban Inpatient PK), C1D8, C1D15, C1D22, C1D29 (End of Treatment Imaging), Day 35 (Follow-up). Range-based columns (e.g., 'Day X±Y') were mapped to their nominal day for calendarization.","Day 0 (C1D1) is the first day of planned 3-4 drug systemic induction ALL chemotherapy and the anchor point.; Screening is assumed to occur on Day -7, as a distinct in-person visit, including a Lumbar Puncture (LP) for WBC and RBC in CSF, which is a required in-person lab procedure.; Randomization occurs on Day 0 (C1D1) and is considered a distinct in-person day, even though screening and randomization can occur on the same day. For the Apixaban arm, this day includes study drug dispensing.; Day 7 is counted as a distinct in-person contact day for the Apixaban arm due to mandatory in-patient PK/anti-FXa sampling and other assessments.; Day 8 is counted as a distinct in-person contact day for both arms, covering general labs and clinic assessments. For the Apixaban arm, it also includes alternate PK/anti-FXa collection for out-patients.; The Day 35 follow-up visit is considered in-person due to the inclusion of 'Targeted Physical Examination' and 'Vital Signs' in its listed procedures (Table 5.1-2), despite being described as 'telephone or in person' elsewhere.; No further scheduled in-person visits occur beyond Day 35 within the 365-day horizon."
37980924,No systemic anticoagulant prophylaxis Arm,control,1,5,6,6,6,6,0,0,0,0,0,0,0,1,1,1,1,1,1,4,4,4,4,4,0,0,1,1,1,1,28,fixed duration (approximately 28 days),"Screening (Day -7), Randomization/C1D1 (Day 0), C1D8, C1D15, C1D22, C1D29 (End of Treatment Imaging), Day 35 (Follow-up). Range-based columns (e.g., 'Day X±Y') were mapped to their nominal day for calendarization.","Day 0 (C1D1) is the first day of planned 3-4 drug systemic induction ALL chemotherapy and the anchor point.; Screening is assumed to occur on Day -7, as a distinct in-person visit, including a Lumbar Puncture (LP) for WBC and RBC in CSF, which is a required in-person lab procedure.; Randomization occurs on Day 0 (C1D1) and is considered a distinct in-person day.; The Day 35 follow-up visit is considered in-person due to the inclusion of 'Targeted Physical Examination' and 'Vital Signs' in its listed procedures (Table 5.1-2), despite being described as 'telephone or in person' elsewhere.; No further scheduled in-person visits occur beyond Day 35 within the 365-day horizon."
38039991,Durvalumab + SoC CCRT,intervention,1,23,33,36,39,43,0,23,31,34,37,41,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,2,2,2,28,until progression or 24 doses (Durvalumab/Placebo); SoC CCRT completed within 56-59 days.,"Screening, Day 0 (C1D1), Day 1, Day 2, Day 3, Day 4, Day 7, Day 8, Day 9, Day 10, Day 11, Day 14, Day 15, Day 16, Day 17, Day 18, Day 21, Day 22, Day 23, Day 24, Day 25, Day 28 (C2D1), Day 29, Day 30, Day 31, Day 32, Day 39, Day 41, Day 42, Day 43, Day 45, Day 56 (C3D1), Day 70, Day 84 (C4D1), Day 112 (C5D1), Day 140 (C6D1), Day 168 (C7D1), Day 196 (C8D1), Day 224 (C9D1), Day 252 (C10D1), Day 280 (C11D1), Day 308 (C12D1), Day 336 (C13D1), Day 364 (C14D1). Range columns (e.g., 'Day 14–21' for PROs) were mapped to one nominal date (Day 14, 42, 70) or as multi-day treatment (EBRT, Brachytherapy).","Screening is considered a single in-person visit day, primarily categorized as 'imaging_diagnostics' due to mandatory CT/MRI and ECG, which take precedence over other assessments like labs and physical exams.; The optional 6th week of cisplatin is not included in the counts.; External Beam Radiotherapy (EBRT) is assumed to be administered 5 days/week for 5 weeks (25 fractions), starting on Day 0.; Brachytherapy is assumed to be 4 fractions, administered on separate days after EBRT completion, within the 56-59 day window (e.g., Day 39, 41, 43, 45).; Mid-cycle patient follow-up/PRO visits on C1D14, C2D14, and C3D14 (Day 14, 42, 70) are counted as distinct in-person contact days. Day 14 overlaps with Cisplatin/EBRT, so it is categorized as 'core_treatment' due to precedence.; Assessments noted as 'As clinically indicated' (e.g., some ECGs, Urinalysis) are excluded unless explicitly tied to a fixed schedule.; All labs (PK, ADA, WB, ctDNA, Clinical Chemistry, Hematology, TSH, Pregnancy Test), vital signs, physical exams, and ECOG performance status assessments that coincide with a core treatment day (Durvalumab/Placebo infusion, Cisplatin, EBRT, Brachytherapy) are subsumed under the 'core_treatment' category due to precedence.; Tumor radiological assessments and pelvic exams on Day 140, 224, and 308 coincide with Durvalumab/Placebo infusion days and are thus subsumed under 'core_treatment' due to precedence.; The follow-up schedule in Table 2 is for after treatment completion (24 cycles, approximately Day 672) and thus falls outside the 365-day horizon."
38039991,Placebo + SoC CCRT,control,1,23,33,36,39,43,0,23,31,34,37,41,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,2,2,2,28,until progression or 24 doses (Durvalumab/Placebo); SoC CCRT completed within 56-59 days.,"Screening, Day 0 (C1D1), Day 1, Day 2, Day 3, Day 4, Day 7, Day 8, Day 9, Day 10, Day 11, Day 14, Day 15, Day 16, Day 17, Day 18, Day 21, Day 22, Day 23, Day 24, Day 25, Day 28 (C2D1), Day 29, Day 30, Day 31, Day 32, Day 39, Day 41, Day 42, Day 43, Day 45, Day 56 (C3D1), Day 70, Day 84 (C4D1), Day 112 (C5D1), Day 140 (C6D1), Day 168 (C7D1), Day 196 (C8D1), Day 224 (C9D1), Day 252 (C10D1), Day 280 (C11D1), Day 308 (C12D1), Day 336 (C13D1), Day 364 (C14D1). Range columns (e.g., 'Day 14–21' for PROs) were mapped to one nominal date (Day 14, 42, 70) or as multi-day treatment (EBRT, Brachytherapy).","Screening is considered a single in-person visit day, primarily categorized as 'imaging_diagnostics' due to mandatory CT/MRI and ECG, which take precedence over other assessments like labs and physical exams.; The optional 6th week of cisplatin is not included in the counts.; External Beam Radiotherapy (EBRT) is assumed to be administered 5 days/week for 5 weeks (25 fractions), starting on Day 0.; Brachytherapy is assumed to be 4 fractions, administered on separate days after EBRT completion, within the 56-59 day window (e.g., Day 39, 41, 43, 45).; Mid-cycle patient follow-up/PRO visits on C1D14, C2D14, and C3D14 (Day 14, 42, 70) are counted as distinct in-person contact days. Day 14 overlaps with Cisplatin/EBRT, so it is categorized as 'core_treatment' due to precedence.; Assessments noted as 'As clinically indicated' (e.g., some ECGs, Urinalysis) are excluded unless explicitly tied to a fixed schedule.; All labs (PK, ADA, WB, ctDNA, Clinical Chemistry, Hematology, TSH, Pregnancy Test), vital signs, physical exams, and ECOG performance status assessments that coincide with a core treatment day (Durvalumab/Placebo infusion, Cisplatin, EBRT, Brachytherapy) are subsumed under the 'core_treatment' category due to precedence.; Tumor radiological assessments and pelvic exams on Day 140, 224, and 308 coincide with Durvalumab/Placebo infusion days and are thus subsumed under 'core_treatment' due to precedence.; The follow-up schedule in Table 2 is for after treatment completion (24 cycles, approximately Day 672) and thus falls outside the 365-day horizon."
38039993,Arm A: Lenvatinib + Pembrolizumab,intervention,2,5,13,27,39,53,0,2,5,9,13,18,1,0,0,0,0,0,1,3,8,18,26,35,0,0,0,0,0,0,21,until progression (capped at Day 365 for this extraction),"Screening (2 days), Cycle Day 1 (C1D1, C2D1, ... C18D1), Cycle Day 8 (C1D8, C2D8, ... C18D8), Cycle Day 15 (C1D15, C2D15, ... C17D15). Range-columns (e.g., 'Day 14–21') were not present; all listed cycle days are treated as single nominal dates.","Cycle length is 21 days, as indicated by '21-Day Cycles' in the SoA and 'Q3W' for IV administration.; Treatment duration for Pembrolizumab/Placebo is up to 35 cycles (approximately 2 years), and Lenvatinib continues until disease progression or intolerable toxicity. For this extraction, all treatment is counted up to Day +365.; The screening period (Day -28 to Day -1) is assumed to require 2 distinct in-person contact days: one for initial labs and clinic procedures, and another for imaging and other time-sensitive labs, based on the volume and varied timing requirements (e.g., 'within 7 days' vs 'within 28 days').; For screening, if a day involved both labs and clinic visits, it was categorized as 'labs' due to the extensive number of mandatory lab tests.; Stool analysis and tumor block/slides in the screening column were excluded as they are explicitly optional or not mandatory in-person contacts.; HIV, HCV genotype, HCV viral load, Anti-HDV, HDV RNA, Anti-HBe and HBeAg in screening were assumed to be performed as in-person labs, as they are conditional on certain statuses but not explicitly optional for those conditions.; On-study imaging assessments performed 'every 9 weeks (Q9W)' (Day 0, Day 63, Day 126, etc.) were found to coincide with Cycle Day 1 visits. Since Cycle Day 1 visits involve drug administration, they are primarily categorized as 'core_treatment', and thus these imaging events do not add new unique 'imaging_diagnostics' days to the treatment period.; Post-treatment follow-up visits (Safety FU, Imaging FU, Survival FU) were not counted as in-person healthcare contact days within the 365-day horizon, as protocol notes indicate potential for remote contact (e.g., telephone or email) for some follow-up activities."
38039993,Arm B: Lenvatinib + Placebo,control,2,5,13,27,39,53,0,2,5,9,13,18,1,0,0,0,0,0,1,3,8,18,26,35,0,0,0,0,0,0,21,until progression (capped at Day 365 for this extraction),"Screening (2 days), Cycle Day 1 (C1D1, C2D1, ... C18D1), Cycle Day 8 (C1D8, C2D8, ... C18D8), Cycle Day 15 (C1D15, C2D15, ... C17D15). Range-columns (e.g., 'Day 14–21') were not present; all listed cycle days are treated as single nominal dates.","Cycle length is 21 days, as indicated by '21-Day Cycles' in the SoA and 'Q3W' for IV administration.; Treatment duration for Pembrolizumab/Placebo is up to 35 cycles (approximately 2 years), and Lenvatinib continues until disease progression or intolerable toxicity. For this extraction, all treatment is counted up to Day +365.; The screening period (Day -28 to Day -1) is assumed to require 2 distinct in-person contact days: one for initial labs and clinic procedures, and another for imaging and other time-sensitive labs, based on the volume and varied timing requirements (e.g., 'within 7 days' vs 'within 28 days').; For screening, if a day involved both labs and clinic visits, it was categorized as 'labs' due to the extensive number of mandatory lab tests.; Stool analysis and tumor block/slides in the screening column were excluded as they are explicitly optional or not mandatory in-person contacts.; HIV, HCV genotype, HCV viral load, Anti-HDV, HDV RNA, Anti-HBe and HBeAg in screening were assumed to be performed as in-person labs, as they are conditional on certain statuses but not explicitly optional for those conditions.; On-study imaging assessments performed 'every 9 weeks (Q9W)' (Day 0, Day 63, Day 126, etc.) were found to coincide with Cycle Day 1 visits. Since Cycle Day 1 visits involve drug administration, they are primarily categorized as 'core_treatment', and thus these imaging events do not add new unique 'imaging_diagnostics' days to the treatment period.; Post-treatment follow-up visits (Safety FU, Imaging FU, Survival FU) were not counted as in-person healthcare contact days within the 365-day horizon, as protocol notes indicate potential for remote contact (e.g., telephone or email) for some follow-up activities."
38060199,Arm A: Ipatasertib + Atezolizumab + Paclitaxel,intervention,2,4,10,20,29,40,0,4,9,17,24,33,1,0,1,3,5,7,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (2 days), then Cycle Day 1, Day 8, Day 15 for each 28-day cycle from Cycle 1 to Cycle 13, plus a single Study Drug Discontinuation Visit (SDDV) at Day 365.","All screening activities (clinic visit, labs, imaging, ECG, cardiac function, tissue sample submission if new biopsy) are consolidated into 2 distinct in-person days within the Day -28 to Day -1 window: one for initial clinic/labs, and one for imaging/diagnostics.; Treatment is assumed to continue for 13 full cycles (364 days), and the Study Drug Discontinuation Visit (SDDV) is assumed to occur on Day 365.; Oral ipatasertib administration itself is not an in-person day, but its dispensing on Cycle Day 1 and Day 15 (and subsequent cycles) is an in-person activity. However, these days already include IV infusions, so they are categorized under 'core_treatment'.; IV infusions of Atezolizumab/Placebo and Paclitaxel are considered 'core_treatment' days.; All listed assessments (labs, vital signs, physical exams, ECOG, concomitant medications review, adverse event review, patient diary review) are assumed to require in-person attendance.; Patient-Reported Outcome (PRO) assessments, Pharmacokinetic (PK) and Anti-Drug Antibody (ADA) samples, and long-term follow-up assessments are explicitly stated as 'no longer collected' as of protocol Version 5/6, and thus are excluded from contact day counts.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits. Any day with multiple activities is assigned to the highest precedence category present."
38060199,Arm B (Cohort 1): Ipatasertib + Paclitaxel + Atezolizumab Placebo,intervention,2,4,10,20,29,40,0,4,9,17,24,33,1,0,1,3,5,7,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (2 days), then Cycle Day 1, Day 8, Day 15 for each 28-day cycle from Cycle 1 to Cycle 13, plus a single Study Drug Discontinuation Visit (SDDV) at Day 365.","All screening activities (clinic visit, labs, imaging, ECG, cardiac function, tissue sample submission if new biopsy) are consolidated into 2 distinct in-person days within the Day -28 to Day -1 window: one for initial clinic/labs, and one for imaging/diagnostics.; Treatment is assumed to continue for 13 full cycles (364 days), and the Study Drug Discontinuation Visit (SDDV) is assumed to occur on Day 365.; Oral ipatasertib administration itself is not an in-person day, but its dispensing on Cycle Day 1 and Day 15 (and subsequent cycles) is an in-person activity. However, these days already include IV infusions, so they are categorized under 'core_treatment'.; IV infusions of Atezolizumab/Placebo and Paclitaxel are considered 'core_treatment' days.; All listed assessments (labs, vital signs, physical exams, ECOG, concomitant medications review, adverse event review, patient diary review) are assumed to require in-person attendance.; Patient-Reported Outcome (PRO) assessments, Pharmacokinetic (PK) and Anti-Drug Antibody (ADA) samples, and long-term follow-up assessments are explicitly stated as 'no longer collected' as of protocol Version 5/6, and thus are excluded from contact day counts.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits. Any day with multiple activities is assigned to the highest precedence category present."
38060199,Arm C (Cohort 1): Paclitaxel + Ipatasertib Placebo + Atezolizumab Placebo,control,2,4,10,20,29,40,0,4,9,17,24,33,1,0,1,3,5,7,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (2 days), then Cycle Day 1, Day 8, Day 15 for each 28-day cycle from Cycle 1 to Cycle 13, plus a single Study Drug Discontinuation Visit (SDDV) at Day 365.","All screening activities (clinic visit, labs, imaging, ECG, cardiac function, tissue sample submission if new biopsy) are consolidated into 2 distinct in-person days within the Day -28 to Day -1 window: one for initial clinic/labs, and one for imaging/diagnostics.; Treatment is assumed to continue for 13 full cycles (364 days), and the Study Drug Discontinuation Visit (SDDV) is assumed to occur on Day 365.; Oral ipatasertib administration itself is not an in-person day, but its dispensing on Cycle Day 1 and Day 15 (and subsequent cycles) is an in-person activity. However, these days already include IV infusions, so they are categorized under 'core_treatment'.; IV infusions of Atezolizumab/Placebo and Paclitaxel are considered 'core_treatment' days.; All listed assessments (labs, vital signs, physical exams, ECOG, concomitant medications review, adverse event review, patient diary review) are assumed to require in-person attendance.; Patient-Reported Outcome (PRO) assessments, Pharmacokinetic (PK) and Anti-Drug Antibody (ADA) samples, and long-term follow-up assessments are explicitly stated as 'no longer collected' as of protocol Version 5/6, and thus are excluded from contact day counts.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits. Any day with multiple activities is assigned to the highest precedence category present."
38060199,Arm B (Cohort 2): Atezolizumab + Paclitaxel + Ipatasertib Placebo,intervention,2,4,10,20,29,40,0,4,9,17,24,33,1,0,1,3,5,7,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (2 days), then Cycle Day 1, Day 8, Day 15 for each 28-day cycle from Cycle 1 to Cycle 13, plus a single Study Drug Discontinuation Visit (SDDV) at Day 365.","All screening activities (clinic visit, labs, imaging, ECG, cardiac function, tissue sample submission if new biopsy) are consolidated into 2 distinct in-person days within the Day -28 to Day -1 window: one for initial clinic/labs, and one for imaging/diagnostics.; Treatment is assumed to continue for 13 full cycles (364 days), and the Study Drug Discontinuation Visit (SDDV) is assumed to occur on Day 365.; Oral ipatasertib administration itself is not an in-person day, but its dispensing on Cycle Day 1 and Day 15 (and subsequent cycles) is an in-person activity. However, these days already include IV infusions, so they are categorized under 'core_treatment'.; IV infusions of Atezolizumab/Placebo and Paclitaxel are considered 'core_treatment' days.; All listed assessments (labs, vital signs, physical exams, ECOG, concomitant medications review, adverse event review, patient diary review) are assumed to require in-person attendance.; Patient-Reported Outcome (PRO) assessments, Pharmacokinetic (PK) and Anti-Drug Antibody (ADA) samples, and long-term follow-up assessments are explicitly stated as 'no longer collected' as of protocol Version 5/6, and thus are excluded from contact day counts.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits. Any day with multiple activities is assigned to the highest precedence category present."
38103088,Arm 1: F-627,intervention,1,27,55,55,55,55,0,4,8,8,8,8,1,0,1,1,1,1,0,23,46,46,46,46,0,0,0,0,0,0,21,4 cycles (84 days of treatment) with a final study visit on Day 84.,"Screening (Day -15), C1D1 (Day 0), C1D2 (Day 1), C1D3-C1D21 (Days 2-20), C2D1 (Day 21), C2D2 (Day 22), C2D3-C2D21 (Days 23, 25, 27, 29, 31, 33, 35, 37, 39), C3D1 (Day 42), C3D2 (Day 43), C3D3-C3D21 (Days 44, 46, 48, 50, 52, 54, 56, 58, 60), C4D1 (Day 63), C4D2 (Day 64), C4D3-C4D21 (Days 65, 67, 69, 71, 73, 75, 77, 79, 81), End of Study (Day 84). Range-columns were mapped to one nominal date or enumerated as distinct days based on frequency rules.","The screening period (Day -15 to Day -1) is counted as one in-person visit, occurring on Day -15 (earliest nominal day in the range). This visit includes ECG and Chest X-Ray, thus categorized as imaging_diagnostics.; Chemotherapy administration on Day 1 of each cycle (Study Days 1, 22, 43, 64) is an in-person visit, categorized as core_treatment.; Investigational drug (F-627) administration on Day 2 of each cycle (Study Days 2, 23, 44, 65) is an in-person visit, categorized as core_treatment.; For Cycle 1, 'daily blood draws' from Day 3-21 (Study Days 3-21) are interpreted as 19 distinct in-person lab visits, categorized as labs.; For Cycles 2-4, 'every other day blood draws' from Day 3-21 (e.g., Study Days 24, 26, ..., 40 for C2) are interpreted as 9 distinct in-person lab visits per cycle, categorized as labs.; The End of Study visit on Day 84 is one in-person visit, including ECG and Chest X-Ray, thus categorized as imaging_diagnostics.; Precedence rule applied for categorization: core_treatment > imaging_diagnostics > labs > clinic_visits.; The 'Study Days' in the SoE (Page 36) are mapped to the 'Day 0' anchor point as follows: Study Day 1 = Day 0, Study Day 2 = Day 1, Study Day 22 = Day 21, Study Day 23 = Day 22, and so on."
38103088,"Arm 2: Placebo (Cycle 1), then F-627 (Cycles 2-4)",control,1,27,55,55,55,55,0,4,8,8,8,8,1,0,1,1,1,1,0,23,46,46,46,46,0,0,0,0,0,0,21,4 cycles (84 days of treatment) with a final study visit on Day 84.,"Screening (Day -15), C1D1 (Day 0), C1D2 (Day 1), C1D3-C1D21 (Days 2-20), C2D1 (Day 21), C2D2 (Day 22), C2D3-C2D21 (Days 23, 25, 27, 29, 31, 33, 35, 37, 39), C3D1 (Day 42), C3D2 (Day 43), C3D3-C3D21 (Days 44, 46, 48, 50, 52, 54, 56, 58, 60), C4D1 (Day 63), C4D2 (Day 64), C4D3-C4D21 (Days 65, 67, 69, 71, 73, 75, 77, 79, 81), End of Study (Day 84). Range-columns were mapped to one nominal date or enumerated as distinct days based on frequency rules.","The screening period (Day -15 to Day -1) is counted as one in-person visit, occurring on Day -15 (earliest nominal day in the range). This visit includes ECG and Chest X-Ray, thus categorized as imaging_diagnostics.; Chemotherapy administration on Day 1 of each cycle (Study Days 1, 22, 43, 64) is an in-person visit, categorized as core_treatment.; Investigational drug (Placebo for C1, F-627 for C2-4) administration on Day 2 of each cycle (Study Days 2, 23, 44, 65) is an in-person visit, categorized as core_treatment.; For Cycle 1, 'daily blood draws' from Day 3-21 (Study Days 3-21) are interpreted as 19 distinct in-person lab visits, categorized as labs.; For Cycles 2-4, 'every other day blood draws' from Day 3-21 (e.g., Study Days 24, 26, ..., 40 for C2) are interpreted as 9 distinct in-person lab visits per cycle, categorized as labs.; The End of Study visit on Day 84 is one in-person visit, including ECG and Chest X-Ray, thus categorized as imaging_diagnostics.; Precedence rule applied for categorization: core_treatment > imaging_diagnostics > labs > clinic_visits.; The 'Study Days' in the SoE (Page 36) are mapped to the 'Day 0' anchor point as follows: Study Day 1 = Day 0, Study Day 2 = Day 1, Study Day 22 = Day 21, Study Day 23 = Day 22, and so on."
38159809,Pembrolizumab Monotherapy,intervention,1,2,9,14,18,23,0,1,5,9,13,18,1,0,0,0,0,0,0,1,4,5,5,5,0,0,0,0,0,0,21,until discontinuation criteria are met or up to 35 cycles,"Screening (1 day), C1D1, C1D15, C2D1, C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C5D15, then CkD1 for k=6 to 18. All range-columns were mapped to one nominal date (e.g., 'Day 15' is mapped to Day 14 for calendarization).","The protocol, as of Amendment 007-06, indicates only one active treatment arm: open-label pembrolizumab monotherapy. All calculations are based on this single arm.; The 'Screening' column in the Schedule of Activities (SoA) table represents a single in-person contact day within the Day -28 to Day -1 window.; The 'Treatment randomization' procedure, marked in the 'Screening' column, is considered part of the single screening contact day.; The 'Day 8' phone contact is excluded as it is not an in-person healthcare contact day.; Mid-cycle Day 15 visits are mandatory for Cycles 1-5, as indicated by the 'X' in the SoA table for these cycles. For Cycles 6-35, the 'Day 15' column is empty, implying no mandatory in-person visit on Day 15 for these cycles.; Tumor scans are scheduled Q9W (every 9 weeks or 63 days) from randomization through Week 54. Within the 365-day horizon, these scans fall on nominal Day 63 (C4D1), Day 126 (C7D1), Day 189 (C10D1), Day 252 (C13D1), and Day 315 (C16D1).; ECG measurements are scheduled at Screening, C1D1, C2D1, and then D1 of every fourth cycle thereafter (C6D1, C10D1, C14D1, C18D1) within the 365-day horizon.; All days with Pembrolizumab administration (Day 1 of each cycle) are categorized as 'core_treatment' due to the highest precedence of drug administration.; Mid-cycle Day 15 visits (C1-C5) are categorized as 'labs' due to the presence of required hematology, clinical chemistry, urinalysis, and thyroid function tests, which take precedence over vital signs and AE monitoring (clinic visits)."
38252907,Arm A: Nivolumab plus Pemetrexed/Platinum,intervention,2,2,6,13,19,26,0,2,5,9,13,18,1,0,1,4,6,8,0,0,0,0,0,0,1,0,0,0,0,0,21,until progression (max 24 months for Nivolumab-containing regimens),"Screening Visit (imaging, biopsy, labs, PE, ECG), Randomization Visit, C1D1, C2D1, Week 7 Tumor Assessment (with re-biopsy), C3D1, C4D1, C5D1, Week 13 Tumor Assessment, C6D1, C7D1, Week 19 Tumor Assessment, C8D1, C9D1, Week 25 Tumor Assessment, C10D1, C11D1, Week 31 Tumor Assessment, C12D1, C13D1, Week 37 Tumor Assessment, C14D1, C15D1, Week 43 Tumor Assessment, C16D1, C17D1, Week 49 Tumor Assessment, C18D1. All range-columns for tumor assessments (e.g., 'Week 7 (± 7 days)') are mapped to the earliest nominal day (e.g., Day 49).","Arm B is closed to enrollment and therefore not included in the extraction.; Day 0 is the first dose administration.; Screening procedures (Table 5.1-1) are assumed to occur on one dedicated 'Screening Visit' day, encompassing all listed in-person assessments (e.g., physical exam, vitals, labs, ECG, PD-L1/T790M tissue biopsy, CT/MRI). This day is categorized as 'imaging_diagnostics' due to the presence of CT/MRI and biopsy.; Randomization (Table 5.1-1) is assumed to be a separate in-person visit from the main screening visit, categorized as 'clinic_visits'.; All 'During Treatment Visit' procedures (Table 5.1-2) occurring on Day 1 of each 21-day cycle are considered in-person contact days. These days include drug administration, safety assessments (PE, vitals, labs, etc.), and outcomes research assessments (EQ-5D-3L, LCSS for the first 6 months, then every second cycle). Due to drug administration, these days are primarily categorized as 'core_treatment'.; Tumor assessments (CT/MRI) are scheduled at Week 7, then every 6 weeks until Week 49, and then every 12 weeks thereafter. These are considered separate in-person contact days, categorized as 'imaging_diagnostics'.; A re-biopsy at Week 7 is highly recommended and is counted as an in-person visit, coinciding with the Week 7 tumor assessment day, and categorized as 'imaging_diagnostics'.; TSH assessments for Arm A (every 6 weeks) are assumed to coincide with Day 1 treatment visits and therefore do not add unique contact days.; Treatment is assumed to continue without disease progression or delays for the full 12-month period for counting purposes."
38252907,Arm C: Pemetrexed/Platinum,control,2,2,6,13,19,26,0,2,5,9,13,18,1,0,1,4,6,8,0,0,0,0,0,0,1,0,0,0,0,0,21,until progression,"Screening Visit (imaging, biopsy, labs, PE, ECG), Randomization Visit, C1D1, C2D1, Week 7 Tumor Assessment (with re-biopsy), C3D1, C4D1, C5D1, Week 13 Tumor Assessment, C6D1, C7D1, Week 19 Tumor Assessment, C8D1, C9D1, Week 25 Tumor Assessment, C10D1, C11D1, Week 31 Tumor Assessment, C12D1, C13D1, Week 37 Tumor Assessment, C14D1, C15D1, Week 43 Tumor Assessment, C16D1, C17D1, Week 49 Tumor Assessment, C18D1. All range-columns for tumor assessments (e.g., 'Week 7 (± 7 days)') are mapped to the earliest nominal day (e.g., Day 49).","Arm B is closed to enrollment and therefore not included in the extraction.; Day 0 is the first dose administration.; Screening procedures (Table 5.1-1) are assumed to occur on one dedicated 'Screening Visit' day, encompassing all listed in-person assessments (e.g., physical exam, vitals, labs, ECG, PD-L1/T790M tissue biopsy, CT/MRI). This day is primarily categorized as 'imaging_diagnostics' due to the presence of CT/MRI and biopsy.; Randomization (Table 5.1-1) is assumed to be a separate in-person visit from the main screening visit, categorized as 'clinic_visits'.; All 'During Treatment Visit' procedures (Table 5.1-2) occurring on Day 1 of each 21-day cycle are considered in-person contact days. These days include drug administration, safety assessments (PE, vitals, labs, etc.), and outcomes research assessments (EQ-5D-3L, LCSS for the first 6 months, then every second cycle). Due to drug administration, these days are primarily categorized as 'core_treatment'.; Tumor assessments (CT/MRI) are scheduled at Week 7, then every 6 weeks until Week 49, and then every 12 weeks thereafter. These are considered separate in-person contact days, categorized as 'imaging_diagnostics'.; A re-biopsy at Week 7 is highly recommended and is counted as an in-person visit, coinciding with the Week 7 tumor assessment day, and categorized as 'imaging_diagnostics'.; TSH assessments are not applicable for Arm C.; Treatment is assumed to continue without disease progression or delays for the full 12-month period for counting purposes."
38319255,IBRUTINIB + VENETOCLAX,intervention,1,3,10,16,19,23,1,2,4,7,9,10,0,0,0,0,0,0,0,1,3,6,7,10,0,0,3,3,3,3,28,"fixed duration (15 cycles for Arm A, 6 cycles for Arm B)","Arm A: Screening (Day -28), C1D1, C1D26, C2D1, C2D26, C3D1, C3D8, C3D15, C3D22, C3D26, C4D1/DE1, C4D8, C4D15, C4D22, C5D1, C6D1, C7D1/DE2, C8D1, C9D1, C10D1/DE3, C11D1, C12D1, C13D1/DE4, C14D1. All range-columns (e.g., 'Day 14–21') were mapped to one nominal date (e.g., Day 14). Arm B: Screening (Day -28), C1D1, C1D8, C1D15, C2D1, C2D15, C3D1, C3D15, C4D1/DE1, C4D15, C5D1, C5D15, C6D1, C6D15, DE2, EOT, DE3, DE4. All range-columns were mapped to one nominal date.","Using Amendment 4 tables (Pages 104, 105, 107, 108, 109) as the most recent and complete schedule.; Cycle length is 28 days for both arms, as stated on Page 103.; Treatment duration for Arm A is 15 cycles (420 days), based on Amendment 2 (Page 96) which removed the last 3 cycles of ibrutinib monotherapy.; Treatment duration for Arm B is 6 cycles (168 days), as stated on Page 103.; Screening is counted as 1 in-person day (Day -28) where all screening procedures occur. Bone marrow aspirate/biopsy and CT scan are considered part of this single screening day, with BMA/BMB taking precedence for categorization.; The End-of-Treatment (EOT) visit is considered a single in-person day, occurring 30 days after the last dose of study treatment. For Arm A, last dose is C15D1 (Day 392), so EOT is Day 422. For Arm B, last dose is C6D15 (Day 154), so EOT is Day 184.; Disease Evaluation (DE) visits (Table 3, Page 109) are considered distinct in-person visits, additional to treatment cycle visits, as they are scheduled at specific weeks (e.g., Week 12, Week 24) and are for disease assessment.; For Arm A, Day 1 of Cycles 9, 11, 12, 14, 15 are counted as in-person visits due to required Vitals/Weight/Labs, as indicated by 'X' marks in Table 1 (Page 104) and footnote 'd' stating 'Pulse/heart rate and blood pressure are expected in all protocol-specified visits', overriding the 'Clinic visit for study medication dispensation and accountability check' row for these specific cycles.; For Arm B, Cycle 1 Day 2 (C1D2) is not counted as a separate in-person visit, assuming the full Obinutuzumab dose is given on Day 1 as per investigator's discretion (footnote 'a', Page 108), following the 'most conservative lower estimate' rule.; For Arm B, Day 15 of Cycles 2-6 are counted as in-person visits due to 'IRR prophylaxis' (Table 2, Page 107), which is an in-person procedure, despite chlorambucil potentially being self-administered and labs done outside the institution (footnote 'b', Page 108).; Category precedence applied: core_treatment > imaging_diagnostics > labs > clinic_visits.; Screening BMA/BMB is categorized as 'core_treatment' due to its invasive nature for diagnosis/staging.; DE visits with BMA/BMB are categorized as 'core_treatment'.; DE visits with CT/ECG but no BMA/BMB or drug administration are categorized as 'imaging_diagnostics'.; Visits with drug administration (IV infusion or oral dispensation) are categorized as 'core_treatment'.; Visits with only labs (phlebotomy) and/or vitals/PROs are categorized as 'labs' if labs are present, otherwise 'clinic_visits'."
38319255,OBINUTUZUMAB + CHLORAMBUCIL,control,1,4,8,15,16,17,1,4,8,13,14,14,0,0,0,0,0,0,0,0,0,1,1,2,0,0,0,1,1,1,28,"fixed duration (15 cycles for Arm A, 6 cycles for Arm B)","Arm A: Screening (Day -28), C1D1, C1D26, C2D1, C2D26, C3D1, C3D8, C3D15, C3D22, C3D26, C4D1/DE1, C4D8, C4D15, C4D22, C5D1, C6D1, C7D1/DE2, C8D1, C9D1, C10D1/DE3, C11D1, C12D1, C13D1/DE4, C14D1. All range-columns (e.g., 'Day 14–21') were mapped to one nominal date (e.g., Day 14). Arm B: Screening (Day -28), C1D1, C1D8, C1D15, C2D1, C2D15, C3D1, C3D15, C4D1/DE1, C4D15, C5D1, C5D15, C6D1, C6D15, DE2, EOT, DE3, DE4. All range-columns were mapped to one nominal date.","Using Amendment 4 tables (Pages 104, 105, 107, 108, 109) as the most recent and complete schedule.; Cycle length is 28 days for both arms, as stated on Page 103.; Treatment duration for Arm A is 15 cycles (420 days), based on Amendment 2 (Page 96) which removed the last 3 cycles of ibrutinib monotherapy.; Treatment duration for Arm B is 6 cycles (168 days), as stated on Page 103.; Screening is counted as 1 in-person day (Day -28) where all screening procedures occur. Bone marrow aspirate/biopsy and CT scan are considered part of this single screening day, with BMA/BMB taking precedence for categorization.; The End-of-Treatment (EOT) visit is considered a single in-person day, occurring 30 days after the last dose of study treatment. For Arm A, last dose is C15D1 (Day 392), so EOT is Day 422. For Arm B, last dose is C6D15 (Day 154), so EOT is Day 184.; Disease Evaluation (DE) visits (Table 3, Page 109) are considered distinct in-person visits, additional to treatment cycle visits, as they are scheduled at specific weeks (e.g., Week 12, Week 24) and are for disease assessment.; For Arm A, Day 1 of Cycles 9, 11, 12, 14, 15 are counted as in-person visits due to required Vitals/Weight/Labs, as indicated by 'X' marks in Table 1 (Page 104) and footnote 'd' stating 'Pulse/heart rate and blood pressure are expected in all protocol-specified visits', overriding the 'Clinic visit for study medication dispensation and accountability check' row for these specific cycles.; For Arm B, Cycle 1 Day 2 (C1D2) is not counted as a separate in-person visit, assuming the full Obinutuzumab dose is given on Day 1 as per investigator's discretion (footnote 'a', Page 108), following the 'most conservative lower estimate' rule.; For Arm B, Day 15 of Cycles 2-6 are counted as in-person visits due to 'IRR prophylaxis' (Table 2, Page 107), which is an in-person procedure, despite chlorambucil potentially being self-administered and labs done outside the institution (footnote 'b', Page 108).; Category precedence applied: core_treatment > imaging_diagnostics > labs > clinic_visits.; Screening BMA/BMB is categorized as 'core_treatment' due to its invasive nature for diagnosis/staging.; DE visits with BMA/BMB are categorized as 'core_treatment'.; DE visits with CT/ECG but no BMA/BMB or drug administration are categorized as 'imaging_diagnostics'.; Visits with drug administration (IV infusion or oral dispensation) are categorized as 'core_treatment'.; Visits with only labs (phlebotomy) and/or vitals/PROs are categorized as 'labs' if labs are present, otherwise 'clinic_visits'."
38319892,durvalumab 1500 mg monotherapy (Arm A),intervention,2,3,7,10,13,16,0,2,4,7,10,13,1,0,0,0,0,0,1,0,0,0,0,0,0,1,3,3,3,3,28,until progression,"Screening Day -28 (labs), Screening Day -1 (imaging/biopsy), C1D1, C1D14, C2D1, C2D14, C3D1, C3D14, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1. Range-columns were mapped to one nominal date.","Screening assessments are consolidated into two distinct in-person visits: one primarily for labs (Day -28) and one for imaging/biopsy (Day -1).; All 'X' marks in the Schedule of Assessments tables (Tables 2 and 3) indicate mandatory in-person procedures unless explicitly stated as optional.; Patient follow-up contact/Patient review for safety on D14 of C1, C2, and C3 are considered in-person clinic visits. These mid-cycle visits are not explicitly listed for cycles beyond C3, so they are not counted after C3.; PRO assessments (EORTC QLQ-C30, QLQ-HCC18, EQ-5D-5L, PRO-CTCAE, PGIC) are performed in-person on the days they are scheduled.; PK/ADA samples require an in-person blood draw.; RECIST imaging (CT/MRI) and mandatory tumor biopsies require in-person attendance.; IV infusions (Durvalumab/Tremelimumab) count as core_treatment days.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
38319892,durvalumab 1500 mg plus tremelimumab 75 mg×4 doses combination therapy (Arm B),intervention,2,3,7,10,13,16,0,2,4,7,10,13,1,0,0,0,0,0,1,0,0,0,0,0,0,1,3,3,3,3,28,until progression,"Screening Day -28 (labs), Screening Day -1 (imaging/biopsy), C1D1, C1D14, C2D1, C2D14, C3D1, C3D14, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1. Range-columns were mapped to one nominal date.","Screening assessments are consolidated into two distinct in-person visits: one primarily for labs (Day -28) and one for imaging/biopsy (Day -1).; All 'X' marks in the Schedule of Assessments tables (Tables 2 and 3) indicate mandatory in-person procedures unless explicitly stated as optional.; Patient follow-up contact/Patient review for safety on D14 of C1, C2, and C3 are considered in-person clinic visits. These mid-cycle visits are not explicitly listed for cycles beyond C3, so they are not counted after C3.; PRO assessments (EORTC QLQ-C30, QLQ-HCC18, EQ-5D-5L, PRO-CTCAE, PGIC) are performed in-person on the days they are scheduled.; PK/ADA samples require an in-person blood draw.; RECIST imaging (CT/MRI) and mandatory tumor biopsies require in-person attendance.; IV infusions (Durvalumab/Tremelimumab) count as core_treatment days.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
38319892,durvalumab 1500 mg plus tremelimumab 300 mg×1 dose combination therapy (Arm C),intervention,2,3,7,10,13,16,0,2,4,7,10,13,1,0,0,0,0,0,1,0,0,0,0,0,0,1,3,3,3,3,28,until progression,"Screening Day -28 (labs), Screening Day -1 (imaging/biopsy), C1D1, C1D14, C2D1, C2D14, C3D1, C3D14, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1. Range-columns were mapped to one nominal date.","Screening assessments are consolidated into two distinct in-person visits: one primarily for labs (Day -28) and one for imaging/biopsy (Day -1).; All 'X' marks in the Schedule of Assessments tables (Tables 2 and 3) indicate mandatory in-person procedures unless explicitly stated as optional.; Patient follow-up contact/Patient review for safety on D14 of C1, C2, and C3 are considered in-person clinic visits. These mid-cycle visits are not explicitly listed for cycles beyond C3, so they are not counted after C3.; PRO assessments (EORTC QLQ-C30, QLQ-HCC18, EQ-5D-5L, PRO-CTCAE, PGIC) are performed in-person on the days they are scheduled.; PK/ADA samples require an in-person blood draw.; RECIST imaging (CT/MRI) and mandatory tumor biopsies require in-person attendance.; IV infusions (Durvalumab/Tremelimumab) count as core_treatment days.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
38319892,sorafenib 400 mg BID therapy (Arm D),control,2,2,4,7,10,13,0,0,0,0,0,0,1,0,1,3,4,5,1,2,3,4,6,8,0,0,0,0,0,0,28,until progression,"Screening Day -28 (labs), Screening Day -1 (imaging/biopsy), C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1. Range-columns were mapped to one nominal date.","Screening assessments are consolidated into two distinct in-person visits: one primarily for labs (Day -28) and one for imaging/biopsy (Day -1).; All 'X' marks in the Schedule of Assessments tables (Tables 2 and 3) indicate mandatory in-person procedures unless explicitly stated as optional.; Patient follow-up contact/Patient review for safety on D14 of C1, C2, and C3 are considered in-person clinic visits. These mid-cycle visits are not explicitly listed for cycles beyond C3, so they are not counted after C3.; PRO assessments (EORTC QLQ-C30, QLQ-HCC18, EQ-5D-5L, PRO-CTCAE, PGIC) are performed in-person on the days they are scheduled.; PK/ADA samples require an in-person blood draw.; RECIST imaging (CT/MRI) and mandatory tumor biopsies require in-person attendance.; Oral drug administration (Sorafenib) does not count as an in-person healthcare contact day.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
38320161,Lumicell imaging directed tissue resection (Intervention Arm),intervention,1,2,2,2,2,2,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,28,treatment ends after the surgery is completed,"Screening (Day -X), Day 0 (Surgery), Post-Op Visit (Day +14). Range-columns were mapped to one nominal date.","The 'Pre-Enrollment /Screening' column represents one in-person visit occurring within the Day -28 to Day -1 window, with 'Radiologic evaluation' being the highest precedence activity for that day.; The 'Day 1 / Enrollment' column represents one in-person visit (the surgery day) occurring on Day 0, with 'LUM015 administration' and 'Main specimen resection' being the highest precedence activities for that day.; The '~2-14 days after surgery' column, which only lists 'Adverse event/adverse device effect evaluation', is subsumed by the more comprehensive 'Routine follow up visit' which is described as the 'first post-operative visit (approximately 2-3 weeks after surgery)'. This 'Routine follow up visit' is counted as one in-person visit, nominally at Day +14, with 'CBC' and 'Serum chemistry' being the highest precedence activities for that day.; The '3-month PROM survey collection' and '6-month PROM survey collection' are explicitly electronic surveys and do not count as in-person healthcare contact days.; The study has no recurring cycles of in-person visits beyond the initial post-operative visit. Follow-up for PROMs is electronic, and other follow-up is 'until medical team determines no further surgical intervention is required' or AE resolution, but no specific scheduled in-person visits are listed in the SoE beyond the first post-op.; The two treatment arms ('to proceed' and 'not to proceed') have the same number of in-person contact days, as LUM015 administration and the main surgery are common to both, and the intraoperative imaging for the intervention arm occurs on the same Day 0 as the surgery."
38320161,Standard of Care alone (Control Arm),control,1,2,2,2,2,2,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,28,treatment ends after the surgery is completed,"Screening (Day -X), Day 0 (Surgery), Post-Op Visit (Day +14). Range-columns were mapped to one nominal date.","The 'Pre-Enrollment /Screening' column represents one in-person visit occurring within the Day -28 to Day -1 window, with 'Radiologic evaluation' being the highest precedence activity for that day.; The 'Day 1 / Enrollment' column represents one in-person visit (the surgery day) occurring on Day 0, with 'LUM015 administration' and 'Main specimen resection' being the highest precedence activities for that day.; The '~2-14 days after surgery' column, which only lists 'Adverse event/adverse device effect evaluation', is subsumed by the more comprehensive 'Routine follow up visit' which is described as the 'first post-operative visit (approximately 2-3 weeks after surgery)'. This 'Routine follow up visit' is counted as one in-person visit, nominally at Day +14, with 'CBC' and 'Serum chemistry' being the highest precedence activities for that day.; The '3-month PROM survey collection' and '6-month PROM survey collection' are explicitly electronic surveys and do not count as in-person healthcare contact days.; The study has no recurring cycles of in-person visits beyond the initial post-operative visit. Follow-up for PROMs is electronic, and other follow-up is 'until medical team determines no further surgical intervention is required' or AE resolution, but no specific scheduled in-person visits are listed in the SoE beyond the first post-op.; The two treatment arms ('to proceed' and 'not to proceed') have the same number of in-person contact days, as LUM015 administration and the main surgery are common to both, and the intraoperative imaging for the intervention arm occurs on the same Day 0 as the surgery."
38483412,ARM I (COPORT),control,1,23,37,38,38,39,0,23,37,37,37,37,0,0,0,0,0,0,0,0,0,1,1,2,1,0,0,0,0,0,,Fixed duration radiation therapy (37 fractions over ~7.4 weeks),"Consent (Day -28), Radiation Therapy (37 fractions over Day 0 to Day 50, assuming 5 fractions/week), Follow-up visits on Day 180, and Day 365. Range-columns (e.g., 'Weekly') were mapped to existing RT days or single nominal dates.","Day 0 is the first day of radiation therapy.; Radiation therapy is administered 5 days a week (Monday-Friday), with weekends off.; Pre-registration eligibility assessments (CT/MRI, Bone Scan, H&P/DRE, PSA) are not counted as trial-mandated contact days within the screening window, as they could occur much earlier and are not explicitly scheduled by the trial within that window.; Informed consent is an in-person contact day and is assumed to occur on Day -28 (start of screening window) as the latest possible date prior to Step 1 registration and subsequent RT start.; Weekly History & Physical and AE evaluations during radiation therapy are assumed to coincide with one of the radiation treatment days, thus not adding extra unique contact days.; Optional specimen collections (Serum, plasma, urine) are not counted.; EPIC and EQ-5D completion at follow-up visits are assumed to be in-person, contributing to the clinic_visits category.; Precedence rule applied for category breakdown: core_treatment > imaging_diagnostics > labs > clinic_visits. Therefore, follow-up visits with Serum PSA (labs) and other clinic activities are categorized as 'labs'."
38483412,ARM II (HYPORT),intervention,1,23,25,26,26,27,0,23,25,25,25,25,0,0,0,0,0,0,0,0,0,1,1,2,1,0,0,0,0,0,,Fixed duration radiation therapy (25 fractions over 5 weeks),"Consent (Day -28), Radiation Therapy (25 fractions over Day 0 to Day 32, assuming 5 fractions/week), Follow-up visits on Day 180, and Day 365. Range-columns (e.g., 'Weekly') were mapped to existing RT days or single nominal dates.","Day 0 is the first day of radiation therapy.; Radiation therapy is administered 5 days a week (Monday-Friday), with weekends off.; Pre-registration eligibility assessments (CT/MRI, Bone Scan, H&P/DRE, PSA) are not counted as trial-mandated contact days within the screening window, as they could occur much earlier and are not explicitly scheduled by the trial within that window.; Informed consent is an in-person contact day and is assumed to occur on Day -28 (start of screening window) as the latest possible date prior to Step 1 registration and subsequent RT start.; Weekly History & Physical and AE evaluations during radiation therapy are assumed to coincide with one of the radiation treatment days, thus not adding extra unique contact days.; Optional specimen collections (Serum, plasma, urine) are not counted.; EPIC and EQ-5D completion at follow-up visits are assumed to be in-person, contributing to the clinic_visits category.; Precedence rule applied for category breakdown: core_treatment > imaging_diagnostics > labs > clinic_visits. Therefore, follow-up visits with Serum PSA (labs) and other clinic activities are categorized as 'labs'."
38499457,Pracinostat + AZA,intervention,1,13,37,67,99,131,0,11,29,50,71,93,1,0,1,3,4,6,0,0,1,2,4,6,0,2,6,12,20,26,28,until progression,"Screening (Day -28 to -1), Cycle 1 (Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 15), Subsequent Cycles (Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 21 [nominal for Day 21-26 window]). All range-columns (Screening, Day 21-26) were mapped to one nominal date.","The 'Day -28 to Day -1' screening column represents a single in-person visit.; The 'Day 21-26' window for assessments represents a single in-person visit within that window, nominally assigned to Day 21 for calculation.; Pharmacokinetic (PK) sampling (both 'Pracinostat Pop PK Sampling' and 'Sub-study pracinostat/AZA PK sampling') are considered in-person visits.; In-Study Long-Term Follow-Up contacts are not mandatory in-person visits, as they 'may be contacted during outpatient visits or by telephone'.; The End of Treatment Visit is not included in the 365-day horizon as its timing is variable and often occurs after Day 365 if treatment continues for many cycles.; Per Section 4.2.1.5, Pracinostat/placebo administration is in-person only on Cycle 1 Day 1, Day 3, and Day 15, and on Day 1 of Cycle 2. For subsequent cycles, only Day 1 is an in-person administration day; other doses are self-administered at home.; Azacitidine administration is considered an in-person visit for 7 consecutive days (Day 1-7) of each cycle, as per the primary schedule (Schedule 1) and confirmed by the SoA table.; When multiple activities occur on the same day, category precedence is applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
38499457,Placebo + AZA,control,1,13,37,67,99,131,0,11,29,50,71,93,1,0,1,3,4,6,0,0,1,2,4,6,0,2,6,12,20,26,28,until progression,"Screening (Day -28 to -1), Cycle 1 (Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 15), Subsequent Cycles (Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 21 [nominal for Day 21-26 window]). All range-columns (Screening, Day 21-26) were mapped to one nominal date.","The 'Day -28 to Day -1' screening column represents a single in-person visit.; The 'Day 21-26' window for assessments represents a single in-person visit within that window, nominally assigned to Day 21 for calculation.; Pharmacokinetic (PK) sampling (both 'Pracinostat Pop PK Sampling' and 'Sub-study pracinostat/AZA PK sampling') are considered in-person visits.; In-Study Long-Term Follow-Up contacts are not mandatory in-person visits, as they 'may be contacted during outpatient visits or by telephone'.; The End of Treatment Visit is not included in the 365-day horizon as its timing is variable and often occurs after Day 365 if treatment continues for many cycles.; Per Section 4.2.1.5, Placebo administration is in-person only on Cycle 1 Day 1, Day 3, and Day 15, and on Day 1 of Cycle 2. For subsequent cycles, only Day 1 is an in-person administration day; other doses are self-administered at home.; Azacitidine administration is considered an in-person visit for 7 consecutive days (Day 1-7) of each cycle, as per the primary schedule (Schedule 1) and confirmed by the SoA table.; When multiple activities occur on the same day, category precedence is applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
38531002,Pazopanib 800 mg,intervention,2,5,10,17,25,33,0,2,4,7,10,13,2,0,1,2,3,5,0,3,5,8,12,15,0,0,0,0,0,0,28,13 cycles,"Screening: Day -28 (Clinical/Labs/ECG/QOL/Blood Sample), Day -21 (Imaging). Treatment Cycles (C1-C13): Day 1 (CkD1) and Day 15 (CkD15) of each 28-day cycle. Additional Imaging: Day 90, Day 180, Day 270, Day 360. End of Treatment: Day 364. Range-columns (e.g., 'Day 15 (±2 days)') were mapped to one nominal date (Day 15).","Assumed 2 distinct in-person screening days: one for clinical assessments, labs, ECG, QOL, and biological sample collection (Day -28), and a separate day for comprehensive imaging (Brain MRI, Chest CT, Abdomen/pelvic CT/MRI, Bone scan, Clinical Tumor Assessment) (Day -21).; INR/aPTT monitoring (footnote 4) is assumed to require an in-person visit weekly during Cycle 1 and once per cycle thereafter if the patient is on warfarin. This is counted as a 'labs' day if it's the primary activity.; Blood pressure monitoring (footnote 1) is assumed to be in-person only when other in-person assessments are scheduled, as the protocol states it can be phoned in (Section 5.7.1).; QOL questionnaires (footnote 12) are assumed to be administered in-person when listed in the Schedule of Events table, despite Section 5.3.2 mentioning a home completion option, as the table's 'X' indicates a scheduled assessment.; Imaging assessments ('Every 3 months' per footnote 15) are assumed to be distinct in-person visits, separate from the routine Day 1 or Day 15 cycle visits.; The 'End of Treatment' visit (Day 364) is assumed to consolidate all listed procedures into a single in-person day.; The treatment duration is 13 cycles * 28 days = 364 days. The 'End of Treatment' visit occurs on Day 364.; No follow-up visits fall within the Day 0 to Day 365 window, as follow-up starts after End of Treatment (Day 364)."
38531002,Placebo,control,2,5,10,17,25,33,0,2,4,7,10,13,2,0,1,2,3,5,0,3,5,8,12,15,0,0,0,0,0,0,28,13 cycles,"Screening: Day -28 (Clinical/Labs/ECG/QOL/Blood Sample), Day -21 (Imaging). Treatment Cycles (C1-C13): Day 1 (CkD1) and Day 15 (CkD15) of each 28-day cycle. Additional Imaging: Day 90, Day 180, Day 270, Day 360. End of Treatment: Day 364. Range-columns (e.g., 'Day 15 (±2 days)') were mapped to one nominal date (Day 15).","Assumed 2 distinct in-person screening days: one for clinical assessments, labs, ECG, QOL, and biological sample collection (Day -28), and a separate day for comprehensive imaging (Brain MRI, Chest CT, Abdomen/pelvis CT/MRI, Bone scan, Clinical Tumor Assessment) (Day -21).; INR/aPTT monitoring (footnote 4) is assumed to require an in-person visit weekly during Cycle 1 and once per cycle thereafter if the patient is on warfarin. This is counted as a 'labs' day if it's the primary activity.; Blood pressure monitoring (footnote 1) is assumed to be in-person only when other in-person assessments are scheduled, as the protocol states it can be phoned in (Section 5.7.1).; QOL questionnaires (footnote 12) are assumed to be administered in-person when listed in the Schedule of Events table, despite Section 5.3.2 mentioning a home completion option, as the table's 'X' indicates a scheduled assessment.; Imaging assessments ('Every 3 months' per footnote 15) are assumed to be distinct in-person visits, separate from the routine Day 1 or Day 15 cycle visits.; The 'End of Treatment' visit (Day 364) is assumed to consolidate all listed procedures into a single in-person day.; The treatment duration is 13 cycles * 28 days = 364 days. The 'End of Treatment' visit occurs on Day 364.; No follow-up visits fall within the Day 0 to Day 365 window, as follow-up starts after End of Treatment (Day 364)."
38552197,Atezolizumab + Cabozantinib,intervention,2,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,21,until progression or unacceptable toxicity,"Screening (2 days), Day 1 of Cycle 1, Day 1 of Cycle 2, ..., Day 1 of Cycle 18. Range-columns (e.g., 'Day 1 (every 21 days)') were mapped to one nominal date (Day 1 of each cycle).","Screening activities are consolidated into two distinct in-person days: one for general clinic visits and routine labs, and another for imaging (CT/MRI/ECG) and any required biopsy.; The first dose of cabozantinib (C1D1) is administered at the clinic, while subsequent doses (Days 2-21 of each cycle) are self-administered at home and do not count as in-person contact days.; All Day 1 visits of each 21-day cycle are considered in-person contact days due to IV infusion (atezolizumab) and various assessments.; Tumor assessments (imaging) and ECGs, though scheduled at specific intervals (e.g., every 6 weeks for imaging, C1D1-C5D1 for ECG), align with the Day 1 treatment visits and therefore do not add separate contact days.; Optional activities, such as optional RBR blood samples or optional tumor biopsies, are not counted as mandatory in-person contact days.; The 'Post-Treatment Follow-Up visit (≤ 30 days after final dose)' is assumed to occur after Day +365 and thus falls outside the 12-month window.; Treatment is assumed to continue up to the 365-day horizon for calculation purposes, as per the 'until progression or unacceptable toxicity' rule."
38552197,Docetaxel Monotherapy,control,2,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,21,until progression or unacceptable toxicity,"Screening (2 days), Day 1 of Cycle 1, Day 1 of Cycle 2, ..., Day 1 of Cycle 18. Range-columns (e.g., 'Day 1 (every 21 days)') were mapped to one nominal date (Day 1 of each cycle).","Screening activities are consolidated into two distinct in-person days: one for general clinic visits and routine labs, and another for imaging (CT/MRI/ECG) and any required biopsy.; All Day 1 visits of each 21-day cycle are considered in-person contact days due to IV infusion (docetaxel) and various assessments.; Tumor assessments (imaging) and ECGs, though scheduled at specific intervals (e.g., every 6 weeks for imaging, C1D1-C5D1 for ECG), align with the Day 1 treatment visits and therefore do not add separate contact days.; Optional activities, such as optional RBR blood samples, are not counted as mandatory in-person contact days.; The 'Post-Treatment Follow-Up visit (≤ 30 days after final dose)' is assumed to occur after Day +365 and thus falls outside the 12-month window.; Treatment is assumed to continue up to the 365-day horizon for calculation purposes, as per the 'until progression or unacceptable toxicity' rule."
38561010,Arm 1: Pembrolizumab + CRT (AFX),intervention,2,22,40,44,48,52,1,22,38,42,46,49,1,0,0,0,0,1,0,0,2,2,2,2,0,0,0,0,0,0,21,until progression (Pembro/Placebo for approx. 1 year),"Screening (Day -28), Priming Pembro/Placebo (Day -7), Pembro/Placebo infusions (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315), Cisplatin infusions (Day 7, 28 for AFX; Day 7, 28, 49 for SFX), daily Radiotherapy fractions (Day 7-12, 14-19, 21-26, 28-33, 35-40, 42-46 for AFX; Day 7-11, 14-18, 21-25, 28-32, 35-39, 42-46, 49-53 for SFX), scheduled clinic/lab visits (Day 14, 35, 49, 56 for AFX; Day 14, 35, 56 for SFX, where not covered by treatment), and Post-Treatment Follow-up (Day 345).","Day 0 is Cycle 1 Day 1 (C1D1), the start of Chemoradiation (CRT) and the first on-CRT pembrolizumab/placebo dose.; The priming dose of pembrolizumab/placebo is administered 7 days prior to C1D1 (Day -7).; The screening period (Day -28 to Day -1) is consolidated into a single in-person visit day (Day -28) for all required screening procedures.; Radiotherapy (RT) for both AFX and SFX regimens starts on Day 7 (Week 2 of Treatment 1).; AFX RT is 6 fractions per week for 6 weeks (35 fractions total), ending on Day 46.; SFX RT is 5 fractions per week for 7 weeks (35 fractions total), ending on Day 53.; Each RT fraction is counted as a distinct in-person healthcare contact day.; Pembrolizumab/Placebo is administered Q3W (every 21 days) for a total of 17 administrations (1 priming dose + 16 regular doses). The regular doses are on Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315.; Cisplatin is administered Q3W on Day 8 of Cycle 1, 2, and 3 (i.e., Day 7, 28, 49). For the AFX regimen, Cisplatin is only given on Day 7 and Day 28 (2 doses). For the SFX regimen, Cisplatin is given on Day 7, 28, and 49 (3 doses).; The 'Scheduled Day(s)' rows (Day 1, 8, 15 for each 3-week cycle) in the Trial Flow Charts (Pages 53, 59) indicate nominal in-person visit days where various procedures are performed. These days are Day 0, 7, 14, 21, 28, 35, 42, 49, 56 for Treatment 1, and Day 63, 84, 105, etc. for Treatment 2.; The 30-Day Safety Follow-up visit occurs 30 days after the last pembrolizumab/placebo dose (Day 315 + 30 = Day 345).; The category precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was strictly applied for days with multiple procedures.; Procedures explicitly marked with 'X' in the Trial Flow Charts are considered mandatory in-person contacts unless explicitly stated as optional or conditional on 'as needed' basis without drug continuation."
38561010,Arm 1: Pembrolizumab + CRT (SFX),intervention,2,19,38,42,46,50,1,19,38,42,46,49,1,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,21,until progression (Pembro/Placebo for approx. 1 year),"Screening (Day -28), Priming Pembro/Placebo (Day -7), Pembro/Placebo infusions (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315), Cisplatin infusions (Day 7, 28 for AFX; Day 7, 28, 49 for SFX), daily Radiotherapy fractions (Day 7-12, 14-19, 21-26, 28-33, 35-40, 42-46 for AFX; Day 7-11, 14-18, 21-25, 28-32, 35-39, 42-46, 49-53 for SFX), scheduled clinic/lab visits (Day 14, 35, 49, 56 for AFX; Day 14, 35, 56 for SFX, where not covered by treatment), and Post-Treatment Follow-up (Day 345).","Day 0 is Cycle 1 Day 1 (C1D1), the start of Chemoradiation (CRT) and the first on-CRT pembrolizumab/placebo dose.; The priming dose of pembrolizumab/placebo is administered 7 days prior to C1D1 (Day -7).; The screening period (Day -28 to Day -1) is consolidated into a single in-person visit day (Day -28) for all required screening procedures.; Radiotherapy (RT) for both AFX and SFX regimens starts on Day 7 (Week 2 of Treatment 1).; AFX RT is 6 fractions per week for 6 weeks (35 fractions total), ending on Day 46.; SFX RT is 5 fractions per week for 7 weeks (35 fractions total), ending on Day 53.; Each RT fraction is counted as a distinct in-person healthcare contact day.; Pembrolizumab/Placebo is administered Q3W (every 21 days) for a total of 17 administrations (1 priming dose + 16 regular doses). The regular doses are on Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315.; Cisplatin is administered Q3W on Day 8 of Cycle 1, 2, and 3 (i.e., Day 7, 28, 49). For the AFX regimen, Cisplatin is only given on Day 7 and Day 28 (2 doses). For the SFX regimen, Cisplatin is given on Day 7, 28, and 49 (3 doses).; The 'Scheduled Day(s)' rows (Day 1, 8, 15 for each 3-week cycle) in the Trial Flow Charts (Pages 53, 59) indicate nominal in-person visit days where various procedures are performed. These days are Day 0, 7, 14, 21, 28, 35, 42, 49, 56 for Treatment 1, and Day 63, 84, 105, etc. for Treatment 2.; The 30-Day Safety Follow-up visit occurs 30 days after the last pembrolizumab/placebo dose (Day 315 + 30 = Day 345).; The category precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was strictly applied for days with multiple procedures.; Procedures explicitly marked with 'X' in the Trial Flow Charts are considered mandatory in-person contacts unless explicitly stated as optional or conditional on 'as needed' basis without drug continuation."
38561010,Arm 2: Placebo + CRT (AFX),control,2,22,40,44,48,52,1,22,38,42,46,49,1,0,0,0,0,1,0,0,2,2,2,2,0,0,0,0,0,0,21,until progression (Pembro/Placebo for approx. 1 year),"Screening (Day -28), Priming Pembro/Placebo (Day -7), Pembro/Placebo infusions (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315), Cisplatin infusions (Day 7, 28 for AFX; Day 7, 28, 49 for SFX), daily Radiotherapy fractions (Day 7-12, 14-19, 21-26, 28-33, 35-40, 42-46 for AFX; Day 7-11, 14-18, 21-25, 28-32, 35-39, 42-46, 49-53 for SFX), scheduled clinic/lab visits (Day 14, 35, 49, 56 for AFX; Day 14, 35, 56 for SFX, where not covered by treatment), and Post-Treatment Follow-up (Day 345).","Day 0 is Cycle 1 Day 1 (C1D1), the start of Chemoradiation (CRT) and the first on-CRT pembrolizumab/placebo dose.; The priming dose of pembrolizumab/placebo is administered 7 days prior to C1D1 (Day -7).; The screening period (Day -28 to Day -1) is consolidated into a single in-person visit day (Day -28) for all required screening procedures.; Radiotherapy (RT) for both AFX and SFX regimens starts on Day 7 (Week 2 of Treatment 1).; AFX RT is 6 fractions per week for 6 weeks (35 fractions total), ending on Day 46.; SFX RT is 5 fractions per week for 7 weeks (35 fractions total), ending on Day 53.; Each RT fraction is counted as a distinct in-person healthcare contact day.; Pembrolizumab/Placebo is administered Q3W (every 21 days) for a total of 17 administrations (1 priming dose + 16 regular doses). The regular doses are on Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315.; Cisplatin is administered Q3W on Day 8 of Cycle 1, 2, and 3 (i.e., Day 7, 28, 49). For the AFX regimen, Cisplatin is only given on Day 7 and Day 28 (2 doses). For the SFX regimen, Cisplatin is given on Day 7, 28, and 49 (3 doses).; The 'Scheduled Day(s)' rows (Day 1, 8, 15 for each 3-week cycle) in the Trial Flow Charts (Pages 53, 59) indicate nominal in-person visit days where various procedures are performed. These days are Day 0, 7, 14, 21, 28, 35, 42, 49, 56 for Treatment 1, and Day 63, 84, 105, etc. for Treatment 2.; The 30-Day Safety Follow-up visit occurs 30 days after the last pembrolizumab/placebo dose (Day 315 + 30 = Day 345).; The category precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was strictly applied for days with multiple procedures.; Procedures explicitly marked with 'X' in the Trial Flow Charts are considered mandatory in-person contacts unless explicitly stated as optional or conditional on 'as needed' basis without drug continuation."
38561010,Arm 2: Placebo + CRT (SFX),control,2,19,38,42,46,50,1,19,38,42,46,49,1,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,21,until progression (Pembro/Placebo for approx. 1 year),"Screening (Day -28), Priming Pembro/Placebo (Day -7), Pembro/Placebo infusions (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315), Cisplatin infusions (Day 7, 28 for AFX; Day 7, 28, 49 for SFX), daily Radiotherapy fractions (Day 7-12, 14-19, 21-26, 28-33, 35-40, 42-46 for AFX; Day 7-11, 14-18, 21-25, 28-32, 35-39, 42-46, 49-53 for SFX), scheduled clinic/lab visits (Day 14, 35, 49, 56 for AFX; Day 14, 35, 56 for SFX, where not covered by treatment), and Post-Treatment Follow-up (Day 345).","Day 0 is Cycle 1 Day 1 (C1D1), the start of Chemoradiation (CRT) and the first on-CRT pembrolizumab/placebo dose.; The priming dose of pembrolizumab/placebo is administered 7 days prior to C1D1 (Day -7).; The screening period (Day -28 to Day -1) is consolidated into a single in-person visit day (Day -28) for all required screening procedures.; Radiotherapy (RT) for both AFX and SFX regimens starts on Day 7 (Week 2 of Treatment 1).; AFX RT is 6 fractions per week for 6 weeks (35 fractions total), ending on Day 46.; SFX RT is 5 fractions per week for 7 weeks (35 fractions total), ending on Day 53.; Each RT fraction is counted as a distinct in-person healthcare contact day.; Pembrolizumab/Placebo is administered Q3W (every 21 days) for a total of 17 administrations (1 priming dose + 16 regular doses). The regular doses are on Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315.; Cisplatin is administered Q3W on Day 8 of Cycle 1, 2, and 3 (i.e., Day 7, 28, 49). For the AFX regimen, Cisplatin is only given on Day 7 and Day 28 (2 doses). For the SFX regimen, Cisplatin is given on Day 7, 28, and 49 (3 doses).; The 'Scheduled Day(s)' rows (Day 1, 8, 15 for each 3-week cycle) in the Trial Flow Charts (Pages 53, 59) indicate nominal in-person visit days where various procedures are performed. These days are Day 0, 7, 14, 21, 28, 35, 42, 49, 56 for Treatment 1, and Day 63, 84, 105, etc. for Treatment 2.; The 30-Day Safety Follow-up visit occurs 30 days after the last pembrolizumab/placebo dose (Day 315 + 30 = Day 345).; The category precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was strictly applied for days with multiple procedures.; Procedures explicitly marked with 'X' in the Trial Flow Charts are considered mandatory in-person contacts unless explicitly stated as optional or conditional on 'as needed' basis without drug continuation."
38648575,Irinotecan Liposome Injection (ONIVYDE®) 70 mg/m² Q2W,intervention,2,6,12,23,36,49,0,3,7,13,20,26,2,1,1,1,1,1,0,2,4,9,15,22,0,0,0,0,0,0,28,until progression,"Screening Day 1 (Day -28), Screening Day 2 (Day -7), C1D1, C1D2, C1D8, C1D15, C1D22, then for subsequent 28-day cycles: CkD1, CkD15, CkD22, CkD29 (where CkD29 is C(k+1)D1). Additionally, Tumor/QoL/Biobanking visits occur every 6 weeks from C1D1 (Day 0, 42, 84, etc.). All day-range columns are mapped to one nominal date.","C1D1 is Day 0.; Treatment duration is assumed to be for the full 365-day horizon for calculation purposes, as 'until progression' is variable.; The 30-day follow-up visit is excluded as it occurs after treatment discontinuation, which for a 365-day horizon would fall outside the window.; Long-term follow-up (LTFU) is excluded as it can be by phone/email and is not explicitly mandated as in-person.; The 'Treatment Pause' column is excluded as visits during this period are conditional ('when/if the patient comes in to clinic').; Screening assessments (Informed Consent, Medical History, Demographics, Physical Exam, UGT1A1, Tumor Assessment, Archived tissue, Concomitant medications, AE reporting, QoL Questionnaires, Vital signs & weight, ECOG PS, CBC, Serum chemistry, Pregnancy test, ECG, Randomization) are consolidated into two distinct in-person screening days based on their respective footnotes and typical trial flow: one for comprehensive screening (Day -28) and one for pre-randomization/pre-treatment assessments (Day -7).; For Irinotecan, PK samples on C1D1 (Pre-dose, Post-dose, 2 hours post-infusion) are counted as one contact day. C1D2 (24 hours post-infusion) is a separate contact day.; For Irinotecan, ECGs on C1D1, C1D8, C1D15 are included as in-person diagnostic visits based on the 'X¹²' in Table 3 for Part 2, despite footnote 12 mentioning 'Part 1 only unless also required for Part 2 at the discretion of the Sponsor'. The presence of 'X¹²' in the table for Part 2 is interpreted as required.; Tumor assessments (CT/MRI) and QoL questionnaires are performed every 6 weeks from C1D1 (Day 0, 42, 84, etc.) and are considered in-person visits.; Biobanking samples are collected at 6 and 12 weeks (Day 42, 84) and are considered in-person visits.; Category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) is applied to assign a single primary category for each contact day."
38648575,IV Topotecan,control,2,13,33,60,89,122,0,10,25,45,65,90,2,0,0,0,0,0,0,3,8,15,24,32,0,0,0,0,0,0,21,until progression,"Screening Day 1 (Day -28), Screening Day 2 (Day -7), C1D1-D5, C1D8, C1D15, then for subsequent 21-day cycles: CkD1-D5, CkD15. Additionally, Tumor/QoL/Biobanking visits occur every 6 weeks from C1D1 (Day 0, 42, 84, etc.). All day-range columns are mapped to one nominal date.","C1D1 is Day 0.; Treatment duration is assumed to be for the full 365-day horizon for calculation purposes, as 'until progression' is variable.; The 30-day follow-up visit is excluded as it occurs after treatment discontinuation, which for a 365-day horizon would fall outside the window.; Long-term follow-up (LTFU) is excluded as it can be by phone/email and is not explicitly mandated as in-person.; The 'Treatment Pause' column is excluded as visits during this period are conditional ('when/if the patient comes in to clinic').; Screening assessments (Informed Consent, Medical History, Demographics, Physical Exam, UGT1A1, Tumor Assessment, Archived tissue, Concomitant medications, AE reporting, QoL Questionnaires, Vital signs & weight, ECOG PS, CBC, Serum chemistry, Pregnancy test, ECG, Randomization) are consolidated into two distinct in-person screening days based on their respective footnotes and typical trial flow: one for comprehensive screening (Day -28) and one for pre-randomization/pre-treatment assessments (Day -7).; Topotecan administration is for 5 consecutive days (D1-D5) of each 21-day cycle, counting each day as a separate contact day.; PK samples are explicitly stated to be for Irinotecan arm only and are therefore not counted for Topotecan.; Tumor assessments (CT/MRI) and QoL questionnaires are performed every 6 weeks from C1D1 (Day 0, 42, 84, etc.) and are considered in-person visits.; Biobanking samples are collected at 6 and 12 weeks (Day 42, 84) and are considered in-person visits.; Category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) is applied to assign a single primary category for each contact day."
38683596,Aspirin 300 mg daily x 5 years,intervention,1,1,1,2,2,3,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,2,0,5 years of study treatment,"Screening (nominal Day -1), Day 0, Day 180, Day 360. All are fixed nominal dates.","The 'Prior to Registration/Randomization' column in the Study Calendar represents a single in-person screening visit occurring within the Day -28 to Day -1 window.; Day 0 is defined as the start of treatment/randomization, which also serves as the first 6-month visit.; Subsequent 'Every 6 months' visits occur at nominal dates Day 180, Day 360, etc., for the 5-year treatment duration.; The return and review of 'Patient Medication Diary' and 'Lifestyle Measures of Inflammation assessments' booklets at 6-month visits requires in-person attendance.; Blood and urine sample collection at baseline (Day 0) and 24 months (Day 720) requires in-person attendance. For the purpose of the 12-month window, only Day 0 is relevant for labs.; The visit schedule is identical for both Aspirin and Placebo arms.; Category assignment follows the specified hierarchy: core_treatment > imaging_diagnostics > labs > clinic_visits."
38683596,Placebo daily x 5 years,control,1,1,1,2,2,3,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,2,0,5 years of study treatment,"Screening (nominal Day -1), Day 0, Day 180, Day 360. All are fixed nominal dates.","The 'Prior to Registration/Randomization' column in the Study Calendar represents a single in-person screening visit occurring within the Day -28 to Day -1 window.; Day 0 is defined as the start of treatment/randomization, which also serves as the first 6-month visit.; Subsequent 'Every 6 months' visits occur at nominal dates Day 180, Day 360, etc., for the 5-year treatment duration.; The return and review of 'Patient Medication Diary' and 'Lifestyle Measures of Inflammation assessments' booklets at 6-month visits requires in-person attendance.; Blood and urine sample collection at baseline (Day 0) and 24 months (Day 720) requires in-person attendance. For the purpose of the 12-month window, only Day 0 is relevant for labs.; The visit schedule is identical for both Aspirin and Placebo arms.; Category assignment follows the specified hierarchy: core_treatment > imaging_diagnostics > labs > clinic_visits."
38833658,Arm A: Lenvatinib Plus Pembrolizumab,intervention,1,3,7,13,20,27,0,1,2,4,5,7,1,0,0,0,2,4,0,2,5,9,13,16,0,0,0,0,0,0,28,"until progressive disease or unacceptable toxicity, with pembrolizumab up to 18 administrations (approx. 2 years) and lenvatinib until progression","Screening, C1D1, C1D15, C2D1, C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C5D15, C6D1, C6D15, C7D1, C7D15, C8D1, C8D15, C9D1, C9D15, C10D1, C10D15, C11D1, C11D15, C12D1, C12D15, C13D1, C13D15, C14D1. Range-columns (e.g., C6* to C26) were mapped to specific nominal dates (D1, D15) within each cycle.","The 'Screening -ing' column represents a single in-person visit day (Day -X) for all marked procedures, with the highest precedence category (imaging_diagnostics) assigned to this day.; Randomization (C1D1) is considered Day 0.; Telephone Contact Visit on C1D8 is not counted as an in-person contact day.; Lenvatinib Dispensing is considered an in-person clinic visit, but if other higher precedence procedures (core_treatment, imaging_diagnostics, labs) occur on the same day, the day is categorized by the highest precedence.; Regorafenib and TAS-102 administration on D1 of each cycle is considered core_treatment. Dispensing/administration checks on D15 are considered clinic_visits, but if other higher precedence procedures (imaging_diagnostics, labs) occur on the same day, the day is categorized by the highest precedence.; Treatment continues until progression, so all scheduled visits within the 365-day horizon are counted.; For days with multiple in-person activities, category precedence is applied (core_treatment > imaging_diagnostics > labs > clinic_visits)."
38833658,Arm B: Regorafenib Treatment,control,1,3,7,13,20,27,0,2,4,7,10,14,1,0,0,0,0,0,0,1,3,6,10,13,0,0,0,0,0,0,28,until progressive disease or unacceptable toxicity,"Screening, C1D1, C1D15, C2D1, C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C5D15, C6D1, C6D15, C7D1, C7D15, C8D1, C8D15, C9D1, C9D15, C10D1, C10D15, C11D1, C11D15, C12D1, C12D15, C13D1, C13D15, C14D1. Range-columns (e.g., C6 to C26) were mapped to specific nominal dates (D1, D15) within each cycle.","The 'Screening -ing' column represents a single in-person visit day (Day -X) for all marked procedures, with the highest precedence category (imaging_diagnostics) assigned to this day.; Randomization (C1D1) is considered Day 0.; Telephone Contact Visit on C1D8 is not counted as an in-person contact day.; Regorafenib administration on D1 of each cycle is considered core_treatment. Dispensing/administration checks on D15 are considered clinic_visits, but if other higher precedence procedures (imaging_diagnostics, labs) occur on the same day, the day is categorized by the highest precedence.; Treatment continues until progression, so all scheduled visits within the 365-day horizon are counted.; For days with multiple in-person activities, category precedence is applied (core_treatment > imaging_diagnostics > labs > clinic_visits)."
38833658,Arm B: TAS-102 Treatment,control,1,3,7,13,20,27,0,2,4,7,10,14,1,0,0,0,0,0,0,1,3,6,10,13,0,0,0,0,0,0,28,until progressive disease or unacceptable toxicity,"Screening, C1D1, C1D15, C2D1, C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C5D15, C6D1, C6D15, C7D1, C7D15, C8D1, C8D15, C9D1, C9D15, C10D1, C10D15, C11D1, C11D15, C12D1, C12D15, C13D1, C13D15, C14D1. Range-columns (e.g., C6 to C26) were mapped to specific nominal dates (D1, D15) within each cycle.","The 'Screening -ing' column represents a single in-person visit day (Day -X) for all marked procedures, with the highest precedence category (imaging_diagnostics) assigned to this day.; Randomization (C1D1) is considered Day 0.; Telephone Contact Visit on C1D8 is not counted as an in-person contact day.; TAS-102 administration on D1 of each cycle is considered core_treatment. Dispensing/administration checks on D15 are considered clinic_visits, but if other higher precedence procedures (imaging_diagnostics, labs) occur on the same day, the day is categorized by the highest precedence.; Treatment continues until progression, so all scheduled visits within the 365-day horizon are counted.; For days with multiple in-person activities, category precedence is applied (core_treatment > imaging_diagnostics > labs > clinic_visits)."
38838287,Arm A: NKTR-214 combined with nivolumab,intervention,1,5,8,12,16,21,0,2,4,7,10,14,1,0,1,2,3,4,0,3,3,3,3,3,0,0,0,0,0,0,42,until progression (maximum 2 years for Arm A),"Screening, C1D1, C1D3, C1D5, C1D8, C1D22, C2D1, C2D22, C3D1, C3D22, C4D1, C4D22, C5D1, C5D22, C6D1, C6D22, C7D1, C7D22, C8D1, C8D22, C9D1, C9D22. All listed days are distinct in-person contact days.","A single in-person screening visit is assumed, occurring within the Day -28 to Day -1 window, primarily categorized as imaging/diagnostics due to the extensive imaging and biopsy requirements.; Cycle length is 42 days (6 weeks) as stated in the protocol.; Treatment duration for counting purposes is assumed up to Day 365, consistent with the 'maximum of 2 years' rule for Arm A.; Oral Hydration Follow-up on C1D3, C1D22, and subsequent Day 22 visits was not counted as a guaranteed in-person visit due to the 'telephone or clinic visit' option and the rule to exclude tele-visits.; Optional Tumor Tissue Sample collection was not counted as a fixed in-person visit.; PK samples on C1D3, C1D5, C1D8 were counted as separate in-person lab visits.; Body and Brain Imaging are scheduled every 9 weeks from randomization (C3D1, C5D1, C7D1, C9D1) and take precedence for categorization on those days.; Urinalysis (central lab) is performed every 3 cycles starting with Cycle 3 (C3D1, C6D1, C9D1).; Nivolumab PK Blood Samples are collected on C1D1, C1D22, C3D22, C6D22, C9D22, C12D22, C15D22 based on Table 6 and Table 2."
38838287,Arm B: Investigator's choice of sunitinib or cabozantinib,control,1,3,6,10,14,19,0,2,4,7,10,14,1,0,1,2,3,4,0,0,0,0,0,0,0,1,1,1,1,1,42,until progression,"Screening, C1D1, C1D8, C1D22, C2D1, C2D22, C3D1, C3D22, C4D1, C4D22, C5D1, C5D22, C6D1, C6D22, C7D1, C7D22, C8D1, C8D22, C9D1, C9D22. All listed days are distinct in-person contact days.","A single in-person screening visit is assumed, occurring within the Day -28 to Day -1 window, primarily categorized as imaging/diagnostics due to the extensive imaging and biopsy requirements.; Cycle length is 42 days (6 weeks) as stated in the protocol.; Treatment duration for counting purposes is assumed up to Day 365, consistent with the 'until progression' rule.; Day 8 (-1 day) in Cycle 1 was counted as a clinic visit (Targeted Physical Examination, Weight, Vital Signs) as no drug dispense or labs were explicitly listed for this specific day in the table.; Day 22 of each cycle was counted as a core_treatment day due to the possibility of Cabozantinib dispensing, which is an in-person activity, and the rule to assume the more burdensome scenario for 'OR' options.; Optional Tumor Tissue Sample collection was not counted as a fixed in-person visit.; Body and Brain Imaging are scheduled every 9 weeks from randomization (C3D1, C5D1, C7D1, C9D1) and take precedence for categorization on those days.; Urinalysis (central lab) is performed every 3 cycles starting with Cycle 3 (C3D1, C6D1, C9D1)."
38872480,Bevacizumab + Chemotherapy arm,intervention,2,3,7,11,15,20,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,1,1,2,2,2,2,21,until progression or maximum 22 cycles,"Screening (Day -28, Day -21), C1D1, C2D1, C2D7, C2D14, C3D1, C4D1 (incl. Scan 2), C5D1, C6D1, C7D1 (incl. Scan 3), C8D1, C9D1, C10D1, C11D1 (incl. Scan 4), C12D1, C13D1, C14D1, C15D1 (incl. Scan 5), C16D1, C17D1, C18D1.","Cycle length is 21 days (Q3W).; Day 0 is Cycle 1 Day 1 (C1D1).; Screening visits (informed consent, H&P, ECOG PS, vitals, labs, PROs, AE, concomitant meds) are consolidated into one in-person day (nominal Day -28).; Initial radiographic assessment (Scan 1) is a separate in-person day during screening (nominal Day -21).; Radiographic assessments (Scans 2, 3, 4, 5) are scheduled to coincide with Day 1 of Cycles 4, 7, 11, and 15 respectively, based on the specified intervals in Appendix 1 footnote 'o' and the 21-day cycle length. Therefore, these are not counted as separate contact days but are subsumed under 'core_treatment' due to precedence.; Weekly vital signs during Cycle 2 (Day 7 and Day 14 of Cycle 2, i.e., Day 28 and Day 35 from C1D1) are in-person clinic visits for both arms, as per Appendix 1 footnote 'e'.; Assessments listed under 'Every Other Course' in Appendix 1 (H&P, ECOG PS, CA-125, PROs) occur on Day 1 of Cycles 1, 3, 5, 7, 9, 11, 13, 15, 17. These days also involve drug administration, so 'core_treatment' takes precedence.; Treatment continues until progression or max 22 cycles; for this analysis, visits are counted up to Day +365."
38872480,Placebo + Chemotherapy arm,control,2,3,7,11,15,20,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,1,1,2,2,2,2,21,until progression or maximum 22 cycles,"Screening (Day -28, Day -21), C1D1, C2D1, C2D7, C2D14, C3D1, C4D1 (incl. Scan 2), C5D1, C6D1, C7D1 (incl. Scan 3), C8D1, C9D1, C10D1, C11D1 (incl. Scan 4), C12D1, C13D1, C14D1, C15D1 (incl. Scan 5), C16D1, C17D1, C18D1.","Cycle length is 21 days (Q3W).; Day 0 is Cycle 1 Day 1 (C1D1).; Screening visits (informed consent, H&P, ECOG PS, vitals, labs, PROs, AE, concomitant meds) are consolidated into one in-person day (nominal Day -28).; Initial radiographic assessment (Scan 1) is a separate in-person day during screening (nominal Day -21).; Radiographic assessments (Scans 2, 3, 4, 5) are scheduled to coincide with Day 1 of Cycles 4, 7, 11, and 15 respectively, based on the specified intervals in Appendix 1 footnote 'o' and the 21-day cycle length. Therefore, these are not counted as separate contact days but are subsumed under 'core_treatment' due to precedence.; Weekly vital signs during Cycle 2 (Day 7 and Day 14 of Cycle 2, i.e., Day 28 and Day 35 from C1D1) are in-person clinic visits for both arms, as per Appendix 1 footnote 'e'.; Assessments listed under 'Every Other Course' in Appendix 1 (H&P, ECOG PS, CA-125, PROs) occur on Day 1 of Cycles 1, 3, 5, 7, 9, 11, 13, 15, 17. These days also involve drug administration, so 'core_treatment' takes precedence.; Treatment continues until progression or max 22 cycles; for this analysis, visits are counted up to Day +365."
38942046,Arm A: Perioperative Nivolumab,intervention,1,2,4,8,12,14,0,2,4,7,11,11,1,0,0,1,1,3,0,0,0,0,0,0,0,0,0,0,0,0,28,1 neoadjuvant dose + 9 adjuvant doses (total 10 doses),"Arm A: Day -28 (Screening), Day 0 (Neoadjuvant Nivolumab), Day +14 (Nephrectomy), Day +42 (Adjuvant Nivolumab 1), Day +70 (Adjuvant Nivolumab 2), Day +98 (Adjuvant Nivolumab 3), Day +126 (Adjuvant Nivolumab 4), Day +140 (Week 20 Visit), Day +154 (Adjuvant Nivolumab 5), Day +182 (Adjuvant Nivolumab 6), Day +210 (Adjuvant Nivolumab 7), Day +238 (Adjuvant Nivolumab 8), Day +266 (Adjuvant Nivolumab 9), Day +280 (Week 40 Visit), Day +294 (Post-Treatment Visit).","The 'Baseline' column in the Therapeutic Parameters Table (Page 59) is assumed to represent a single in-person screening visit occurring on Day -28 (the earliest day in the screening window).; Nephrectomy for Arm A, required within 7-28 days from the neoadjuvant dose, is assumed to occur on Day +14 (mid-point).; The first adjuvant nivolumab dose for Arm A, required within 4-10 weeks post-nephrectomy, is assumed to occur 4 weeks after nephrectomy (Day +14 + 28 = Day +42).; Subsequent adjuvant nivolumab doses are administered every 4 weeks (q28 days) as per Footnote 1 (Page 60) and Section 5.1.1.2.1 (Page 24).; QOL assessments are generally self-administered or conducted via phone/mail (Section 5.9.3, Page 69) and are therefore not counted as in-person contact days unless explicitly tied to other mandatory in-person procedures.; The 'Telephone call for symptom assessment' (Arm B, Page 64) is explicitly excluded as it is not an in-person contact.; For visits with multiple procedures, the contact day is categorized based on the highest precedence: core_treatment > imaging_diagnostics > labs > clinic_visits.; For Arm A, the 'Week 20' (Day +140), 'Week 40' (Day +280), and 'Within 6 Weeks after Final Treatment' (Day +294) visits are considered distinct in-person visits for assessments, separate from nivolumab administration days."
38942046,Arm B: Observation,control,1,1,3,5,6,7,0,1,1,1,1,1,1,0,0,1,1,3,0,0,2,3,4,3,0,0,0,0,0,0,28,observation,"Arm B: Day -28 (Screening), Day +28 (Nephrectomy), Day +56 (Post-Surgery Visit), Day +84 (Week 12 Visit), Day +105 (Week 15 Visit), Day +140 (Week 20 Visit), Day +210 (Week 30 Visit), Day +280 (Week 40 Visit).","The 'Baseline' column in the Therapeutic Parameters Table (Page 64) is assumed to represent a single in-person screening visit occurring on Day -28 (the earliest day in the screening window).; Nephrectomy for Arm B, required within 8 weeks after randomization, is assumed to occur on Day +28 (mid-point of 56 days).; The 'Within 6 Weeks after Surgery' visit is assumed to occur on Day +56 (mid-point of 42 days after Day +28 surgery).; The 'Telephone call for symptom assessment' (Arm B, Page 64) is explicitly excluded as it is not an in-person contact.; For visits with multiple procedures, the contact day is categorized based on the highest precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
35660812,Arm A: Conventional Dose Treatment (RVD) followed by Lenalidomide Maintenance,intervention,3,14,34,70,73,77,0,14,31,70,70,70,1,0,0,0,0,0,1,0,0,0,0,0,1,0,3,0,3,7,21,until progression (capped at Day 365 for calculation),"Screening (Day -14, -7, -1), C1D1, C1D2, C1D4, C1D5, C1D8, C1D9, C1D11, C1D12, C2D1, C2D2, C2D4, C2D5, C2D8, C2D9, C2D11, C2D12, C3D1, C3D2, C3D4, C3D5, C3D8, C3D9, C3D11, C3D12, PBSC_Collection (6 days), C4D1, C4D2, C4D4, C4D5, C4D8, C4D9, C4D11, C4D12, C5D1, C5D2, C5D4, C5D5, C5D8, C5D9, C5D11, C5D12, C6D1, C6D2, C6D4, C6D5, C6D8, C6D9, C6D11, C6D12, C7D1, C7D2, C7D4, C7D5, C7D8, C7D9, C7D11, C7D12, C8D1, C8D2, C8D4, C8D5, C8D8, C8D9, C8D11, C8D12, Maintenance (Day 1 of each 28-day cycle). Range-columns were mapped to one nominal date for the start of the range.","Screening period: Assumed 3 distinct in-person visits for comprehensive screening procedures (Day -14 for initial labs/counseling, Day -7 for extensive diagnostics/BM aspiration, Day -1 for final checks/pregnancy test).; RVD cycles: Each 21-day RVD cycle involves 8 in-person visits for drug administration (Days 1, 2, 4, 5, 8, 9, 11, 12 relative to cycle start). Oral lenalidomide and dexamethasone are considered self-administered on non-visit days. All RVD administration days are categorized as 'core_treatment'.; PBSC Collection (Arm A): Assumed 1 day for Cyclophosphamide IV, followed by 5 days of Filgrastim/G-CSF administration and apheresis procedures. Total 6 days, all categorized as 'core_treatment'. This phase starts on Day 77 (21 days after C3D14).; Maintenance Therapy (Arm A): Initiated after 8 RVD cycles and PBSC collection. Maintenance is lenalidomide oral (self-administered), with scheduled in-person visits on Day 1 of each 28-day cycle for monitoring/assessments. These are categorized as 'clinic_visits'. Duration is capped at Day 365 for calculation.; Category assignment: Applied precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits). For example, if labs and core treatment occur on the same day, it's counted as 'core_treatment'."
35660812,Arm B: High-Dose Treatment (RVD + PBSCT) followed by Lenalidomide Maintenance,intervention,3,14,37,59,62,66,0,14,33,54,54,54,1,0,1,1,1,1,1,0,3,4,4,4,1,0,0,0,3,7,21,until progression (capped at Day 365 for calculation),"Screening (Day -14, -7, -1), C1D1, C1D2, C1D4, C1D5, C1D8, C1D9, C1D11, C1D12, C2D1, C2D2, C2D4, C2D5, C2D8, C2D9, C2D11, C2D12, C3D1, C3D2, C3D4, C3D5, C3D8, C3D9, C3D11, C3D12, PBSC_Collection (6 days), PBSC_Transplant (13 days), C4D1, C4D2, C4D4, C4D5, C4D8, C4D9, C4D11, C4D12, C5D1, C5D2, C5D4, C5D5, C5D8, C5D9, C5D11, C5D12, Maintenance (Day 1 of each 28-day cycle). Range-columns were mapped to one nominal date for the start of the range.","Screening period: Assumed 3 distinct in-person visits for comprehensive screening procedures (Day -14 for initial labs/counseling, Day -7 for extensive diagnostics/BM aspiration, Day -1 for final checks/pregnancy test).; RVD cycles: Each 21-day RVD cycle involves 8 in-person visits for drug administration (Days 1, 2, 4, 5, 8, 9, 11, 12 relative to cycle start). Oral lenalidomide and dexamethasone are considered self-administered on non-visit days. All RVD administration days are categorized as 'core_treatment'.; PBSC Collection (Arm B): Assumed 1 day for Cyclophosphamide IV, followed by 5 days of Filgrastim/G-CSF administration and apheresis procedures. Total 6 days, all categorized as 'core_treatment'. This phase starts on Day 77 (21 days after C3D14).; PBSC Transplant (Arm B): Assumed 1 day for pre-transplant assessments (Day 83), 2 days for Melphalan conditioning (Day 85, 86), 1 day for PBSC reinfusion (Day 87), 4 days for inpatient monitoring/labs (Day 88-91), and 5 days for Filgrastim administration/monitoring (Day 92-96).; Maintenance Therapy (Arm B): Initiated after 5 RVD cycles (3 initial + 2 consolidation) and PBSC collection/transplant. Maintenance is lenalidomide oral (self-administered), with scheduled in-person visits on Day 1 of each 28-day cycle for monitoring/assessments. These are categorized as 'clinic_visits'. Duration is capped at Day 365 for calculation.; Category assignment: Applied precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits). For example, if labs and core treatment occur on the same day, it's counted as 'core_treatment'. Inpatient daily labs/vitals without active drug administration are categorized as 'labs'."
36996380,Arm A: Enzalutamide alone,intervention,1,2,5,10,14,17,0,0,0,0,0,0,1,0,1,3,4,5,0,2,4,7,10,12,0,0,0,0,0,0,28,until confirmed disease progression or unacceptable toxicity (calculated up to Day 365),"Screening (Day -7); Cycle 1 Day 1 (Day 0), Cycle 2 Day 1 (Day 28), Cycle 3 Day 1 (Day 56), Week 9 Imaging (Day 63), Cycle 4 Day 1 (Day 84), Cycle 5 Day 1 (Day 112), Week 17 Imaging (Day 119), Cycle 6 Day 1 (Day 140), Cycle 7 Day 1 (Day 168), Week 25 Imaging (Day 175), Cycle 8 Day 1 (Day 196), Cycle 9 Day 1 (Day 224), Cycle 10 Day 1 (Day 252), Week 37 Imaging (Day 259), Cycle 11 Day 1 (Day 280), Cycle 12 Day 1 (Day 308), Cycle 13 Day 1/Week 48 Imaging (Day 336). Range-columns were mapped to one nominal date.","A single consolidated in-person screening visit is assumed to occur at Day -7 to cover all pre-registration requirements (labs within 16 days, imaging within 28 days). This visit is categorized as 'imaging_diagnostics' due to the comprehensive imaging requirements.; Day 1 of each cycle for Arm A involves in-person assessments (H&P, vitals, labs, etc.) but no in-person drug administration, thus categorized as 'labs' (due to extensive lab panel).; Imaging visits at Week 9, 17, 25, 37, 48 are distinct in-person visits, categorized as 'imaging_diagnostics'.; When multiple activities (e.g., Day 1 labs and imaging) fall on the same calendar day, the category with higher precedence is assigned (imaging_diagnostics > labs). This occurs on Day 336 (C13D1 and Week 48 imaging)."
36996380,"Arm B: Enzalutamide, Abiraterone, and Prednisone",intervention,1,3,8,13,17,20,0,2,4,7,10,12,1,0,1,3,4,5,0,1,3,3,3,3,0,0,0,0,0,0,28,until confirmed disease progression or unacceptable toxicity (calculated up to Day 365),"Screening (Day -7); Cycle 1 Day 1 (Day 0), Cycle 1 Day 14 (Day 14), Cycle 2 Day 1 (Day 28), Cycle 2 Day 14 (Day 42), Cycle 3 Day 1 (Day 56), Week 9 Imaging (Day 63), Cycle 3 Day 14 (Day 70), Cycle 4 Day 1 (Day 84), Cycle 5 Day 1 (Day 112), Week 17 Imaging (Day 119), Cycle 6 Day 1 (Day 140), Cycle 7 Day 1 (Day 168), Week 25 Imaging (Day 175), Cycle 8 Day 1 (Day 196), Cycle 9 Day 1 (Day 224), Cycle 10 Day 1 (Day 252), Week 37 Imaging (Day 259), Cycle 11 Day 1 (Day 280), Cycle 12 Day 1 (Day 308), Cycle 13 Day 1/Week 48 Imaging (Day 336). Range-columns were mapped to one nominal date.","A single consolidated in-person screening visit is assumed to occur at Day -7 to cover all pre-registration requirements (labs within 16 days, imaging within 28 days). This visit is categorized as 'imaging_diagnostics' due to the comprehensive imaging requirements.; Day 1 of each cycle for Arm B involves in-person assessments (H&P, vitals, labs, etc.) and initiation/dispensing/education for oral study drugs (enzalutamide, abiraterone, prednisone), thus categorized as 'core_treatment'.; Arm B has additional in-person visits at Day 14 of Cycles 1, 2, and 3 for AST/ALT, Alk. Phos., Bili collection, categorized as 'labs'.; Imaging visits at Week 9, 17, 25, 37, 48 are distinct in-person visits, categorized as 'imaging_diagnostics'.; When multiple activities (e.g., Day 1 core treatment and imaging) fall on the same calendar day, the category with higher precedence is assigned (imaging_diagnostics > core_treatment). This occurs on Day 336 (C13D1 and Week 48 imaging)."
37499670,Experimental arm: Camrelizumab (SHR-1210) plus rivoceranib mesylate,intervention,3,3,7,14,20,27,0,3,7,14,20,27,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening: Day -28, Day -14, Day -7. Treatment: Cycle 1-3: Day 1, Day 15. Cycle 4 onwards: Day 1, Day 15.","All D1 and D15 visits during the treatment period are considered in-person healthcare contact days due to required safety assessments and drug administration.; Tumor radiological evaluations (every 8 weeks for 48 weeks, then every 12 weeks) coincide with existing D1 visits and do not add new contact days.; For screening, Day -28, Day -14, and Day -7 are counted as distinct in-person contact days based on the Schedule of Activities table and associated footnotes detailing required procedures.; For categorization, drug administration takes precedence, making all treatment period contact days 'core_treatment'. For screening, the highest precedence activity determines the category.; Treatment duration is assumed to continue through Day +365 for calculation purposes, as per instruction, given 'until progression' rule."
37499670,Control arm: Sorafenib,control,3,3,7,10,13,17,0,3,7,10,13,17,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening: Day -28, Day -14, Day -7. Treatment: Cycle 1-3: Day 1, Day 15. Cycle 4 onwards: Day 1 only.","All D1 and D15 visits during Cycles 1-3, and all D1 visits from Cycle 4 onwards, are considered in-person healthcare contact days due to required safety assessments and drug administration.; Tumor radiological evaluations (every 8 weeks for 48 weeks, then every 12 weeks) coincide with existing D1 visits and do not add new contact days.; For screening, Day -28, Day -14, and Day -7 are counted as distinct in-person contact days based on the Schedule of Activities table and associated footnotes detailing required procedures.; For categorization, drug administration takes precedence, making all treatment period contact days 'core_treatment'. For screening, the highest precedence activity determines the category.; Treatment duration is assumed to continue through Day +365 for calculation purposes, as per instruction, given 'until progression' rule."
38889373,Amcenestrant (SAR439859) plus palbociclib,intervention,1,3,6,9,12,16,0,2,4,7,10,14,1,0,0,0,0,0,0,1,2,2,2,2,0,0,0,0,0,0,28,until progression,"Screening, C1D1, C1D15, C2D1, C2D15, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1. No day-range columns were present that required mapping to a single nominal date.","The 'Screening up to 28 days before randomization' period is consolidated into a single in-person visit day for all listed screening procedures.; All procedures marked with 'X' in the Schedule of Activities (SoA) table for a given visit column are assumed to occur on that single in-person visit day.; The D15 (±1) column refers to a nominal Day 15 visit within Cycles 1 and 2.; For any day with multiple in-person activities, the category precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to assign the day to a single primary category.; Palbociclib administration (D1-D21) and continuous Amcenestrant/Letrozole administration, along with Goserelin administration (D1 every 28 days), are considered 'core_treatment' activities.; The protocol states 'Participants will continue to receive their assigned treatment until objective disease progression', which is interpreted as continuing treatment and associated visits through Day +365 for the purpose of this extraction.; Optional visits, such as the EOT tumor biopsy, are excluded from the contact day count."
38889373,Letrozole plus palbociclib,control,1,3,6,9,12,16,0,2,4,7,10,14,1,0,0,0,0,0,0,1,2,2,2,2,0,0,0,0,0,0,28,until progression,"Screening, C1D1, C1D15, C2D1, C2D15, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1. No day-range columns were present that required mapping to a single nominal date.","The 'Screening up to 28 days before randomization' period is consolidated into a single in-person visit day for all listed screening procedures.; All procedures marked with 'X' in the Schedule of Activities (SoA) table for a given visit column are assumed to occur on that single in-person visit day.; The D15 (±1) column refers to a nominal Day 15 visit within Cycles 1 and 2.; For any day with multiple in-person activities, the category precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to assign the day to a single primary category.; Palbociclib administration (D1-D21) and continuous Amcenestrant/Letrozole administration, along with Goserelin administration (D1 every 28 days), are considered 'core_treatment' activities.; The protocol states 'Participants will continue to receive their assigned treatment until objective disease progression', which is interpreted as continuing treatment and associated visits through Day +365 for the purpose of this extraction.; Optional visits, such as the EOT tumor biopsy, are excluded from the contact day count."
